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Abstract
The expansion of the ischemic core into surrounding penumbral tissue has
prompted researchers to finds ways to limit this progression in hopes of providing better
outcomes for patients suffering from stroke. Current therapeutic strategies are limited,
and new therapies that can be delivered at late time-points are needed. Zn2+ has been
well documented to contribute to ischemic injury progression, and chelation of Zn2+
significantly improves neuronal survival, even when administered hours after the initial
insult. However, determining the source of this Zn2+ and the toxic mechanisms involved
in ischemia remain unclear.
Over the past 10 years, clinical recordings have provided strong evidence that the
occurrence of spreading depolarizations (SD) significantly contributes to the progression
of numerous forms of brain injuries, including ischemic stroke. As these events occur
iii

repetitively for hours to days following the initial ischemic event, they pose as a prime
candidate for the development of new therapeutic targets. These depolarizing events
have the potential capability to release large amounts of synaptic Zn2+ into the
extracellular space.
The dissertation work presented here addresses whether synaptic Zn2+ release
occurs during SD and if this source of Zn2+ is neurotoxic in the post-ischemic period. SD
generated by either localized K+ applications or an in vitro model of ischemia
(oxygen/glucose deprivation, OGD), resulted in large releases of synaptic Zn2+ in both
hippocampal and neocortical tissues in vitro and led to postsynaptic accumulation. Zn2+
chelation was sufficient to delay the onset of OGD-SD, providing a mechanism for the
beneficial effects of Zn2+ chelation seen previously. Additionally, elevating intracellular
Zn2+ levels worsened the recovery after SD, likely through impaired metabolic function.
Finally, synaptic Zn2+ release was detected following SD in vivo and this source of Zn2+
significantly contributed to ischemic injury.
These results suggest that targeting synaptic Zn2+ stores or release during SD
events could be a novel approach in treating ischemic brain injury. As SD events
continue to occur days following the initial ischemic event, this suggests the ability to
target these events at late time-points where current therapeutics are limited.

iv

Table of Contents
Abstract

iii

List of Figures

viii

Chapter 1: Introduction

1

1.1 The Need for New Therapeutic Targets in Treating Ischemic Stroke

1

1.2 Zn2+ in the Central Nervous System

3

1.2.1 First Evidence of Synaptic Zn2+ Release

4

1.2.2 Tools to Visualize Synaptic Zn2+

5

1.2.3 Synaptic Zn2+ Transporters

8

1.2.4 Zinc and Neuronal Injury

10

1.2.5 Metabolic Inhibition and Zn2+ Accumulation

12

1.2.6 Involvement of Zn2+ in Ischemia

14

1.2.7 Potential Sources and Measurements of Zn2+ Accumulation during
Ischemia

15

1.3 Spreading Depolarization

18

1.3.1 General Mechanisms Underlying Spreading Depolarization

19

1.3.2 Experimental Evidence for Spreading Depolarization in
Stroke Injury

23

1.3.3 Clinical Relevance of Spreading Depolarizations in Brain Injury

26

1.3.4 Therapeutic Potential for Blocking Spreading Depolarizations

28

1.3.5 Potential for Synaptic Zn2+ Release during
Spreading Depolarizations

30

1.4 Goals and Summary of the Presented Work

v

31

Chapter 2: Spreading Depression and Related Events are Significant
Sources of Neuronal Zn2+ Release and Accumulation

34

2.1 Abstract

35

2.2 Introduction

35

2.3 Materials and Methods

38

2.4 Results

41

2.5 Discussion

50

2.6 Figure Legends

56

Chapter 3: Zn2+ Chelation Improves Recovery by Delaying Spreading
Depression-Like Events

71

3.1 Abstract

72

3.2 Introduction

72

3.3 Materials and Methods

74

3.4 Results

75

3.5 Discussion

78

3.6 Conclusions

80

3.7 Figure Legends

81

Chapter 4: Intracellular Zn2+ Accumulation Enhances Suppression of
Synaptic Activity following Spreading Depolarization

86

4.1 Abstract

87

4.2 Introduction

87

4.3 Materials and Methods

89

4.4 Results

92

vi

4.5 Discussion

99

4.6 Figure Legends

105

Chapter 5: Fluorescence Detection of Synaptic Zn2+ Release during
Spreading Depolarization in vivo and Implications for Ischemic Injury

117

5.1 Abstract

118

5.2 Introduction

118

5.3 Materials and Methods

121

5.4 Results

126

5.5 Discussion

132

5.6 Figure Legends

138

Chapter 6: Discussion

150

6.1 Summary of Dissertation Studies

150

6.2 Imaging Synaptic Zn2+ Release

151

6.3 Targets for Synaptically Released Zn2+

156

6.4 Routes of Zn2+ Influx

158

6.5 Potential Mechanisms Linking Synaptic Zn2+ to Ischemic Damage

160

6.6 Beneficial Effects of Spreading Depolarizations

165

6.7 Differing Effects of Extracellular and Intracellular Zn2+

167

6.8 Critiques of the Current Work

170

6.9 Concluding Remarks

173

Appendix

175

Abbreviations Used

177

References

180

vii

List of Figures
Chapter 1: Introduction
Figure 1.1

6

Figure 1.2

16

Figure 1.3

19

Chapter 2: Spreading Depression and Related Events are Significant Sources
of Neuronal Zn2+ Release and Accumulation
Figure 2.1

62

Figure 2.2

63

Figure 2.3

64

Figure 2.4

65

Figure 2.5

66

Figure 2.6

67

Figure 2.7

68

Supplemental Figure 2.1

69

Supplemental Figure 2.2

70

Chapter 3: Zn2+ Chelation Improves Recovery by Delaying Spreading
Depression-Like Events
Figure 3.1

83

Figure 3.2

84

Figure 3.3

85

Chapter 4: Intracellular Zn2+ Accumulation Enhances Suppression of
Synaptic Activity following Spreading Depolarization

viii

Figure 4.1

110

Figure 4.2

111

Figure 4.3

112

Figure 4.4

113

Figure 4.5

114

Figure 4.6

115

Figure 4.7

116

Chapter 5: Fluorescence Detection of Synaptic Zn2+ Release during
Spreading Depolarization in vivo and Implications for Ischemic Injury
Figure 5.1

143

Figure 5.2

144

Figure 5.3

145

Figure 5.4

146

Figure 5.5

147

Figure 5.6

148

Supplemental Figure 5.1

149

Appendix
Figure A1

176

ix

Chapter 1: INTRODUCTION
1.1 The Need for New Therapeutic Targets in Treating Ischemic Strokes
Ischemic stroke is the third leading cause of death in the United States (LloydJones et al., 2009). In addition to high mortality, the aftermath of stroke brings lifelong
suffering, functional impairment and substantial economic burdens to stroke survivors
and their families (Lloyd-Jones et al., 2009). Ischemic strokes are caused by a sudden
loss of blood flow through cerebral vessels, and are typically caused by thrombosis. The
disruption in cerebral blood flow can create regions where the tissue can no longer
sustain ionic gradients due to lack of continuous supply of metabolic substrates. Such
hypoperfused tissue rapidly undergoes sustained depolarization which can lead to cell
death and the formation of a so-called “ischemic core”. Surrounding tissue can still
survive based on collateral blood supply from nearby vessels, however due to the loss of
the primary source of metabolic substrates this tissue can lose synaptic activity as cells
use remaining available energy stores to simply maintain ionic gradients required for
survival. Regions where brain tissue is functionally silent but where no observed damage
is present was originally termed the “ischemic penumbra” by Astrup (Astrup et al., 1977).
It was originally thought that over the course of hours to days following the initial
ischemic event, the ischemic core simply expanded progressively into the surrounding
penumbral tissue, thereby increasing the total volume of non-recoverable tissue (Dirnagl
et al., 1999). More recently, it has emerged that the penumbra and ischemic core can be
highly dynamic (Lo, 2008, del Zoppo et al., 2011), and even in some cases an ischemic
stroke can involve multiple mini-cores, surrounded by corresponding mini-penumbras,
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which form and coalesce to create the overall infarct (Olivot et al., 2009). Much work in
the last two decades has been concentrated on approaches to reduce or prevent the
expansion of ischemic injury, however the current clinical therapeutic strategies for
stroke remain very limited.
Currently, the only FDA approved treatment for ischemic stroke is the
administration of recombinant tissue plasminogen activator (t-PA). The administration of
t-PA can facilitate in the breakdown of the thrombotic clot, by converting plasminogen
into plasmin, which in turn promotes the digestion of the thrombi to restore proper blood
flow to the hypoperfused tissue. This can be a very effective treatment for some ischemic
stroke patients, however, extended treatment with t-PA can enhance the breakdown of the
blood-brain barrier (BBB) and increase the risk of hemorrhage (Wang et al., 2004). This
increased risk has limited the utilization of t-PA to within a short time frame, usually 34.5hrs, following the initial ischemic insult (NINDS Study Group, 1997). Many stroke
victims cannot be treated with t-PA within this time period due to, in some cases, lack of
knowledge of when the initial stroke occurred, but often the length of time from the
initial stroke to the time the patient can receive medical care. While t-PA administration
has only been shown to be beneficial soon after stroke, many ischemic brain injuries
continue to develop in the hours and days following the onset (Baird et al., 1997,
Karonen et al., 1999, Parsons et al., 2002). New therapeutic strategies that are effective
at later time points following the onset of ischemic insults are likely to have substantial
benefit and it is a significant problem that no such agents are approved for clinical use.
The work presented here addresses two potential mechanisms that could contribute
together to the enlargement of ischemic injury, and could be a target for interventions at
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late time points after the initial stroke insult: 1) Zn2+ accumulation; and 2) the
phenomenon of spreading depolarization.

1.2 Zn2+ in the Central Nervous System
In the late 1950s, while studying several curious cases of anemia in Iran
potentially linked with iron deficiency, Dr. Ananda Prasad made a profound discovery.
The patients were severely malnourished, and consumed mostly bread and small amounts
of clay. No animal protein was consumed. The cases presented with classical symptoms
of iron deficiency, however, there was no apparent loss of blood in these patients. In
addition, there was severe growth retardation and hypogonadism, which were not
apparent in animal models of iron deficiency. While investigating further, Dr. Prasad
speculated that zinc (Zn2+) deficiency could account for the symptoms presented that iron
deficiency could not. This paper was published in the early 1960s and speculated that
dietary Zn2+ deficiency was very prevalent in the Middle East (Prasad et al., 1961).
Shortly after this work, numerous other cases were reported to be linked with Zn 2+
deficiency throughout the world, all rapidly responding positively with oral Zn2+
supplements (Sandstead et al., 1967). From these initial observations demonstrating the
importance of Zn2+ for human biology, the study of Zn2+ has expanded dramatically, and
encompasses nearly all aspects of biological function. This rapid expansion has been
summarized by Dr. Prasad in a recent review (Prasad, 2012).
Zn2+ is now known to be critically important for the function of a vast array of
cellular processes, with over 300 proteins (e.g. Zn-fingers) and nearly 2000 transcription
factors requiring Zn2+ as a co-factor for proper function (Prasad, 2012). While the
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importance for Zn2+ in proper development and biological function was highlighted by
the works of Dr. Prasad and colleagues, significant amounts of brain Zn2+ had actually
been identified earlier, a serendipitous finding during investigations of Zn2+ release from
insulin secreting cells of the pancreas (Maske, 1955). At that time, Maske’s finding
received little attention as Zn2+ was not, at the time, thought to be important for CNS
functions. However as described below, subsequent studies confirmed Maske’s finding,
and studies of Zn2+ in CNS physiology and pathophysiology have since expanded greatly.

1.2.1 First Evidence of Synaptic Zn2+ Release
Several techniques were developed and utilized to visualize Zn2+ localization and
these methods revealed a broad distribution of Zn2+ throughout the brain. One such
technique arose with the development of electron microscopy. An enhanced silversulfide staining procedure was developed to visualize Zn2+ with ultra-structural resolution
(Timm, 1958), and was used to detect Zn2+ localized in clear synaptic vesicles within the
mossy fiber terminals of the hippocampus (Haug, 1967). This Zn2+ pool was described as
“exchangeable Zn2+”, meaning that it was not bound tightly to binding proteins and was
therefore available for interactions with the histochemical staining procedure.

In

addition, the fact that Zn2+ staining was seen in synaptic vesicles but not in other
subcellular compartments (such as mitochondria), suggested that there was a discrete
pool of synaptic Zn2+ that is stained by this procedure. The presence of Zn2+ in synaptic
vesicles also raised the possibility that Zn2+ may be released during synaptic vesicle
fusion and participates in synaptic physiology.
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It was later confirmed that Zn2+ can indeed be taken up into presynaptic terminals
and subsequently released upon stimulation. The first evidence for Zn2+ release from
presynaptic terminals was provided by two laboratories at nearly the same time (Assaf
and Chung, 1984, Howell et al., 1984). One of these studies utilized hippocampal slices
incubated with the radiolabeled Zn2+ tracer, 65Zn2+. Radiolabeled Zn2+ was taken up into
hippocampal slices and a subsequent brief (60s) electrical stimulation resulted in
significant

65

Zn2+ release into the superfusate, indicating activity-dependent release

(Howell et al., 1984). Concurrent work by Assaf and Chung reported increased levels of
extracellular Zn2+, detected by atomic absorption spectrophotometry, following high K+
(23.8mM) depolarization in slice or kainic acid injections in vivo to induce seizure-like
activity (Assaf and Chung, 1984). It was estimated that total extracellular Zn2+ could
reach levels as high as 300µM, however the concentration in the synapse could be even
higher. These two seminal works were an important next step in suggesting that synaptic
Zn2+ release may be important for physiological and pathophysiological activity.

1.2.2 Tools to Visualize Synaptic Zn2+
Another useful technique for visualizing Zn2+ in the CNS arose with the
development of specific fluorescent compounds that were able to detect the
“exchangeable Zn2+” described above. The first compound, the quinoline analogue 6methoxy-8-p-toluene sulfonamide quinolone (TSQ) was found to have a distribution of
Zn2+ labeling similar to Timm’s staining throughout the CNS (Frederickson et al., 1987)
(see Figure 1.1). However, this technique required the use of either fresh-frozen or fixed
tissue sections and could not be used in live tissue. This concern was later addressed
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when

another

fluorescent

Zn2+

indicator,

2-methyl-8-p-toluenesulphonamido-6-

quinolyloxy acetic acid (Zinquin), was identified that could detect Zn2+ in live human
leukemia lymphocytes (Zalewski et al., 1993). These techniques, along with Timm’s
staining,

greatly

added

to

studying the localization of
Zn2+.
Widely

used

Ca2+

indicators, such as Fura-2, were
known to be responsive and
more selective to Zn2+ than to
Ca2+,

by almost

100

fold

(Grynkiewicz et al., 1985),
however
recently,

until
this

relatively
feature

was

largely ignored, and signals

Figure 1.1: Sagittal section of rat brain after
Timm’s staining technique. The brown staining
represents the presence of the “exchangeable
2+
pool” of Zn . Counter staining was performed
with Nissl to indicate cell bodies. Note the dense
staining in the subiculum (s), hilus of the dentate
gyrus (h), and in the mossy fibers of the
hippocampus. Zn2+ staining was also prevalent in
other brain regions. Accessory olfactory bulb (ao),
caudatoputamen (cp), amygdala (am). (Adapted
From: Frederickson et al., 2000)

from the Fura family of indicators were generally ascribed solely to Ca2+ dynamics.
However, “Ca2+” indicators (such as Fura-2 and MagFura-2) have been exploited to
investigate changes in intracellular Zn2+ levels in cultured neurons, under conditions that
limited intracellular Ca2+ changes (Cheng and Reynolds, 1998). In a later report it was
suggested that all of the Ca2+ response following simulated ischemia and reperfusion in
hippocampal slices was mediated by Zn2+ (Stork and Li, 2006), suggesting the possibility
that the majority of previous reports on intracellular Ca2+ could have been contaminated
by intracellular Zn2+.
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In response to the need for selective Zn2+ indicators, a high affinity Zn2+ indicator,
FluoZin-3, was developed by Molecular Probes to investigate Zn2+ release from
pancreatic β-cells in the early 2000s (Gee et al., 2002). This indicator has a much higher
affinity for Zn2+ and signal to noise ratio than previous Zn2+ indicators, and was better
restricted to the extracellular space.

To test whether Zn2+ was contributing to the

classical Ca2+ responses described above, FluoZin-3 was used alongside “Ca2+” indicators
to simultaneously detect changes in intracellular Zn2+ and Ca2+ (Devinney et al., 2005).
These authors were able to clearly show and distinguish intracellular Zn2+ and Ca2+
responses in cortical cultures exposed to glutamate (Devinney et al., 2005), highlighting a
role for both ions in excitotoxicity. This technique was further developed in our lab
(Dietz et al., 2008, Vander Jagt et al., 2009a), and in a collaborator’s lab (Medvedeva et
al., 2009), for imaging neurons in brain slices by co-loading single cells with Fura-6F and
FluoZin-3. These studies differentiated responses attributed to both Ca2+ and Zn2+, and
supported that early rises in intracellular Zn2+ can contribute subsequent, true, Ca2+
increases leading to cellular injury, and suggested that the claims above, made by (Stork
and Li, 2006), may have been over exaggerated.
Dr. Noebels’ laboratory utilized FluoZin-3 to directly investigate synaptic Zn2+
release at the mossy fiber synapse. In an elegant study, they showed that upon single
action potential stimulation of the mossy fibers, extracellular fluorescence of FluoZin-3
increased, and these signals were completely lost in animals lacking synaptic Zn 2+, ZnT3
KO animals (see below) (Qian and Noebels, 2005). In addition, the degree of Zn2+
release, as assessed by extracellular FluoZin-3 fluorescence, positively correlated with
the amplitude of the electrophysiological response of the postsynaptic potentials (Qian
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and Noebels, 2005), suggesting that imaging synaptic Zn2+ release could be used as a
surrogate for glutamate release during neuronal activity. In a follow-up study, the same
group showed that synaptic Zn2+ release could be visualized in the CA1 region of the
hippocampus from Schaffer collateral stimulation (Qian and Noebels, 2006). These
studies provided strong real-time fluorescence evidence that Zn2+ is co-released with
glutamate during synaptic stimulation.
However, some controversy arose over the use of high affinity indicators when
interpreting the collected data. Alan Kay (Kay, 2003) suggested that Zn2+ is associated
with proteins in the intraluminal space of synaptic vesicles, and upon fusion, Zn2+ is
externalized to the extracellular space, but still bound to these proteins. In the presence
of a high affinity Zn2+ indicator in the extracellular space, such as FluoZin-3, it was
hypothesized that Zn2+ removed from these binding sites by the indicator gives an
artificial signal of synaptic Zn2+ release (Kay, 2003). This hypothesis does not appear to
fully explain the original works by Assaf and Chung, and Howell et al., in 1984 (Assaf
and Chung, 1984, Howell et al., 1984) that did not use high affinity indicators, however
this hypothesis does raise an important issue for potential artifacts while using high
affinity indicators.

1.2.3 Synaptic Zn2+ Transporters
In the 1990s, a Zn2+ transporter was identified that facilitates Zn2+ accumulation
into synaptic vesicles. The transporter, ZnT3, was cloned based on the homology to
another recently characterized Zn2+ transporter, ZnT2 that was known to be involved in
endosomal loading of Zn2+ (Palmiter et al., 1996a). The cloned ZnT3 gene had ~52%

8

base pair homology to ZnT2, and corresponded to a protein of approximately 40kDa
(Palmiter et al., 1996b). While the structure of ZnT3 has not been confirmed, it and
other ZnTs, are predicted to have six transmembrane domains based on homology to
bacterial Zn2+ transporters (Gaither and Eide, 2001a).

The expression of ZnT3 is

restricted to the brain and testis, and within the brain, mRNA and protein staining for
ZnT3 mirrored the staining profile for the detection of vesicular Zn2+ with Timm’s stain
(Palmiter et al., 1996b). In addition, a gene with ~86% homology to mouse ZnT3 was
cloned from human cDNA, indicating the presence of a similar transporter in humans.
Three years after publication of the ZnT3 sequence, Palmiter’s group developed a
genetic knockout of ZnT3 (ZnT3 KO) (Cole et al., 1999). The generation of these KO
animals, from electroporation of the target vector into embryonic stem cells, results in the
absence of the ZnT3 gene throughout life.

ZnT3 KO mice were found to have

approximately 20% reduction in total Zn2+ in the neocortex and hippocampus, two
regions normally highly enriched with Zn2+ (Cole et al., 1999). The deletion of the ZnT3
transporter corresponded with an elimination of Timm’s staining and TSQ fluorescence,
implying that ZnT3 regulates the uptake of Zn2+ into synaptic vesicles. This suggests that
~20% of the total brain Zn2+ is stored in synaptic vesicles. The presence of synaptic Zn2+
has been primarily observed in glutamatergic synapses, and a co-targeting mechanism of
vesicular glutamate transporter 1 (Vglut1) and ZnT3 was identified in PC12 cells (Salazar
et al., 2005), although there is also evidence for synaptic Zn2+ present at inhibitory
synapses within the spinal cord (Danscher et al., 2001). In PC12 cells, it was found that
the levels of both transporters reciprocally influenced the transport capabilities of the
other. Interestingly, it was observed that glutamatergic signaling was not affected in
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young ZnT3 KO animals as evidenced by the lack of impairment in spatial learning,
memory, or sensorimotor functions (Cole et al., 2001). However, it was found that these
animals had an increased susceptibility to seizures induced by kainic acid injections (Cole
et al., 2001), suggesting that synaptic Zn2+ had a physiological role in limiting seizures.
Additionally, synaptic Zn2+ is required for the induction of long term potentiation (LTP)
at the mossy fiber/CA3 synapse (Li et al., 2001). More recent studies have revealed that
ZnT3 KO mice have an age-dependent decline in cognitive function (Adlard et al., 2010),
further suggesting a physiological role for synaptic Zn2+.

1.2.4 Zinc and Neuronal Injury
Assuf and Chung originally speculated that Zn2+ might play a role in neuronal
injury following seizures based on previous observations that the CA3 region of the
hippocampus was strongly susceptible to seizure-induced injury and from the
measurements of elevated Zn2+ in the CA3 area following seizure-like activity (Assaf and
Chung, 1984). This idea gained some important, but circumstantial support when it was
subsequently found that degeneration of CA3 neurons following strong mossy fiber
electrical stimulation was accompanied by a loss of vesicular Zn2+ shown by a loss of
Timm’s staining (Sloviter, 1985). These initial studies prompted the idea that synaptic
Zn2+ release may play a role in neuronal degeneration.
Zn2+ was clearly described to be toxic to both neurons and glial in culture by the
work of Dr. Denis Choi and colleagues in the late 1980s. They reported that exposures of
neuronal cultures to 300µM Zn2+ for 15min induced rapid morphological changes, and
near-complete cell degeneration 24hrs later (Yokoyama et al., 1986, Choi et al., 1988).
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These cellular responses (increased cell swelling and abnormal morphology) shared some
similarities with the classical responses to excessive glutamate exposures and subsequent
Ca2+ excitotoxicity.

However, it was noteworthy that the degenerative process in

response to Zn2+ occurred even in the absence of extracellular Na+ and Ca2+, suggesting
that Zn2+ itself can contribute directly to neuronal injury.
Zn2+ can directly affect mitochondrial function and cell survival through several
mechanisms.

Uptake of cytosolic Zn2+ into mitochondria was shown by using a

fluorescent probe directed to accumulate into mitochondria, to detect Zn2+ signals in
cultured cortical neurons (Sensi et al., 2000). It was concluded that mitochondrial Zn2+
accumulation, depended on mitochondrial membrane potential, likely via the same
mechanisms as utilized by Ca2+ (Sensi et al., 2000). Additionally, the increases in
fluorescence were abolished upon total Zn2+ chelation by a membrane permeable Zn2+
chelator, N,N,N’,N’-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN) (Sensi et al.,
2000). Later it was shown that low nM Zn2+ (10nM) could induce swelling in isolated
mitochondria, and this swelling was due to Zn2+ uptake into mitochondria, through the
Ca2+ uniporter, and subsequent opening of the mitochondrial permeability transition pore
(mPTP) (Jiang et al., 2001). Once the mPTP is opened, pro-apoptotic factors such as
apoptosis-inducing factor (AIF) and cyctochrome C can be released, leading to apoptotic
signaling cascades and cell death (Jiang et al., 2001). It was subsequently found that
cytochrome C release from mitochondria was significantly reduced, by selectively
chelating extracellular Zn2+ with CaEDTA following brief (10min) global ischemia in
rats (Calderone et al., 2004), further suggesting that Zn2+ disrupts mitochondrial integrity
and triggers neuronal injury pathways.
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1.2.5 Metabolic Inhibition and Zn2+ Accumulation
Zn2+ has also been suggested to contribute to neuronal injury as a consequence
of inhibition of cellular energy production through several mechanisms. Zn2+ can bind
directly to and inhibit multiple enzymes in the production of ATP.

Inhibition of

glycolysis can occur from Zn2+ binding to phosphofructokinase (PFK) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Inhibition contributing to

neuronal injury likely occurs preferentially at GAPDH, as the reported IC 50s for Zn2+ of
the purified enzymes are 1.5µM (Ikeda et al., 1980) and 300nM (Krotkiewska and Banas,
1992), respectively. GAPDH inhibition was supported when it was found that elevated
levels of intracellular Zn2+ resulted in neuronal death by a buildup of metabolites
upstream of GAPDH and depletion of metabolites downstream of GAPDH (Sheline et al.,
2000). Importantly, neuronal survival after Zn2+ exposures was improved by pyruvate
supplementation, which can bypass glycolysis and permit ATP production from oxidative
phosphorylation within mitochondira, supporting the hypothesis that Zn2+ inhibits
glycolysis and contributes to neuronal injury (Sheline et al., 2000). One surprising
finding from that study was that intracellular Zn2+ accumulation also resulted in a
depletion of NAD+, which is normally reduced by GAPDH, leading the authors to
suggest that an unidentified NAD+-catabolizing enzyme was responsible for this
decrease. Later, it was found that Zn2+ accumulation lead to activation of poly(ADPribose) polymerase-1 (PARP-1) (Kim and Koh, 2002). The activation of PARP-1, in
response to DNA strand breaks, results in the activation of the DNA repair processes by
the consumption of NAD+ to create poly(ADP-ribose) moieties (D'Amours et al., 1999).
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This process is usually very transient, however with prolonged activation, the decrease in
NAD+ levels can contribute to neuronal injury. Additionally, it was found that a family
of NAD+-catabolizing deacetylaces, the sirtuin family, was activated in response to toxic
Zn2+ exposures in culture and lead to a decrease in NAD+ levels (Cai et al., 2006), further
implicating NAD+ depletion, and subsequent energy depletion, as a mechanism of Zn2+
toxicity.
Within mitochondria, Zn2+ has been shown to disrupt both the tricarboxylic acid
(TCA) cycle and the electron transport chain (ETC).

Zn2+ can interfere with the

functions of α-ketoglutarate dehydrogenase complex (KGDHC), with an estimated Ki of
around 100nM, thereby inhibiting the TCA cycle (Brown et al., 2000). Zn2+ has also
been shown to inhibit the mitochondrial ETC. While inhibition at multiple sites within
the ETC has been hypothesized, complex III is proposed to be the major site of Zn2+
inhibition (Dineley et al., 2005). Under conditions of impaired mitochondrial respiration,
cells can usually resort to anaerobic respiration and survive on glycolysis for some time.
However, due to the potent effects of Zn2+ on both mitochondrial respiration and
glycolysis, combined with the substantial energy needed to maintain ionic gradients,
neurons and astrocytes are particularly vulnerable to prolonged Zn2+ elevations. While
tremendous progress has identified several pathways with which Zn2+ contributes to
neuronal injury, the mechanism(s) underlying Zn2+-dependent neuronal injury in
ischemic strokes remains uncertain.
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1.2.6 Involvement of Zn2+ in Ischemia
It has been well established that cells normally maintain very low levels of free
intracellular Zn2+ in order to mitigate the toxic effects of this ion (Sensi et al., 2011).
However, disruptions in Zn2+ homeostasis can be seen in several pathophysiological
states of the brain, such as ischemia. The first report linking excess endogenous Zn2+
accumulation and poor neuronal outcome following ischemia was shown in the mid1990s (Koh et al., 1996), expanding on prior studies linking exogenous Zn2+ exposures to
neuronal injury.

Koh and co-workers showed that degenerating neurons in the

hippocampus accumulated high levels of intracellular Zn2+, assessed by TSQ staining,
following a 10min period of global ischemia in rats.

In cultured neurons, excess

intracellular Zn2+ accumulation contributes to neuronal death, and by utilizing a
membrane impermeable Zn2+ chelator (CaEDTA), the authors showed a decrease in the
number of degenerating neurons in culture. By expanding their work in vivo, they
showed that intracerebroventricular injections of CaEDTA, prior to the onset of global
ischemia, significantly reduced the number of degenerating neurons in the hippocampus
(Koh et al., 1996). This seminal work provided the first evidence that endogenous
extracellular Zn2+ could significantly contribute to ischemic injury. Results from this
work were later reproduced (Lee et al., 2002), and more surprisingly and clinically
relevant, CaEDTA administration at time points long after the initial ischemic insult (up
to 60hrs) prevented neurotoxic Zn2+ accumulation and subsequent neuronal injury
(Calderone et al., 2004). These findings suggest the potential to target neurotoxic Zn2+ at
later stages following ischemia when current therapeutic targets are not beneficial.
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Some discrepancies exist regarding the time-course of extracellular/intracellular
Zn2+ accumulation following stroke. Microdialysis studies have revealed a large transient
increase in extracellular Zn2+ accumulation in the neocortex following transient occlusion
of the middle cerebral artery in rats (Kitamura et al., 2006b). This Zn2+ accumulation
peaked around 30min after the onset of ischemia, and returned to baseline concentrations
within 1 hour, suggesting that extracellular Zn2+ accumulates rapidly but transiently
following ischemia. It was reported that early administration of CaEDTA did not prevent
early increases in intracellular Zn2+ accumulation, but did block late accumulations
(Calderone et al., 2004), suggesting the possibility for a secondary phase of extracellular
Zn2+ accumulation.

It still remains unclear as to what source(s) contribute to the

extracellular accumulation and subsequent intracellular accumulation of neurotoxic Zn2+.
Determining how and when Zn2+ accumulation occurs could help in the development of
new strategies and time-courses to decrease ischemic neuronal injury.

1.2.7 Potential Sources and Measurements of Zn2+ Accumulation during Ischemia
In neurons, there are two major pools of intracellular Zn2+ (see Figure 1.2). The
first is bound to a large population of intracellular metal binding proteins
(metallothioneins, MT), including MTIII in neurons and astrocytes (Palmiter et al., 1992).
While the previous work of Koh and colleagues described above reported a role for toxic
effects of extracellular Zn2+ accumulation (Koh et al., 1996), evidence exists that
intracellular release from MTIII can play a significant role under some conditions.
Metallothioneins act as a buffer for intracellular Zn2+, and other metals, to prevent the
metals from reaching toxic levels.

Under conditions similar to those generated by
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ischemia, such as oxidative stress and intracellular pH changes, intracellular Zn2+ can be
liberated from MTIII (Aizenman et al., 2000). This oxidative-induced release of Zn2+
prevents MTIII from sequestering Zn2+ until the redox state of the protein has been
restored. As these oxidative conditions can persist during ischemia, it is possible that the
Zn2+-buffering potential of cells is severely compromised and toxic levels of Zn2+ can be
achieved rapidly, thus contributing to neuronal
Presynaptic

degeneration.

In

agreement

with

this

hypothesis, MTIII-KO mice have significantly

2. ZnT3 Containing
Synaptic Vesicle

larger infarct volumes compared to wild-type
controls after transient ischemia followed by
Zn2+

reperfusion (Koumura et al., 2009).
Another potential source of neurotoxic

1. Zn2+-Metallothionein

Zn2+ may be from the second pool of Zn2+,
Postsynaptic

Figure
1.2:
Schematic
representation of the two major
2+
sources of intracellular Zn . The
first source is bound to intracellular
metal
binding
proteins,
metallothioneins (1.).
A second
2+
source of Zn is co-localized with
glutamate in synaptic vesicles, via
2+
the actions of the Zn transporter
ZnT3 (2.).

synaptic

Zn2+

(see

section

1.2.1).

Interestingly, the location of the highest
enrichment

of

synaptic

Zn2+,

the

hippocampus, was also the site highly
susceptible to ischemia and

Zn2+ mediated

toxicity (Koh et al., 1996). While the levels of
synaptic Zn2+ only account for approximately

20% of the total Zn2+ in the hippocampus and cortex (Cole et al., 1999), levels released
into the extracellular space during neuronal activation are estimated to reach significant
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levels (up to 300µM) as described above, and could provide toxic levels of Zn2+
accumulation.
Ischemia results in the slow depolarization of neurons due to the loss of energy
substrates available to maintain ionic gradients across the plasma membrane.

This

depolarization may result in synaptic vesicle fusion and release and accumulation of
synaptic Zn2+ in the extracellular space. Synaptic Zn2+ release has been suggested to
translocate from presynaptic sites to postsynaptic neuronal cell bodies following
electrical stimulation (Suh, 2009) and traumatic brain injury (Suh et al., 2006). This
“translocation” hypothesis could explain the extracellular accumulation and subsequent
intracellular accumulation in postsynaptic cells following ischemia.

One adjunct

hypothesis for the increased infarct volumes in MTIII KOs described above could be
explained by the inability to sufficiently buffer synaptic Zn2+ accumulations as opposed
to intracellular release. However, there have been very few studies investigating the role
of synaptic Zn2+ release, by utilizing ZnT3 KO animals, on neuronal injury.
Following the generation of ZnT3 KO mice, it was found that these animals had
an increased susceptibility to seizures (Cole et al., 2000) as well as an increase in
intracellular Zn2+ accumulation in degenerating neurons of the hippocampus following
seizures (Lee et al., 2000). The observation of increased intracellular Zn2+ accumulation,
despite the lack of vesicular Zn2+ in the ZnT3 KO animals, argued against the
translocation hypothesis. It was further suggested that a different source of Zn2+, other
than synaptic Zn2+, was more important for neuronal injury, at least in the context of
seizure (Lee et al., 2000).

However, in a more recent study, ZnT3 KO animals

demonstrated less photoreceptor degeneration in the retina following light-induced retinal
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degeneration (Bai et al., 2013), which contrasts against seizure work done above and
suggests that synaptic Zn2+ is involved in retinal injury. Clearly, the source of neurotoxic
Zn2+ following numerous pathological states is still debated.

Currently, studies of

ischemia in ZnT3 KO mice are lacking. One possibility for a recurring source of synaptic
Zn2+ release following ischemia could be from repetitive waves of depolarization that
propagate through neuronal tissue, for many days following the initial ischemic event,
termed spreading depolarizations.

1.3 Spreading Depolarization
In 1944 the Brazilian physiologist Aristides Leao was investigating seizure
mechanisms following electrical stimulation of the rabbit cortex (Leao, 1944c). While
monitoring the spontaneous electrical activity for signs of seizure-like activity following
electrical stimulation, he discovered an unusual silencing of spontaneous electrical
activity when the brain was strongly stimulated.

By using a series of differential

electrical recordings of the exposed cortex, Leao noticed that the suppression of activity
originated from the site of stimulation and propagated outward from that site, eventually
encompassing the entire cortical hemisphere, at a rate calculated to be approximately 26mm/min. The suppression of spontaneous electrical activity was transient and recovered
fully within several minutes, in a similar manner to that which it was suppressed (Leao,
1944c). He also discovered that this suppression of activity could be elicited in the cortex
of cats and pigeons, suggesting that this phenomenon was likely widespread throughout
species (Leao, 1944c).
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Leao subsequently showed that accompanying the depression of spontaneous
cortical activity was a large, slow, potential change recorded from the extracellular space
(Leao, 1947). This slow extracellular direct current (DC) potential shift was recorded as
a multi-phasic response, starting
with a large negative component
followed by a recovery and slight
overshoot into the positive range
with a return to baseline within
minutes (see Figure 1.3). This DC
shift is now considered as the
classical hallmark of spreading
depolarization (SD).

Subsequent

studies by Leao also showed that a
similar DC shift occurred following

Figure 1.3: Representative recording of the
extracellular DC potential shift associated
with SD.
Following intense electrical
stimulation (S), there was an initial slow
negative potential change (note that negative
is plotted upwards) followed by a rapid
recovery (A) and subsequent overshoot (B).
The response returned to baseline values
approximately 5min following the event.
(From: Leao, 1947).

a global ischemia model in rabbits (Leao, 1947), thus establishing the possibility for the
occurrence of SD under pathological conditions such as ischemia.

The “spreading

depression of activity” originally discovered by Leao is now recognized as one of the
consequences resulting from the propagation of SD through nervous tissue, as discussed
below.

1.3.1 General Mechanisms Underlying Spreading Depolarization
Numerous stimuli can generate SD, including elevated extracellular K+, simulated
in vitro models of ischemia (hypoxia or oxygen-glucose deprivation (OGD)), mechanical
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stimuli, as well as the intense electrical stimulation and transient ischemia in vivo
mentioned above (Somjen, 2001). During the passage of SD, there is a near complete
depolarization of both neurons and glia. Whole cell recordings during SD have measured
the membrane potential to approach near 0mV (Czeh et al., 1992). This prolonged
depolarization mirrors the length of the DC shift and is accompanied by dramatic
disruptions in ionic gradients. Due to the membrane potential changes, non-selective ion
channels open resulting in extracellular increases of [K+] up to 60mM, along with
extracellular decreases in [Na+], [Ca2+], and [Cl-]

to about 60, 0.08, and 75mM,

respectively (Hansen and Zeuthen, 1981, Somjen, 2001). These severe ionic fluxes
contribute to the generation of the negative extracellular DC potential shift that can be
measured with electrophysiological techniques, as originally described by Leao. The
large negative DC shift associated with SD (up to -20mV) is the largest depolarization
event recorded in brain tissue, larger than the DC changes seen during brain activity
(Somjen, 2001). Additionally, the dramatic changes in ionic gradients result in the
corresponding influx of water, generating a marked swelling response.
Once initiated, SD propagates in a feed-forward manner throughout grey matter.
The feed-forward nature was originally proposed to arise solely from the effects of
extracellular K+ accumulation caused by SD, which would be sufficient to depolarize
neighboring neurons and continue the wave of depolarization (Grafstein, 1956). While
there is little doubt that increased extracellular K+ can lead to neuronal depolarization,
this hypothesis did have some inconsistencies. One concern with the K+ hypothesis was
that application of tetrodotoxin (TTX), to prevent voltage-gated Na+ channels from
contributing to full depolarization and neuronal action potential generation, failed to
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prevent the propagation of SD, suggesting that depolarization by K+ alone was not
sufficient to drive SD propagation (Tobiasz and Nicholson, 1982).

Additionally,

extracellular K+ elevations were not detected immediately prior to the onset of the DC
shift (Somjen et al., 1992), as were expected if K+ were contributing to the propagation of
SD. A second hypothesis to explain the feed-forward nature of SD was based on the
release and actions of the excitatory neurotransmitter glutamate. This hypothesis was
based on the observations that: 1) exogenous application of glutamate could induce SD
when applied to the cortical surface; and 2) glutamate release was not suppressed by
TTX, suggesting that glutamate can be released in the absence of action potentials (Van
Harreveld, 1959). The exact mechanisms underlying SD initiation and propagation under
different conditions are still incompletely understood, and a dual hypothesis has emerged
for the initiation and propagation of SD that includes contributions of both K+ and
glutamate (Van Harreveld, 1978, Somjen, 2001).
Large amounts of energy are required to restore the ionic gradients after SD, to
allow for normal neuronal function to resume. ATP is required to activate ATPdependent transporters, including the Na+/K+-ATPase and Na+/Ca2+-ATPase. A major
role for Na+/K+-ATPase function was supported by studies utilizing ouabain, a selective
Na+/K+-ATPase inhibitor which can generate SD in brain slices. At a high enough
concentration to cause complete pump inhibition, ouabain resulted in SD followed by
irrecoverable injury. However at a lower concentration that produced only partial pump
inhibition, SD was still generated, but neuronal function recovered in only approximately
half of these slices (Xiong and Stringer, 2000).
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The large energy demand generated by the activation of ATP-dependent
transporters requires that neurons have sufficient metabolic substrates to recover fully
from SD.

Consistent with an increase in metabolism, large increases in glucose

utilization (Shinohara et al., 1979) and dramatic decreases in glucose and ATP levels (up
to 72% and 54% of baseline, respectively (Mies and Paschen, 1984)) have been measured
following the passage of SD. These effects are also accompanied by increases in lactate
levels (Selman et al., 2004), presumably due to the conversion of pyruvate to lactate in
order to restore NADH levels to continue an increase in glycolytic activity. In support of
an increase in glycolysis, Takano and co-workers utilized two-photon imaging during SD
to show a heterogeneous distribution of NADH fluorescence with the increased NADH
levels associated in close proximity to blood vessels and NADH decreases farther away
from blood vessels (Takano et al., 2007). The authors also observed a transient decrease
in tissue O2 levels during the passage of SD, and taken together with the NADH
fluorescence observations above, suggest an increase in anaerobic glycolysis following
SD (Takano et al., 2007).
Upon neuronal activity, there is an increase in blood flow to provide metabolic
substrates to compensate for the increase in metabolism, a process termed neurovascular
coupling (Attwell et al., 2010). Based on the substantial neuronal activity during the
passage of SD, it seems likely that there would be a corresponding increase in blood
flow. The early work of Leao demonstrated dilation of pial vessels and an increase in
blood flow following SD under normal healthy conditions (Leao, 1944a). The changes in
cerebral blood flow (CBF) following SD are complex, with experimental evidence
reporting a hyperemic response occurring initially after the passage of SD followed by a
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long-lasting olegemia for up to 1hr (Lauritzen et al., 1982). Yet, despite the large
metabolic challenge associated with SD, under normal healthy conditions, SD is fully
recoverable and is non-injurious (Nedergaard and Hansen, 1988).

However, the

consequences of SD may drastically change depending on the current metabolic status of
the tissue involved.

1.3.2 Experimental Evidence for Spreading Depolarization in Stroke Injury
As mentioned above, Leao observed a slow negative DC potential shift following
electrical stimulation and also after experimental ischemia in the rabbit cortex. While the
characteristics of the DC shift recordings with the two different stimuli were somewhat
different, Leao postulated that the underlying event, seen during ischemia and that
observed during his characterized spreading depression, were likely of the same nature
(Leao, 1947). Increases in extracellular K+ levels, similar to those seen during SD, were
subsequently found to spontaneously occur in primate cortex following ischemia
(Branston et al., 1977) and were also later observed in the ischemic cortex of the cat
(Strong et al., 1983). The occurrence of SD following ischemia prompted investigators to
speculate that these events may contribute to the evolution of the ischemic region as more
laboratories began to report the occurrence of spontaneous SDs following ischemia
(Nedergaard and Astrup, 1986, Back et al., 1994).
In the early 1990s an important study revealed that there was a significant
correlation between the number of spontaneous SD events and the total infarct volume
following ischemia in rats (Mies et al., 1993). The authors reported a step-wise increase
in infarct volume after each SD. The DC shift durations and the recovery of the electrical
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activity during the repetitive SDs also grew steadily longer with each depolarizing event.
Shortly following that study, it was reported that experimentally inducing SD, by high K +
applications, following ischemia in rats lead to larger infarct volumes assessed by both
histological methods (Back et al., 1996) and diffusion-weighted MRI (Busch et al.,
1996). It was also observed that by using a glutamate receptor antagonist (MK-801), the
number of spontaneous SDs following ischemia decreased and the infarct area was also
smaller in MK-801 treated animals (Iijima et al., 1992). The results of these studies
suggested that SDs may be a causative factor in the enlargement of ischemic lesions and
by blocking or preventing the occurrence of spontaneous SDs following ischemia could
be therapeutically beneficial.
The majority of early animal studies assessing infarct growth with relation to the
number of SDs were limited by the time course of the experimental recordings,
terminating within a few hours following the induction of ischemia. This presents a
problem with trying to develop new therapeutics that could be delivered at late timepoints following the initial ischemic event, when infarct enlargement can still occur. In
2003 an important paper addressing this point showed that SDs can occur for many hours
following ischemia (Hartings et al., 2003). Rats were subjected to either a 2hr transient
(allowing reperfusion) or permanent middle cerebral artery occlusion (MCAO) and DC
potential changes were continuously recorded for 24hrs and up to 72hrs in nonanesthetized, freely-moving animals.

In the transiently-occluded animals, an initial

cluster of SDs was observed during the period of occlusion but ceased following
reperfusion. However, around 6hrs after the initial ischemic event (i.e. 4hrs following
reperfusion) a secondary phase of SDs was recorded which slowly decreased towards the
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end of the recording session (24hrs). Animals undergoing permanent occlusion had SDs
occurring throughout the entire 24hr recording period. The secondary phase in the
transiently-occluded animals significantly contributed to the overall infarct volume, as
blocking SDs in this phase with an NMDA receptor antagonist significantly reduced the
infarct volume measured at 24hrs (Hartings et al., 2003). That report was the first
evidence that SD events can occur continuously throughout the evolution of MCAO
infarcts in rodents and shed new light on the possibility of targeting the occurrence of
SDs for new therapeutics at later time-points.
As described above, SD occurring in healthy tissue is typically followed by an
increase in blood flow to compensate for the increased metabolic needs of the tissue.
However, when SD occurs in compromised brain tissue, surprisingly a rather opposite
effect occurs. An inverse neurovascular coupling (i.e. decrease in blood flow in response
to intense neuronal activation) was shown to occur during SD in experimental ischemia
in rats (Back et al., 1994), and is what is thought to contribute to the deleterious effects of
SD in pathological states. In experimental settings, the first SD following ischemia was
found to propagate radially outwards in all directions, with subsequent SDs continuously
cycling around the ischemic lesion in both rats and cats (Nakamura et al., 2010, Kumagai
et al., 2011). Inverse CBF responses were observed following the continuously cycling
SDs, and with each cycle around the core, the SD event never propagated through the
region of tissue that it previously invaded. This observation suggested that the persistent
decrease in blood flow, and therefore the sustained metabolic burden following SD,
significantly contributes to the recruitment of surrounding penumbral tissue into the
ischemic core.
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Despite strong supporting evidence from animal stroke studies, a major problem
in the field was that many investigators were hesitant to extrapolate the experimental
finding of SD to human patients. This was mainly due to the difficulty of non-invasively
electrically detecting the occurrence of these depolarizations in humans. The difficulty
was in part due to the high impedance of the skull and dura combined with the small area
of tissue undergoing depolarization, and the slow propagation of SD, to be detected by
large scalp electroencephalogram (EEG) recordings (Lauritzen et al., 2011). However, in
2002, a significant breakthrough occurred when the first potential evidence for the
electrical detection of SD in the acutely injured human brain was reported.

1.3.3 Clinical Relevance of Spreading Depolarizations in Brain Injury
In the 2002 study, 14 patients with intracranial hematomas that required a
decompressive craniotomy for recovery were recruited for SD recording.

The

craniotomy procedure allowed for the placement of a subdural electrode strip with four
differential electrical recording channels to monitor ECoG activity, in a similar fashion to
that of the original works of Leao, for up to 63hrs. In 5 of the 14 patients (36%)
suppression of ECoG activity was recorded that spread from one recording channel to the
next in a propagating nature (Strong et al., 2002). The ECoG suppression and the spread
of the ECoG suppression to subsequent channels were both similar to the propagation of
SD previously reported in animal models. While changes in DC potentials were not able
to be recorded in that study, subsequent advancements in the subdural electrode strips and
data analysis allowed for simultaneous recording of ECoG and DC potentials. These
strips were implemented in numerous subsequent studies and allowed for the further
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characterization of SDs in the injured human brain. This prompted the formation of an
international research group in 2002 named COSBID (CoOperative Study of Brain Injury
Depolarizations), to pool collected data from across the globe to further help understand
these events. The first of these studies recorded ECoG and DC potentials from 12
intracranial hematoma patients, in which 6 of those patients showed classical negative
DC potential shifts associated with suppression of ECoG activity (Fabricius et al., 2006).
As a result of the COSBID work, in 2008 repetitive SDs were found to occur in
humans following ischemic stroke. In that study, the authors recorded an average of
~100hrs in each of 16 patients who had middle cerebral artery occlusions (Dohmen et al.,
2008). SDs were recorded in 14 of the 16 patients, and in the 2 where SDs were not seen,
it was found that the electrode strips were placed over tissue that was already infarcted
and non-responsive. Repetitive SDs were seen up to 5 days following the electrode
placement.

Importantly, in some patients it was observed that when an SD event

propagated through the tissue it could lead to a permanent irrecoverable suppression of
ECoG activity. The spread of permanent electrical silencing matched post-operative MRI
and computed tomography (CT) scans showing the enlargement of the infarct (Dohmen
et al., 2008). Thus, these results further supported that SD events propagate through
penumbral tissue and are likely responsible for the recruitment of partially compromised
tissue into the ischemic core.
Most clinical SD recordings have concentrated on recordings in the intensive care
unit, but a recent study has demonstrated SD events at earlier time-points during
neurosurgical procedures for acute brain injury.

Twenty patients with malignant

hemispheric stroke, where a craniotomy was required, were monitored with laser speckle
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imaging (LSI) to record blood flow changes during a 20min period immediately
following the craniotomy procedure (Woitzik et al., 2013). Multiple SDs were observed
in 7 of the patients that had spatiotemporal propagation patterns similarly documented in
experimental animal models (Nakamura et al., 2010). These and other parallel findings
from animal and clinical recordings strongly validate the usefulness for studying SD in
animal models and the subsequent consequences following numerous brain injuries.

1.3.4 Therapeutic Potential for Blocking Spreading Depolarizations
Based on early experimental work describing the effectiveness of NMDA receptor
antagonists on reducing the number of SDs and subsequently reducing overall infarct
expansion (see above), the potential to block these deleterious events in humans and
improve outcome was suggested as a new therapeutic strategy (Strong et al., 2007,
Dreier, 2011, Lauritzen et al., 2011). This has the potential to become very clinically
relevant as SD events occur for many days after the initial insult and would greatly
increase the therapeutic window for new interventions. The obvious candidate would be
NMDA receptor blockers, as they have already been shown to reduce the number of SD
events in animal models as described above.

Unfortunately, a competitive NMDA

receptor antagonist (Selfotel) failed to provide any beneficial effects in two Phase III
clinical trials of severe brain injury where SDs were likely to occur (Morris et al., 1999).
While SDs were not directly measured in those patients, there are concerns, however,
about the use of competitive NMDA receptor antagonists in the prevention of SDs. First,
there is a massive increase in the extracellular levels of glutamate during SD (Fabricius et
al., 1993), which could outcompete the antagonist. Secondly, it was found that elevated
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levels of extracellular K+ reduced the ability for NMDA receptor antagonists to prevent
SDs (Petzold et al., 2005). As increased levels of extracellular K+ occur not only in
metabolically compromised tissue in the penumbra, but also during SD, NMDA receptor
antagonists might not be able to prevent SD.

On the other hand, ketamine, a

noncompetitive NMDA receptor antagonist used for general anesthesia, has been shown
to decrease the number of SDs following brain injury (Sakowitz et al., 2009, Hertle et al.,
2012). It is unclear if this ability is due to the noncompetitive nature of inhibition or to
some other effect, but the results are promising.
Another possibility would be to not prevent the occurrence of SD, but to
therapeutically target deleterious consequences following the event. Surprisingly, SD has
been shown to be neuroprotective when experimentally induced in healthy tissues. If SD
is induced 24hrs prior to the induction of ischemia, infarct volumes were significantly
smaller in those animals compared to animals not receiving SD beforehand (Matsushima
et al., 1998, Yanamoto et al., 1998). It is possible that following ischemia, when SDs
propagate out from the infarct and into healthier tissues, the effects of SD are beneficial
in normally perfused tissue, preconditioning the tissue making it more resilient to the
expansion of the ischemic core.

If this were true, then completely blocking SD

occurrence could actually contribute to infarct progression. While this has not been
experimentally shown in the context of ongoing ischemia, it raises the question of
whether deleterious consequences of SD can be targeted. One potential target that might
have a large impact on the expansion of the ischemic infarct could be the release and
accumulation of synaptic Zn2+ following SD.
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1.3.5 Potential for Synaptic Zn2+ Release during Spreading Depolarizations
As mentioned above, glutamate release is thought to contribute to SD (Van
Harreveld, 1959). Microdialysis studies have shown that extracellular levels of glutamate
significantly increase following SD (Fabricius et al., 1993). As a major source for
glutamate release from nerve terminals is from synaptic vesicles, one hypothesis is that
SD results in large amounts of synaptic glutamate release. Consistent with this is the
requirement for both the presence of extracellular Ca2+ and NMDA receptor activation
for the initiation and propagation of SD. One requirement for synaptic vesicle fusion and
release of neurotransmitters is the influx of Ca2+ into the presynaptic terminal to activate
the final vesicle fusion machinery. Inhibition of presynaptic Ca2+ channels (P/Q-type
Ca2+ channels) blocks SD generated in organotypic hippocampal slice cultures (Kunkler
and Kraig, 2004), supporting the idea that synaptic glutamate release contributes to SD.
Additionally, by utilizing a different approach that allows glutamate release but blocks
postsynaptic NDMA receptors, SD can also be blocked in experimental settings
(Lauritzen and Hansen, 1992), and in some clinical settings (Sakowitz et al., 2009).
As described above in section 1.2.3, Zn2+ is co-stored with glutamate in synaptic
vesicles, via the actions of the ZnT3 transporter. While the exact mechanism underlying
Zn2+ uptake through this transporter remains unclear, the concentration of Zn2+ in these
vesicles has been estimated to be in the millimolar range with accumulations of up to
300µM in the extracellular space following intense depolarization (Assaf and Chung,
1984). Similar glutamate signaling is present in young ZnT3 knockout (KO) mice (Cole
et al., 2001), suggesting that glutamate filling appears to not be affected by the lack of
vesicular Zn2+. As Zn2+ is co-stored with glutamate, and synaptic Zn2+ has been detected
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following direct electrical stimulation of nerve fibers, it seems reasonable to propose that
significant synaptic Zn2+ would be released during SD events.
SD events occur repetitively for up to several days following ischemia (Dohmen
et al., 2008). If synaptic Zn2+ release occurs during SD, this may provide a source of
repetitive extracellular Zn2+ accumulations following ischemia which could contribute to
the toxic Zn2+ described above. Previous work in our lab has demonstrated for the first
time that Zn2+ may be involved in the generation of SD (Dietz et al., 2008). Intracellular
Zn2+ increases, in single neurons, were found to occur prior to the onset of SD, and this
accumulation significantly contributed to the initiation of SD induced by ouabain and
OGD (Dietz et al., 2008).

Furthermore, a large increase in extracellular FluoZin-3

fluorescence was observed following ouabain-induced SD (Dietz et al., 2008), suggesting
the possibility for SD to result in extracellular Zn2+ accumulation.

Currently,

investigations into the potential contributions of synaptic Zn2+ release, with the use of
ZnT3 KO animals, following SD is lacking. Synaptic Zn2+ release during repetitive SDs
following ischemia could help explain not only the beneficial effects of chelating
extracellular Zn2+ during the initial ischemic event (Lee et al., 2002), but also at much
later time-points (Calderone et al., 2004), where SDs can occur.

1.4 Goals and Summary of the Presented Work
The goal of the dissertation work presented here was to test the overall hypothesis
that synaptic Zn2+ release during repetitive SD episodes is a major source of neurotoxic
Zn2+ in the post-ischemic period. Studies in Chapter 2 examined the mechanisms of Zn2+
accumulation following SD in the hippocampus of the brain slice model. These studies
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tested whether synaptic Zn2+ release could be detected extracellularly by the selective
Zn2+ fluorescent indicator, FluoZin-3, following SD generated by either microinjections
of KCl (high K+-SD) or oxygen/glucose deprivation (OGD-SD). This study provided
real-time fluorescence visualization of Zn2+ release during SD the first verification of its
synaptic source, and also demonstrated postsynaptic accumulation of Zn2+ from a
synaptic origin.
Experiments found in Chapters 3 and 4 examined consequences of Zn2+
accumulation on SD. In Chapter 3, the goal was to elucidate the mechanism behind the
protective effect of total (intracellular and extracellular) Zn2+ chelation previously
reported in the OGD model of ischemia in brain slices (Medvedeva et al., 2009). Under
conditions of Zn2+ chelation, complete recovery was seen following a period of OGD
when SD was not initiated, however irrecoverable injury still occurred if OGD-SD was
generated, suggesting that the major contributor to neuronal injury following OGD was
the generation of SD, and the beneficial effect of Zn2+ chelation was in delaying the onset
of SD, in agreement with our previous work (Dietz et al., 2008).
Studies in Chapter 4 investigated whether Zn2+ accumulation can worsen the
outcome of SD. The results showed that intracellular Zn2+ accumulation prior to the
onset of SD significantly delayed the recovery of neuronal activity in brain slices. The
effects of Zn2+ accumulation were consistent with an increased metabolic burden
following SD, providing a potential mechanism of how Zn2+ and SD might contribute
together in worsening neuronal injury following metabolic compromise.
Chapters 2-4 concentrated on in vitro studies in hippocampal slice preparations.
Experiments in Chapter 5 expanded these investigations to neocortical tissues more
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relevant for clinical studies of ischemic strokes, and also provided the first visual
evidence of synaptic Zn2+ release in vivo. Technical aspects of in vivo fluorescence
imaging are also examined. Finally, this study also provided evidence that synaptic Zn 2+
release occurs during ischemia following SD in vivo, and significantly contributes to
ischemic infarction.
Overall, these studies provide evidence that targeting either the release or
postsynaptic accumulation of synaptic Zn2+ in the postischemic period could lead to the
development of new therapeutics for the treatment of stroke which could be delivered at
late time-points. This is encouraging as current therapeutic strategies are limited in most
patients to a relatively short time window following initial stroke insults.
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2.1 Abstract
Spreading depression (SD) involves coordinated depolarizations of neurons and
glia that propagate through brain tissue.

Repetitive SD-like events are common

following human ischemic strokes, and are thought to contribute to the enlargement of
infarct volume. Accumulation of Zn2+ is also implicated in ischemic neuronal injury.
Synaptic glutamate release contributes to SD propagation, and since Zn 2+ is co-stored
with glutamate in some synaptic vesicles, we examined whether Zn2+ is released by SD
and may therefore provide a significant source of Zn2+ in the post-ischemic period. SDlike events were generated in acutely-prepared murine hippocampal slices by depletion of
oxygen and glucose (OGD) and Zn2+ release was detected extracellularly by a Zn2+selective indicator FluoZin-3.

OGD-SD produced large FluoZin-3 increases which

propagated with the event, and signals were abolished in tissues from ZnT3 KO animals
lacking synaptic Zn2+. Synaptic Zn2+ release was also maintained with repetitive SDs
generated by microinjections of KCl under normoxic conditions.

Intracellular Zn2+

accumulation in CA1 neurons, assessed using microinjection of FluoZin-3, showed
significant increases following SD that was attributed to synaptic Zn2+ release. These
results suggest that Zn2+ is released during SDs and could provide a significant source of
Zn2+ that contributes to neurodegeneration in the post-ischemic period.

2.2 Introduction
The phenomenon of spreading depression (SD) involves a wave of coordinated
neuronal and glial depolarization that spreads in a regenerative manner across brain tissue
(Leao, 1944b, Somjen, 2001). SD does not generally cause injury to healthy brain, as
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ionic gradients are restored by the action of ATP-dependent transporters. However SD
can cause irreversible loss of membrane potential and neuronal injury if metabolic
substrates are not sufficient for timely repolarization (Hossmann, 1996, Somjen, 2001).
Spreading waves of depolarization that are very similar to SD are observed in animal
models of stroke, and accumulating evidence suggests that these SD-like events play a
causative role in the evolution of ischemic brain injury (Strong et al., 2000, Hartings et
al., 2003). Recent long-term recording in ischemic stroke patients has revealed that SDlike events occur repetitively for many hours and days following stroke onset (Dohmen et
al., 2008), suggesting that approaches to limit the onset or consequences of these events
may be of benefit at quite late time points.
We recently examined factors contributing to the onset of SD in brain slices, and
found that Zn2+ accumulation can contribute to initiation of forms of SD that are relevant
for ischemia. Chelation of Zn2+ could delay or prevent SD-like events generated by
either combined oxygen and glucose deprivation (OGD-SD) or by the Na+/K+/ATPase
inhibitor ouabain (ouabain-SD), and these effects were more prominent when adenosine
A1 receptor activation was enhanced (Dietz et al., 2008). Zn2+ is present at high levels in
the brain, located in intracellular binding proteins and also concentrated into many nerve
terminals via the activity of the ZnT3 transporter (Palmiter et al., 1996b, Frederickson et
al., 2005). A large body of literature has shown that disruption of Zn2+ homeostasis can
cause neuronal injury, via disruption of both glycolytic and mitochondrial function, and
actions on a range of other intracellular targets (Choi and Koh, 1998, Dineley et al., 2003,
Galasso and Dyck, 2007, Sensi et al., 2009). Reducing Zn2+ accumulation has also been
shown to limit neuronal injury in animal focal and global ischemia models (Koh et al.,
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1996, Lee et al., 2002, Calderone et al., 2004, Galasso and Dyck, 2007). In addition to
preventing a number of deleterious intracellular signaling cascades, it is possible that
limiting the onset of SD-like events could contribute to beneficial effects of Zn2+
chelation in some stroke models.
Previous work has identified glutamate release as a contributor to SD propagation,
based on the effectiveness of glutamate receptor blockers and microdialysis
measurements of extracellular glutamate accumulation (Fabricius et al., 1993, Somjen,
2001). Although the regulation of glutamate release during SD is not well understood, it
is likely that depolarization of nerve terminals due to K+ elevations contributes. In the
present study we have examined whether significant amounts of Zn2+ may be released
from nerve terminals during SD. Zn2+ is co-stored with glutamate in many hippocampal
and neocortical synaptic vesicles (Frederickson et al., 2005). High levels of Zn2+ can be
visualized in nerve terminals by using histochemical staining methods and Zn2+ release
can be detected following nerve stimulation (Frederickson et al., 2005, Sensi et al., 2009),
including studies using the Zn2+-sensitive indicator FluoZin-3 (Qian and Noebels, 2005,
2006), but see also (Kay, 2003)). Knockout of ZnT3 prevents accumulation of Zn2+ in
synaptic terminals without influencing other essential Zn2+ stores (Cole et al., 1999), and
prevents fluorescence signals attributed to synaptic Zn2+ release (Qian and Noebels,
2006).
We have used fluorescence imaging of Zn2+ and ZnT3 knockout (ZnT3 KO)
tissues to show here that SD and related events indeed cause large Zn2+ releases that
appear due to release from synaptic vesicles, and that this source of Zn2+ contributes to
accumulation in postsynaptic neurons. Releasable Zn2+ stores were not readily depleted
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with repetitive SD trials, and these results therefore identify SD and related spreading
depolarizations as new and potentially significant sources of Zn2+ for neuronal injury in
the post-ischemic period.

2.3 Materials and Methods
Slice preparation
Acute brain slices were prepared from mice as previously described (Dietz et al.,
2008). All procedures were carried out in accordance with the National Institute of Health
guidelines for the humane treatment of laboratory animals, and the protocol for these
procedures was reviewed annually by the Institutional Animal Care and Use Committee
at the University of New Mexico School of Medicine. After cutting in ice-cold solution
and then holding for 1 hour at 35oC, artificial cerebrospinal fluid (ACSF) was changed,
and slices were held at room temperature until used for recording. Individual slices were
then transferred to the recording chamber, and were superfused with oxygenated artificial
cerebrospinal fluid (ACSF) at 2 ml/min.
Mice homozygous for deletion of the ZnT3 gene were originally obtained from
Dr. Richard Palmiter (Cole et al., 1999) and backcrossed onto C57Bl/6 for >13
generations. A homozygous breeding colony of ZnT3 KO animals was then established
at the University of New Mexico. Initial studies of intracellular and extracellular Zn2+
transients were made in slices from wild-type FVB/N mice, as were used for previous
studies of Zn2+ and SD initiation (Dietz et al., 2008). Because no differences were noted
in SD-FluoZin-3 responses between wild-type C57Bl/6 and FVB/N mice, responses from
ZnT3 KO tissues were either compared with responses from populations of wild-type
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C57Bl/6 tissues, or pooled populations of C57Bl/6 and FVB/N tissues, as noted in figure
legends. Wild-type animals were obtained from Harlan Laboratories (Bar Harbor, ME)
and all animals were housed in standard conditions (12hr/12hr light/dark cycle) before
sacrifice at 4-6 weeks of age.

SD initiation and recording
Extracellular measurements of DC potentials were made using borosilicate glass
microelectrodes, filled with ACSF (~5MΩ) and placed in stratum radiatum ~50 μm
below the surface of the slice. SD was generated by localized microinjection of KCl,
delivered by using brief pressure pulses (10-40psi, 100-250ms, 1M solution) from a
conventional patch electrode (3-5ΩM) placed under the surface of the slice, ~350μm
from the recording electrode. Oxygen-glucose deprivation (OGD) was used to generate
the closely-related propagating event (OGD-SD). In both cases (SD and OGD-SD), the
passage of the coordinated, spreading depolarization was identified as a sharp drop in DC
potential, as previously described (Somjen, 2001). In some experiments, the spread of
SD or OGD-SD was monitored by using intrinsic optical signals, generated by
transmission of red (>575nm) light.

Zn2+ indicator measurements
Extracellular Zn2+ measurements were made using the charged form of the Zn2+sensitive indicator FluoZin-3, using approaches developed by (Kay, 2003, Qian and
Noebels, 2005, 2006) and utilized in our recent work (Dietz et al., 2008). FluoZin-3 was
dissolved in ACSF at 1.5-2µM and superfused over the slice at 35oC. Background
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fluorescence was then reduced by addition of CaEDTA (1mM) in all experiments, except
where indicated otherwise. Responses are reported as (%ΔF/F0), as Zn2+ binds to multiple
components of the recording buffer (Rumschik et al., 2009), making absolute calibration
from addition of exogenous Zn2+ standards problematic. Fluorescence increases due to
addition of FluoZin-3 were very similar in wild-type and ZnT3 KO slices, and addition of
CaEDTA reduced fluorescence to very similar levels in both wild-type and ZnT3 KO
tissues (see Supplemental Figure 1). FluoZin-3 was excited at 495nm, and emission was
detected at 535/50nm using a monochromator-based imaging system (Till Photonics).
Intracellular Zn2+ measurements were made from single CA1 pyramidal neurons.
The procedures for intracellular recording/indicator injection were as described
previously (Dietz et al., 2008) using electrodes tip-filled with 1mM FluoZin-3 for
recordings from slices superfused at 32oC. Since high resistance intracellular electrodes
were used, a lower final indicator concentration was achieved by loading into neurons
with passage of hyperpolarizing current (300-800pA, 20 min), and the recording/filling
electrode was then slowly withdrawn in 0.5μm steps from the neuron (Dietz et al., 2008).
Because high resistance intracellular recording/filling electrodes were used, this
withdrawal procedure did not result in significant indicator leak or extracellular
accumulation of FluoZin-3. Signals from cell bodies were background subtracted using
adjacent regions in the cell body layer, to take into account changes in autofluorescence
caused by SD events.

40

Reagents and solutions
Slice cutting solution contained (in mM): 3 KCl, 1.25 NaH2PO4, 6 MgSO4, 26
NaHCO3, 0.2 CaCl2, 10 glucose, 220 sucrose and 0.43 ketamine. ACSF contained (in
mM): 126 NaCl, 3 KCl, 1.25 NaH2PO4, 1 MgSO4, 26 NaHCO3, 2 CaCl2, and 10 glucose
and was equilibrated with 95%O2 / 5%CO2. Cutting and recording solutions were both
315-320 mOsm.

In oxygen/glucose deprivation (OGD) experiments, ACSF was

modified by equimolar replacement of glucose with sucrose, and extensively equilibrated
with 95%N2 / 5%CO2. FluoZin-3 was obtained from Invitrogen (Carlsbad, CA), and all
other reagents were obtained from Sigma (St. Louis, MO).

Statistical Analysis
Data are reported as mean ± standard error of the mean (S.E.M.). Significant
differences between group data were evaluated using unpaired or paired Student’s t-tests,
with correction for multiple comparisons where appropriate.

2.4 Results
Synaptic Zn2+ release following OGD-SD
Figure 1A shows a representative example of Zn2+ increases associated with SDlike events in the OGD model (OGD-SD). OGD-SD was detected as a sharp DC shift
after about 10 min OGD exposure, and was accompanied by a large increase in
fluorescence of extracellular FluoZin-3.
Extracellular Zn2+ accumulation was detected by using the charged form of
FluoZin-3 (1.5-2µM), which is confined to the extracellular space.
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As described

previously (Qian and Noebels, 2005, 2006) a Zn2+ chelator with high affinity but slow
Zn2+ binding kinetics (CaEDTA, 1mM) was also included to improve signal/noise in the
initial measurements. This chelator is effective for these studies because it does not
reduce extracellular Ca2+ concentrations, but effectively reduces the large background
extracellular Zn2+ fluorescence signal, due to the higher affinity of this cation than the
pre-bound Ca2+ (KDZn=10-16M, KDCa=10-10M) (see Supplemental Fig 1). Because of the
time taken for exchange of Zn2+ with Ca2+ on the EDTA molecule (Kay, 2004),
extracellular Zn2+ is readily detected as FluoZin-3 transients before sequestration by
CaEDTA.
In order to test the hypothesis that Zn2+ is synaptically released during OGD-SD,
mice lacking synaptic Zn2+ (ZnT3 KO mice, (see Cole et al., 1999)) were used. ZnT3 is a
Zn2+ transporter localized selectively to synaptic vesicles (Palmiter et al., 1996b, Cole et
al., 1999), which is responsible for transporting cytosolic Zn2+ into synaptic vesicles. We
previously showed that Zn2+ accumulation can contribute to the onset of OGD-SD, and
described conditions of high adenosine A1 receptor activation where chelation of Zn2+
was sufficient to completely prevent the onset of SD (Dietz et al., 2008). In the present
experiments, exogenous A1 receptor agonists were not applied, to ensure that OGD-SD
was still generated and allow consequences of these events on Zn2+ release to be
determined. Under these conditions, OGD-SD was generated in all wild-type and ZnT3
KO tissues (mean onset time 10.09 ± 1.01 min in ZnT3 KO, vs. 8.97 ± 0.50 min in wildtype, p=0.37), however Figure 1B shows that FluoZin-3 increases were abolished in a
paired slice from a ZnT3 KO animal. Figure 1C shows mean data from a group of such
experiments. Instead of fluorescence increases, small decreases were observed following
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the propagation of OGD-SD in ZnT3 KO tissues that were due to changes in
autofluorescence and/or tissue swelling (see below).
During OGD exposures, small decreases in FluoZin-3 fluorescence were
observed prior to the onset of OGD-SD but these were not significantly different between
wild-type and ZnT3 KO preparations (-5.45±1.52 vs. -6.83±1.53 % ΔF/F0 respectively,
p=0.54, n=6 each). As CaEDTA was present throughout these studies, it is unlikely that
this is caused by decreases in extracellular Zn2+ levels, as is likely caused by small,
uniform changes in tissue optical properties before the onset of OGD-SD (see below).
No FluoZin-3 fluorescence increases were observed before the onset of OGD-SD,
regardless of whether CaEDTA was present or not (n=17 and n=5, respectively).
Figure 2 illustrates the wave-like spread of the FluoZin-3 increases, and
examines the relationship with the onset of OGD-SD. A movie file demonstrating the
spread of fluorescence increases is available in the Supplementary Data. Figure 2A
shows that the fluorescence increase propagated slowly across the slice (mean 3.68±0.55
mm/min, n=11). This rate was very similar to the propagation rate of OGD-SD observed
in this model with intrinsic optical methods in a separate population of slices (4.82±0.70
mm/min, n=9, p=0.22), and consistent with many previous reports for the propagation
rate of SD and related events generated in hypoxia or ischemia models (see Somjen,
2001). FluoZin-3 increases were also largest in stratum radiatum (Fig 2B), a region
which is expected to contain high concentrations of Zn2+-containing excitatory synaptic
inputs (Qian and Noebels, 2006) and be the site of initial current sink during SD initiation
(Kunkler et al., 2005). Figure 2C shows that the onset of Zn2+ increases was coincident
with the onset of OGD-SD measured in the same slices, suggesting that Zn2+ increases
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occur together with the spread of OGD-SD, rather than significantly leading or following
the response.

Relative Amplitude of Signals
As noted above, the methods used to evaluate Zn2+ release follow previously
published work, where a Zn2+ chelator with high affinity but slow Zn2+ binding kinetics
(CaEDTA) was used to improve signal/noise (Qian and Noebels, 2005). We tested the
hypothesis that this chelator greatly reduced the time course of FluoZin-3 transients from
OGD-SD by comparing results from parallel studies in the absence of CaEDTA. Figures
3A and B illustrate the greatly enhanced background FluoZin-3 fluorescence in the
absence of CaEDTA, and shows fluorescence transients generated by OGD-SD
superimposed on these different background fluorescence levels. Figure 3C shows mean
data from a set of such experiments, and shows a substantial increase in mean time
constant of decay of transients (0.61 ± 0.11 min vs. 2.03 ± 0.25 min, with and without
CaEDTA, respectively, n=5, p=0.0023). The peak amplitude of average raw fluorescence
transients was increased without CaEDTA (136.46 ± 23.12 vs. 82.43 ± 18.47 arbitrary
fluorescence units, 0mM vs. 1mM CaEDTA respectively, p>0.10, n=5 each), but because
of the very different background fluorescence levels, the signal/noise ratio of these
signals was substantially less than in experiments with CaEDTA (86.13 ± 35.43 (0mM
CaEDTA) vs. 241.28 ± 41.04 (1mM CaEDTA) (%ΔF/F0), p=0.022, n=5 each).

As

described previously (Dietz et al., 2008) CaEDTA did not interfere with OGD-SD
initiation, with the event occurring at 7.38 ± 0.93 min, compared with 7.80 ± 0.34
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without CaEDTA (n=5 for both groups, p=0.65), or propagation (2.86 ± 0.62 vs. 3.68 ±
0.94 mm/min, respectively, p=0.49, n=5 each).
Figure 4A compares extracellular FluoZin-3 responses to electrical stimulation of
synaptic inputs with OGD-SD in the same 6 preparations. Responses to relatively short
trains of high frequency stimulation (50Hz, up to 200ms trains) were not reliably detected
with the CCD methods used in this study, but Figure 3C shows robust extracellular
FluoZin-3 transients with 1s trains (50Hz). After recovery from synaptic stimulation (10
min), the same slices demonstrated much larger extracellular FluoZin-3 increases during
OGD-SD. When the areas under the curve were compared, FluoZin-3 signals were ~50
fold larger following OGD-SD (1.6±0.71 vs. 85.77±12.36 (%ΔF/F0)*min, n=6).
As has been noted by others, autofluorescence signals could interfere with
FluoZin-3 signals (Kay, 2003, Qian and Noebels, 2005). However Figure 4B shows that
differences in background autofluorescence changes are identical in wild-type and ZnT3
KO tissues, and as such cannot be responsible for the conclusions concerning synaptic
Zn2+ release made above. Figure 4B shows the time courses of autofluorescence signals
recorded in paired sets of wild-type and ZnT3 KO slices that were not bathed in FluoZin3. These signals are recorded at the same wavelength as used for FluoZin-3 studies
(495nm), and show small decreases that are due to a combination of flavoprotein
autofluorescence changes (Shuttleworth et al., 2003) and tissue swelling that
accompanies SD.

If differences in baseline fluorescence between unloaded tissues and

FluoZin-3 fluorescence are taken into account, the decrease in autofluorescence is
calculated to lead to an average underestimation of Fluozin-3 transients of 28.08 ± 5.00
% (n=4).

Figure 4C shows that tissue swelling responses (assessed by changes in
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transmitted light signals, rather than autofluorescence) were also identical in wild-type
and ZnT3 KO tissues.
Taken together, results from Figures 3 and 4 imply that: 1) Zn2+ release signals
are large, but underestimated due to slow binding to CaEDTA, and by concomitant
decreases in background autofluorescence; and 2) differences in autofluorescence
changes or tissue swelling do not underlie the difference between wild-type and ZnT3
KO data described above. These results reinforce the idea that FluoZin-3 increases
following OGD-SD are indeed due to synaptic Zn2+ release.

Responses to High K+ SD
Repetitive SD-like events have been proposed as an important contributor to the
spread of ischemic infarcts in animal models (Hossmann, 1996, Hartings et al., 2003) and
recent clinical recordings strongly support this idea for human ischemic stroke (Strong et
al., 2002, Dohmen et al., 2008).

To determine whether Zn2+ release pools are

significantly depleted by a single SD event, or alternatively whether significant Zn2+
release could occur during repetitive SD events, we examined responses to local
microinjections of KCl (high K+-SD, see Methods). This stimulus produces SD which
can be delivered repetitively without neuronal injury in superfused slices.
Figure 5A shows FluoZin-3 measurements in response to a pair of high K+-SD
responses. Similar to the OGD stimulus, K+-SD induced a large increase in FluoZin-3
fluorescence coincident with electrical SD recordings, that propagated with
characteristics consistent with SD (4.05 ± 0.30 mm/min, n=5). The second SD (triggered
15 min after the first) resulted in a very similar electrical SD and FluoZin-3 response. In
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a population of 5 slices (Figure 5B) there was no significant decrease in amplitude of
FluoZin-3 transients, and no change in the propagation rate of the responses (4.05 ± 0.30
vs. 4.09 ± 0.37 mm/min, p=0.93, respectively).
An additional set of experiments was performed to determine whether additional
rounds of SD might lead to some progressive decrement in the amplitude of responses.
Five SDs were generated in each slice (15 min interval between trials), and FluoZin-3
was included during the 1st and 5th trials. Intrinsic optical imaging was used to verify that
reproducible SDs were generated throughout the series (see Supplemental Figure 2), and
also showed that the propagation rate of the events was not altered (4.54 ± 0.16 vs. 4.61 ±
0.22 mm/min for 1st and 5th event, respectively, p=0.77, n=5).
Although there was no demonstrable change in the amplitude of FluoZin-3
transients, it was noted that first transient recovered somewhat more slowly to baseline
than in the second trial, although there was not a significant difference in the area of
responses (29.36±6.51 vs. 22.20±2.97 (%ΔF/F0)min, 1st vs. 5th, respectively, p=0.25, n=5
each). This may suggest some small additional, delayed Zn2+ release during the first
event, but it may also be due to tissue swelling that does not recover fully following the
first SD. The fact that there was no difference in the recovery of the 2 nd or 5th SDs
(supplemental Figure 2), provides some support for the latter possibility, since otherwise
a progressive decline in response area would be expected.
Figure 5B also shows that FluoZin-3 increases generated by high K+-SD are
abolished in ZnT3 KO preparations. As with OGD-SD in ZnT3 KO tissues, a small
propagating fluorescence decrease is noted, that is attributed to optical (autofluorescence
and swelling) changes that occur coincident with SD (see above). These observations
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imply that the first SD event does not deplete available synaptic Zn2+ pools, and that
repetitive SDs could lead to repetitive, large extracellular Zn2+ increases in the postischemic period.

Chelator and optical effects on high K+-SD responses
Figure 6 demonstrates that (like the situation with OGD-SD), the duration of Zn2+
accumulation is significantly underestimated due to CaEDTA binding. If CaEDTA is
omitted, Zn2+ increases persist for ~10min after each SD and the increases also invariably
appear biphasic, with a second peak occurring ~4-6 min after the onset of SD. These
biphasic signals could be the result of two distinct phases of Zn2+ release, but could also
be due to interruption of a monophasic Zn2+ signal by an optical artifact. Figure 6B
provides some support for the second possibility.

In these studies, the kinetics of

FluoZin-3 signals were directly compared with intrinsic optical signals (IOS), as
determined from transmission signals in un-labeled tissue (after FluoZin-3 washout in the
same tissues).

The IOS is attributed to rapid swelling of neurons associated with

propagation of SD and passive accumulation of extracellular K+ by astrocytes (Zhou et
al., 2010b). As can be seen, a large, delayed swelling response occurred at ~ 2min after
SD, and corresponded to the time course of the dip in the sustained FluoZin-3 increase. It
appeared that the second large peak in IOS interrupted the decay in FluoZin-3 response,
and indeed this was observed in all 4 preparations examined, with the delayed IOS peak
interrupting (at mean 2.39min, n=4) the decay in FluoZin-3 decline (peaks at 0.11 ±
0.02min and 4.53±0.61 min, n=4) in the same preparations. These findings do not rule
out a second delayed phased of Zn2+ release, but they are consistent with the possibility
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that Zn2+ increases following high K+-SD could involve a single large release event
which can be rapidly terminated by CaEDTA. Detection of prolonged increases (without
CaEDTA) may be interrupted by tissue swelling before a slow decline to baseline.

Intracellular accumulation of Zn2+ following SD
We examined whether Zn2+ released following SD is accumulated by postsynaptic
CA1 neurons. If this is the case, it could provide a significant source of Zn2+ that could
contribute to neuronal vulnerability and/or potentially contribute to preconditioning (see
Discussion). Postsynaptic Zn2+ increases were assessed following single-neuron injection
of FluoZin-3 via sharp microelectrodes, rather than by using bulk-loading with
membrane-permeable indicators, in order to minimize compartmentalization of indicator
and difficulty with effective bulk-loading of slices from 4-6 week old mice. The
recording electrode was withdrawn prior to the onset of SD.
Figure 7 shows mean intracellular FluoZin-3 increases from two sets of
experiments utilizing high K+ as a stimulus to trigger SD. In the first set, the recording
conditions were identical to that used in Figure 5 where CaEDTA was included in the
superfusate to remove contaminating Zn2+ and thereby improve signal/noise of
extracellular FluoZin-3 increases generated by SD. Here, the same approach was used to
test the possible contributions of extracellular contaminating Zn2+ to intracellular
FluoZin-3 responses following SD. As can be seen, in wild-type preparations, there were
robust intracellular Zn2+ increases in wild-type neurons. In contrast, there was not a
significant intracellular transient in ZnT3 KO slices, implying that the main source of
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Zn2+ available for entry after SD derived from presynaptic vesicles under these
conditions.
Figure 7B shows a parallel set of experiments, conducted without CaEDTA in the
superfusate. In these experiments, signals in wild-type preparations were larger than
observed without CaEDTA (p<0.03, n=5) and a significant postsynaptic transient is
demonstrable in ZnT3 KO tissues. It is possible that CaEDTA could contribute to
depletion of Zn2+ that is released intracellularly due to oxidative processes (Frederickson
et al., 2002). However as discussed below, an alternative interpretation of these findings
is that (if CaEDTA is not included) there is sufficient contaminating Zn2+ to cause
significant postsynaptic accumulation after SD, even without the additional source of
coordinated release of Zn2+ from synaptic vesicles.

2.5 Discussion
General
This study provides the first evidence that SD causes a coordinated release of
Zn2+ from nerve terminals that depolarize as the SD event propagates across a brain
region. Zn2+ release following OGD or localized high K+ stimulation propagated with
characteristics entirely consistent with SD, with the wavefront of FluoZin-3 increases
occurring coincident with the DC potential shift and progressing at ~2-5 mm/min across
the slice.

Similar release was observed with two different types of initiating stimuli,

suggesting that Zn2+ release could contribute to consequences of SD associated with
diverse conditions including brain ischemia, trauma and migraine aura. A single SD
event did not deplete the pool of releasable Zn2+, and Zn2+ released during SD was
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accumulated in postsynaptic neurons. Thus repetitive SDs that occur following ischemia
could provide a major source of Zn2+, that in turn could contribute to the progression of
ischemic brain injury.

Synaptic Zn2+ release
Zn2+ is accumulated in synaptic vesicles via the ZnT3 transporter (Palmiter et al.,
1996b), and evidence has accumulated that Zn2+ release is observed following electrical
stimulation of synaptic inputs (Frederickson et al., 2005, Sensi et al., 2009), including
from studies utilizing extracellular FluoZin-3 in hippocampal slices (Qian and Noebels,
2005, 2006).

Despite the fact that ZnT3 KO lack synaptic Zn2+, basic aspects of

excitatory transmission and brain function appear relatively normal (Cole et al., 1999,
Cole et al., 2001), but a recent report has described cognitive loss in aged ZnT3 KO
animals (Adlard et al., 2010). In the present study, SD was still generated in ZnT3 KO
tissues and appeared indistinguishable from SD in wild-type tissues, consistent with
previous conclusions that glutamateric transmission is not substantially impaired in these
tissues. The observation that FluoZin-3 increases due to SD were abolished in ZnT3 KO
tissues implies that these signals detected by the indicator are due to Zn2+ derived from
synaptic vesicles. The pattern of release was also consistent with synaptic release, as
largest increases were observed in regions involved in SD and with high synaptic density
(stratum oriens and radiatum, Fig 2B).
Although detection of Zn2+ in the extracellular space is usually interpreted to
imply Zn2+ is released and serves as a neurotransmitter/modulator (Qian and Noebels,
2005, Sensi et al., 2009), it has also been suggested that Zn2+ is not normally released, but
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remains loosely bound to extracellular binding sites exposed during stimulation (Kay,
2003). In the latter case, FluoZin-3 increases could occur as the high affinity indicator in
the extracellular space artificially removes Zn2+ from binding sites within vesicles, to
give the appearance of vesicular release. However the experiments in Figure 6 do not
utilize extracellular indicators that might interfere with release, and yet, Zn2+ increases
were detected in postsynaptic neurons following intracellular indicator injections. The
fact that intracellular Zn2+ transients were abolished in the ZnT3 KO tissues (Fig 6A)
strongly suggests that Zn2+ moves across the synapse and accumulates postsynaptically.
It is noted that SD is an exceptionally strong stimulus, involving coordinated and likely
severe depolarization of a large population of nerve terminals, and the conclusions here
may not apply to more moderate synaptic stimuli. However similar conclusions of
transsynaptic flux of Zn2+ have recently been made from bulk-loading of Newport green
into area CA1, and electrical stimulation of afferent fibers (Suh, 2009).

Other potential sources for extracellular Zn2+ increases during OGD
A previous study has reported that OGD and subsequent reperfusion in rat
hippocampal slices produces slowly-developing and sustained extracellular Zn2+
increases (Wei et al., 2004), that appear very different from the abrupt transient increases
we describe in the present study following the passage of SD. The different kinetics are
consistent with different sources of Zn2+, since in the prior study it was concluded that
release was not from synaptic vesicles, but rather was due to oxidative release from
intracellular binding proteins.

The slice preparation methods and recording conditions

between the two studies are quite different, and appear sufficient to prevent SD from
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being generated in the earlier study. It is also possible that the differences in recording
conditions made oxidative release of Zn2+ less prominent in our recording conditions,
since significant Zn2+ increases were not observed prior to SD in the current study,
including in experiments where CaEDTA was not included in the recording media.
However it seems likely that in intact brain, extracellular Zn2+ levels in peri-infarct areas
could increase due to a combination of oxidative release from damaged neurons, together
with periodic large synaptic Zn2+ release events as SDs sweep through a brain region.
Zn2+ elevations have been reported in microdialysis studies of forebrain ischemia and
middle cerebral artery occlusion in rats (Kitamura et al., 2006b, a), however studies with
higher temporal resolution will be required to determine whether there is pulsitile Zn 2+
release (due to SD) superimposed on an elevated Zn2+ baseline in different regions
surrounding an ischemic infarct.

Contaminating Zn2+
Zn2+ is likely present at low levels in most in vitro recording solutions, as a
contaminant of salts and also leached from glass and possibly stimulating electrodes
(Kay, 2004). One approach to remove the contributions of exogenous Zn2+ is to use
solutions containing CaEDTA, a chelator which binds Zn2+ with much higher affinity
than Ca2+ (Kay, 2004).

CaEDTA reduces background FluoZin-3 fluorescence to a

similar degree in wild-type and ZnT3 KO tissues (Supplemental Figure 1), suggesting
that synaptically-derived Zn2+ does not contribute significantly to basal Zn2+ levels in the
superfusate. Similar to previous descriptions of electrically-evoked FluoZin-3 transients
in hippocampal slice (Qian and Noebels, 2005), removing contaminating Zn2+ improved
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the signal-noise ratio of FluoZin-3 transients following SD, and was therefore used in
most of the experiments described in this study. However, some experiments were
conducted without CaEDTA to determine the possible contribution of contaminating Zn2+
to postsynaptic Zn2+ increases after SD (Fig 6B).
Ca2+ loading of CA1 pyramidal neurons is expected to occur following SD via
reverse operation of sodium-calcium exchangers, multiple voltage-dependent channels,
and possibly other non-selective cation channels (Somjen, 2001, Dietz et al., 2008).
Many of these pathways will also flux Zn2+ (Weiss et al., 2000), and thus any Zn2+ that
contaminates the recording solutions is likely to enter postsynaptic neurons following SD,
together with Zn2+ derived from the coordinated release from synaptic vesicles. Results
of Figure 6B, support this conclusion. When CaEDTA was present, significant FluoZin3 increases were observed in wild-type neurons but abolished in ZnT3 KO tissues. This
implies that synaptic release leads to accumulation close to influx sites that is rapid
enough to lead to significant influx before displacement of Ca2+ from the chelator. When
CaEDTA was not used, FluoZin-3 increases were larger, and importantly, were also
significant in cells from ZnT3 KO animals. This strongly suggests that contaminating
Zn2+ can enter during the large postsynaptic depolarization accompanying SD, together
with Zn2+ derived from synaptic vesicles. These observations may have implications for
other studies of Zn2+ accumulation, if significant amounts of free Zn2+ are present in
recording solutions and enter during postsynaptic activation.
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Possible consequences of synaptic Zn2+ release
Repetitive SD events accompany and appear to contribute to enlargement of
ischemic infarcts (Strong et al., 2000, Hartings et al., 2003, Dohmen et al., 2008). Zn2+
chelation has been demonstrated to reduce injury following global ischemia (Koh et al.,
1996, Calderone et al., 2004, Galasso and Dyck, 2007) and a large body of literature has
identified mechanisms coupling Zn2+ accumulation to neuronal injury (Choi and Koh,
1998, Weiss et al., 2000, Dineley et al., 2003, Sensi et al., 2009). It is therefore tempting
to speculate that large Zn2+ increases that occur following SD contribute to the
progression of ischemic injuries. Zn2+ increases could lead to disruption of mitochondrial
function and/or glycolysis (Sheline et al., 2000, Sensi et al., 2009) and serve as an
upstream trigger of deleterious neuronal Ca2+ overload (Medvedeva et al., 2009, Vander
Jagt et al., 2009b).
The fact that the vesicular release pool is not depleted by a single SD event
implies that there is either small fractional release and/or effective refilling of vesicular
Zn2+ pools between repetitive SD events. SDs could therefore provide a source for
substantial Zn2+ release throughout the post-ischemic period, as repetitive SDs have been
recorded for 10s of hours, or even days following experimental or clinical strokes (Strong
et al., 2002, Hartings et al., 2003, Dohmen et al., 2008).
While most studies have concentrated on deleterious functions of Zn2+ elevations,
it is also possible that a bolus of Zn2+ release could limit neuronal excitability and prevent
damage under some circumstances.

For example, Zn2+ is an effective inhibitor of

NMDA-type glutamate receptors (Sensi et al., 2009) and limiting flux through these
channels after SD has passed through a brain region could limit activation of excitotoxic
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processes. SD is also known to confer ischemic preconditioning, and Zn2+ release during
the event might contribute to this process, via mechanisms that have recently been
described for Zn2+ in cultured cortical neurons (Aras et al., 2009).
From these considerations, opposing effects of Zn2+ may underlie conflicting
reports of the consequences of Zn2+ chelation on infarction following focal ischemia,
where CaEDTA has been reported to both significant delay (Lee et al., 2002) and
aggravate injury (Kitamura et al., 2006c). It is possible SD-dependent Zn2+ release close
to an infarct core may contribute to injury, whereas important beneficial effects may be
derived from Zn2+ released as SD sweeps further through peri-infarct tissue.
Understanding the relative contribution of Zn2+ to injury at different times following
stroke should also be helpful to determine whether extracellular Zn2+ levels can be
effectively targeted to improve stroke outcome.

2.6 Figure Legends
Figure 2.1.

Synaptic Zn2+ release during OGD-SD. A: OGD-SD generated a

substantial extracellular FluoZin-3 increase in a wild-type C57Bl/6 preparation.
Representative traces that show FluoZin-3 response from a region of interest in stratum
radiatum, aligned to the electrical (DC) recording of SD by use of an extracellular
electrode at the same location. OGD was initiated at the arrow and present throughout
the remainder of the experiment. B: Identical recording conditions as in A, except in a
slice from a ZnT3 KO animal, which lacks synaptic Zn2+. SD was still generated under
these conditions (as indicated by the sharp DC shift), however the FluoZin-3 response
was abolished. C: Mean FluoZin-3 responses generated by OGD-SD from wild-type
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C57Bl/6 (n=6) and ZnT3 KO slices (n=5) indicating a synaptic origin of Zn2+ release
during OGD-SD.

Figure 2.2.

Propagation of extracellular Zn2+ increases following OGD-SD.

A:

Spread of FluoZin-3 increases across a wild-type C57Bl/6 slice during OGD-SD. The
brightfield image (left panel) shows the orientation of the slice (s.o., stratum oriens; s.p.,
stratum pyramidale; s.r., stratum radiatum; s.l.m., stratum lacunosum-moleculare). The
color panels are a series of 25 images taken at 3s intervals from this slice, showing the
spread of the event. Scale bar, 200µm. B: Summary data of regional differences in
FluoZin-3 increases generated by OGD-SD from the different hippocampal subfields of 4
wild-type C57Bl/6 preparations. Greatest increases were seen in s.r. and s.o.

C:

Coincidence between onset of FluoZin-3 increases and SD in the same population of
slices from B. FluoZin-3 and DC recordings are each both normalized to peak responses
and plotted against the time to SD onset (t=0), identified from the DC shift.

Figure 2.3.

Effects of CaEDTA on FluoZin-3 transients. A: FluoZin-3 transients in

the presence of CaEDTA. Representative trace from a wild-type C57Bl/6 slice showing
the change in raw fluorescence during FluoZin-3 and CaEDTA wash-in. FluoZin-3 and
CaEDTA were added to the extracellular recording solution (indicated by the arrows) and
were present throughout the remainder of the experiment. Addition of CaEDTA reduced
the fluorescence of FluoZin-3 and enhanced signal/noise. OGD was then administered
for the remainder of the experiment and the left side of the plot shows the FluoZin-3
response ~2min prior to the onset of SD. B: FluoZin-3 transients in the absence of
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CaEDTA. Representative trace showing the wash in of FluoZin-3 without CaEDTA.
The fluorescence remains elevated and following OGD administration, a similar FluoZin3 transient is observed during OGD-SD. C: CaEDTA significantly accelerated the rate
of decay of FluoZin-3 transients, and reduced the F of FluoZin-3 transients during
OGD-SD in wild-type tissues (n=5each).

Figure 2.4.

Factors influencing the amplitude of extracellular FluoZin-3 transients

during OGD-SD. A: Comparison of extracellular FluoZin-3 signals generated by strong
electrical stimulation of Schaffer collateral inputs (50 Hz, 1 sec), followed by OGD-SD
in the same preparation. Data collected from wild-type FVB/N slices, and are normalized
to OGD-SD peak responses in each slice (n=6). B: Autofluorescence changes are small
and opposite in sign to FluoZin-3 responses. Signals are from unlabeled preparations
(n=6, both groups), excited at the same wavelength (495nm) as utilized in FluoZin-3
studies. Error bars are smaller than the symbol size, and are overlapping for wild-type
C57Bl/6 (filled circles) and ZnT3-KO tissues (open squares).

C:

Tissue swelling

associated with SD is not responsible for difference in FluoZin-3 signals between wildtype and ZnT3 KO preparations. Mean intrinsic optical signals (see methods) from 6
wild-type C57Bl/6 and 6 ZnT3 KO preparations.

Figure 2.5.

Zn2+ release following high K+-SD. A: Representative images and plots of

extracellular FluoZin-3 and DC recordings during two episodes of high K+-SD in the
same wild-type C57Bl/6 preparation. Similar to OGD-SD, a large propagating FluoZin3 increase was observed with SD. Repetitive SDs could be generated with the high K+-
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stimulus, and little decrement in the peak amplitude of FluoZin-3 increases was observed.
The location of the K+-ejection pipette and the recording sites are indicated in the
brightfield image, and the color panels show the spread of FluoZin-3 increases during the
two SD events. Arrows on DC recording indicate when the microinjection of high K+
was administered. Elapsed time of each montages is ~1 min. B: Summary data showing
no significant decrease in peak FluoZin-3 increases with pairs of repetitive high K+-SD
trials (wild-type C57Bl/6, n=5), or when comparing the 1st and 5th SDs in a separate
series of experiments. Abolition of FluoZin-3 increases was observed in ZnT3 KO
tissues indicating synaptic release of Zn2+ during high K+-SD.

Figure 2.6.

Factors influencing the amplitude of FluoZin-3 transients during high K+-

SD. A: Like the situation with OGD-SD, omission of CaEDTA resulted in substantially
longer-lasting FluoZin-3 transients and revealed an additional component to the decay
phase. Responses to pairs of high K+-SD (15min interval) are shown in 1mM CaEDTA
(blue) and 0mM CaEDTA (red). B: Intrinsic optical signal changes are synchronous
with the interruption of the FluoZin-3 decay. The figure shows superimposition of
responses from a slice exposed to high-K+ bathed in FluoZin-3, followed by a washout
period and a second exposure to high-K+ measuring the intrinsic optical signal (IOS)
from the same slice (in the absence of FluoZin-3, see Methods).

A large delayed

swelling response reported by the IOS (peak ~2min) appeared to interrupt the slow decay
in the FluoZin-3 signal.
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Figure 2.7. Intracellular accumulation of synaptically released Zn2+ following high K+SD. Each plot shows mean intracellular FluoZin-3 increases from single CA1 neurons
loaded with FluoZin-3 via sharp microelectrodes (see Methods). SD was generated by
localized high K+ microinjection, as shown in Figs 5 and 6. A: In CaEDTA, a large
increase in intracellular Zn2+ accumulation can be seen in wild-type tissues (n=5, pooled
C57Bl/6 and FVB/N), but not in ZnT3 KO tissues (n=5). B: When experiments were
repeated without CaEDTA, intracellular FluoZin-3 increases were observed in both wildtype (n=5, pooled C57Bl/6 and FVB/N) and ZnT3 KO tissues (n=5) indicating that
contaminating extracellular Zn2+ also accumulates postsynaptically following high K+SD.

Supplemental Figure 2.1:

Extracellular FluoZin-3 fluorescence levels are virtually

identical in wild-type and ZnT3 KO tissues. Plots show FluoZin-3 wash-in in 11 wild
type (filled diamonds) and 10 ZnT3 KO slices (open diamonds).

After signals reach a

plateau level, CaEDTA (1mM) is added to reduce background signals, and results in
near-identical reductions in fluorescence in both wild-type and KO slices.

Supplemental Figure 2.2:

A: Optical and electrical (DC) recordings from a

representative slice subjected to five rounds of high K+-SD, where FluoZin-3 was present
during the 1st (a) and 5th (e) trial. Following the wash out of FluoZin-3 and CaEDTA,
three high K+-SDs were elicited (b-d), confirmed by sharp negative DC shifts.
Following the 4th SD, FluoZin-3 and CaEDTA were washed back in, and a 5th high K+SD was generated, showing little decrement in the peak response compared to the 1st
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FluoZin-3 response. B: Mean data showing the kinetics of the 1st and 5th FluoZin-3
responses to high K+-SD (n=5 each). A small, but not significant increase in recovery
rate was observed in the 5th response. C: Mean data from two different experiments
comparing the kinetics of the 2nd and 5th responses (n=5 each). A lack of increased
recovery was observed when comparing the 5th to the 2nd response, indicating that the
kinetics of the response is not increasing with each SD.
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Figure 2.3
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Figure 2.4
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Figure 2.5
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Figure 2.6
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3.1 Abstract
We previously reported Zn2+ chelation improved recovery of synaptic potentials
after transient oxygen and glucose deprivation in brain slices. Such an effect could be
due to reduced accumulation of Zn2+ in postsynaptic neurons, or could also be due to
prevention of the onset of spreading depression-like events. A combination of optical
and electrical recording was used here to demonstrate that Zn2+ chelation is effective
because it delays spreading depression-like events. If the duration of oxygen/glucose
deprivation was sufficient to generate a spreading depression-like event, irrecoverable
Ca2+-dependent loss of synaptic potentials occurred, regardless of Zn2+ availability.
These results identify a key mechanism underlying protective effects of Zn 2+ chelation,
and emphasize the importance of evaluating spreading depression-like events in studies
of neuroprotection.

3.2 Introduction
Transient removal of oxygen and glucose is widely used as an in vitro model of
aspects of ischemic brain injury (Lipton, 1999). When applied to brain slice preparations,
relatively short periods of oxygen and glucose deprivation are used (often 10 min) and
neuronal viability can be continuously monitored from the amplitude of evoked
excitatory postsynaptic potentials (EPSPs).

An initial suppression of EPSPs occurs

within minutes due to accumulation of adenosine and A1 receptor activation (Dale and
Frenguelli, 2009), however this suppression is readily reversible following restoration of
metabolic substrates. Longer periods of substrate removal can lead to persistent loss of
EPSPs which is indicative of neuronal injury (Kass and Lipton, 1982).
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We recently showed that chelation of Zn2+ significantly enhanced recovery of
EPSPs after a fixed 10 min period of oxygen and glucose deprivation in the hippocampal
CA1 region of murine brain slices (Medvedeva et al., 2009). Other studies have also
implicated Zn2+ accumulation in injury following substrate removal in rat hippocampal
slices (Stork and Li, 2009). The brain contains a large amount of Zn2+ (Frederickson et
al., 2000) and while levels of this cation are normally tightly regulated within neurons,
excessive Zn2+ accumulation is toxic to neurons (Choi and Koh, 1998, Bonanni et al.,
2006). The beneficial effects of Zn2+ chelation could be due to preventing deleterious
actions of Zn2+ on neuronal mitochondria or other intracellular targets in CA1 neurons
(Medvedeva et al., 2009).
An additional possibility is that Zn2+ chelation interferes with the onset of
spreading depression (SD)-like events in the brain slice model. SD is a coordinated
depolarization of neurons and glia that can occur in a variety of experimental and
pathological conditions including ischemia (Somjen, 2001), and a form of SD can be
readily initiated in brain slices by oxygen and glucose deprivation (Dietz et al., 2008)
(termed here OGD-SD). If metabolic substrates are not immediately available to restore
ionic gradients, OGD-SD causes rapid neuronal injury (Somjen, 2001), and these
responses may therefore be primary causes of neuronal injury in many slice ischemia
studies (Obeidat et al., 2000).

We recently showed that accumulation of Zn2+ can

contribute to the initiation of SD-like events in brain slices (Dietz et al., 2008), and in the
present study have examined whether delay of these events by Zn2+ chelation may be
sufficient to explain beneficial effects of this intervention.
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3.3 Materials and Methods
All procedures were performed in accordance with the National Institutes of
Health guidelines for the humane treatment of laboratory animals and the Institutional
Animal Care and Use Committee at the University of New Mexico.

Methods for

preparation of brain slices (350µm, coronal) were as described previously (Dietz et al.,
2008) using C57Bl/6 mice at 4-6 weeks of age of either sex.

Experiments were

performed on submerged slices, continuously superfused at 2 ml/min at either 32 or 35C
(see Results).

OGD-SD was monitored by intrinsic optical signals generated from

transmission of >590nm light. Extracellular measurements of slow DC potential shifts or
field EPSPs (fEPSPs) evoked by Schaffer collateral stimulation were made from stratum
radiatum of hippocampal area CA1. Electrical stimuli (70µs, 0.1Hz) were at a stimulus
intensity that generated a response 70% of maximal. The superfusion system allowed for
rapid (~0.5min) bath solution exchange after OGD-SD.
Superfusion buffer contained (in mM): 126 NaCl, 3 KCl, 1.25 NaH2PO4, 1
MgSO4, 26 NaHCO3, 2 CaCl2, and 10 glucose, equilibrated with 95%O2/5%CO2. Icecold cutting solution contained (in mM): 3 KCl, 1.25 NaH2PO4, 6 MgSO4, 26 NaHCO3,
0.2 CaCl2, 10 glucose, 220 sucrose, and 0.43 ketamine, equilibrated with 95% O2/ 5%
CO2.

For oxygen and glucose deprivation, buffer was modified by equimolar

replacement of glucose with sucrose and equilibrated with 95% N2/ 5% CO2. Nominally
Ca2+-free solutions were prepared by equimolar replacement of Ca2+ with Mg2+.
N,N,N’,N’-tetrakis(2-pyridylmethyl)-ethylenediamine

(TPEN)

was

obtained

from

Invitrogen and all other reagents were obtained from Sigma. TPEN was prepared fresh
daily as a 20mM stock in 0.25% DMSO. Data are reported as mean±standard error of the
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mean.

Significant differences between group data were evaluated using unpaired

Student’s t-tests.

3.4 Results
Irreversible loss of synaptic potentials following spreading depression-like events
Figure 1A shows the propagation of oxygen/glucose deprivation-induced
spreading depression (OGD-SD) as assessed by intrinsic optical imaging. A propagating
band of increased light transmission is a consequence of tissue swelling that accompanies
the coordinated depolarization (Andrew et al., 1999).

In this example, OGD-SD

propagated from left to right at 3.03 mm/min and evoked field potentials were abolished
coincident with passage of the SD wave front past the recording site. Figure 1B shows
mean data from five such experiments.

The mean onset time to OGD-SD was

12.7±0.2min and normal buffer was reintroduced into the chamber within 30 seconds of
the passage of OGD-SD past the microelectrode recording site. OGD caused an initial
loss of fEPSPs (to 7.8±1.0% baseline), and a transient period of recovery then occurred
~4min prior to the onset of OGD-SD (peak response of 51.8±7.3% baseline). This
transient recovery of fEPSPs has been described during anoxia and is thought to be due to
the accumulation of extracellular K+ (Sick et al., 1987). Coincident with passage of
OGD-SD, fEPSPs were abolished (Fig. 1C), and even though normal buffer was restored
quickly following the event, there were no signs of fEPSP recovery within the time frame
of these experiments.
In a separate set of experiments (n=7), slices exposed to brief episodes of OGD (7
min) that were not sufficient to produce SD were compared with exposures sufficient to
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generate OGD-SD. The short exposures produced a transient loss of fEPSPs (6.5±0.8%
baseline) that recovered to near baseline levels (90.1±2.3%) after 15 min restoration of
normal buffer. When the same slices were then subjected to OGD-SD (mean onset time
of 10.2 ± 0.3min) an irrecoverable loss of fEPSPs (to 3.5±0.5% baseline) was observed,
consistent with results shown in Figure 1B.

These results are consistent with the

hypothesis that the deleterious consequences of SD are responsible for the persistent loss
of field potentials following transient OGD exposures.

Delay of spreading depression-like events by Zn2+ chelation
We recently showed that chelation of Zn2+ with TPEN (KDZn=10-15.6M; KDCa=104.4

M (Arslan et al., 1985)) can inhibit the initiation of some forms of spreading depression

in hippocampal slices (Dietz et al., 2008).

That prior study identified conditions

(including activation of A1 receptors with exogenous application of an A1 receptor
agonist) where Zn2+ chelation was sufficient to prevent the onset of spreading depression
generated by the Na+/K+/ATPase inhibitor, ouabain. It was also shown that OGD-SD
could be delayed or prevented by Zn2+ chelation (Dietz et al., 2008). We confirmed a
small but significant delay in OGD-SD onset using a combination of intrinsic optical
recording and DC recordings of slow potential shifts (Somjen, 2001) under the recording
conditions of the current study (no A1 agonists) (12.0±0.5 vs 14.5±0.4 min, control and
TPEN, respectively, n=6, p<0.001). This difference appeared potentially large enough to
explain beneficial effects of Zn2+ chelation, depending on the duration of the challenge
with oxygen and glucose removal.
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Lack of injury if Zn2+ chelation prevents OGD-SD during transient challenges
From the results above, a set duration (13min) of oxygen and glucose removal
was chosen as a test challenge, to test whether beneficial effects of TPEN were due to
preventing OGD-SD onset.

With 13 min challenges, OGD-SD should always be

generated in vehicle controls, while TPEN-exposed preparations should never experience
OGD-SD during these exposures. Indeed, as shown in Figure 2, a 13min oxygen and
glucose removal challenge in the presence of TPEN (50M, 20min pre-exposure, n=5,
open triangles) produced only a transient loss of fEPSPs (to 8.91.2%), followed by full
recovery of fEPSPs to pre-stimulus levels (to 109.913.5% baseline). This significant
protection was due to TPEN, since in matched vehicle controls, OGD-SD was generated
by this 13 min exposure and resulted in irrecoverable loss of synaptic potentials (filled
circles).
A separate set of studies was conducted to monitor fEPSP responses to OGD in
the presence of TPEN. Figure 2C shows that if SD is allowed to occur, there is no
significant benefit from Zn2+ chelation. In these experiments, OGD was maintained until
SD occurred in the presence of TPEN (onset 14.00.4 min, n=5) and rapid restoration of
normal buffer did not restore synaptic function (6.00.5% at 60 min). Together, these
results imply that preventing Zn2+ accumulation is not sufficient to prevent neuronal
injury following OGD-SD, but Zn2+ chelation can completely prevent neuronal injury by
preventing the onset of SD during transient OGD exposures.
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Contribution of Ca2+ to persistent neuronal injury after OGD-SD
A final set of experiments confirmed that excessive Ca2+ (rather than Zn2+)
accumulation following OGD-SD is the most likely contributor to neuronal injury
following OGD-SD in slice (Fig 3). Effects of Ca2+ removal were tested by exposure to
modified buffer lacking added Ca2+ and without addition of any chelators (nominally
Ca2+-free, estimated free Ca2+ ~ 4µM (Chinopoulos et al., 2007)). Under the recording
conditions used in studies above (300µm slices at 32°C), SD could not be generated by
OGD in nominally Ca2+-free buffer (n=3), and alternative recording conditions were
identified (350µm slices at 35°C) that allowed reliable generation of OGD-SD in
nominally Ca2+-free buffer. Ca2+ was removed 5min prior to onset of OGD exposures,
and Ca2+-free conditions maintained for a further 5 min after OGD exposure. Under
these conditions, SD was generated at 5.50.4min (n=5), compared with 6.40.6min
(n=5) in normal buffer. After OGD-SD no recovery of fEPSPs was observed in slices
with Ca2+ present throughout, but a substantial recovery of fEPSP amplitude (to
69.28.2%) was seen in slices where Ca2+ was not available during the passage of SD.
These results contrast with the lack of effect of Zn2+ removal in slices where SD was
allowed to occur (Fig 2C), and confirm that Ca2+ (rather than Zn2+) is a main contributor
to persistent loss of synaptic activity following SD events triggered by OGD.

3.5 Discussion
Zn2+ accumulation is strongly implicated in ischemic neuronal injury, and there is
significant interest in understanding the cellular and molecular mechanisms underlying
Zn2+ toxicity (Choi and Koh, 1998, Weiss et al., 2000, Sensi et al., 2009). Studies of
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dispersed neuronal cultures have identified pathways that contribute to Zn2+ toxicity
during excessive glutamate receptor activation or challenge with oxygen and glucose
deprivation (OGD) (Sensi et al., 1999, Dineley et al., 2002, Yin et al., 2002, Dineley et
al., 2008).

When OGD is undertaken in brain slices, deleterious Zn2+ dependent

mechanisms that have been identified in dispersed cultures may be activated in neurons.
However in brain slices, OGD also triggers a profound depolarization event that
propagates slowly through the well-organized structure of the slice (Obeidat et al., 2000,
Somjen, 2001, Dietz et al., 2008).

These events share many similarities with the

phenomenon of spreading depression (SD), and cannot be generated in dispersed
cultures, as the very large extracellular volume prevents glutamate and K+ levels
accumulating to threshold concentrations for maintaining a feed-forward depolarization.
The results of the present study indicate that beneficial effects of Zn2+ chelation in the
brain slice OGD model can be attributed to prevention of the onset of OGD-SD. Other
deleterious effects of intracellular Zn2+ accumulation may be activated in CA1 neurons
during the OGD exposure, however preventing these effects is not sufficient to prevent
the injury caused by massive Ca2+ accumulation if SD occurs during this challenge.
It is not fully understood how Zn2+ contributes to the onset of OGD-SD, but
mitochondrial disruption is one possibility (Dietz et al., 2008, 2009, Medvedeva et al.,
2009). As a note, relatively high concentrations (0.4%) of the vehicle used here (DMSO)
have been reported to delay the onset of SD induced by hypoxia (Hulsmann et al., 1999).
However no delay was observed with the lower DMSO concentrations used here (0.25%,
data not shown) and since this vehicle was included all experiments, DMSO effects are
not expected to explain the delay of SD and subsequent recovery seen by TPEN.
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In previous work, removal of Ca2+ following SD induced by OGD restored
membrane potential (Tanaka et al., 1999). Consistent with those results, removal of Ca2+
during OGD-SD allowed for partial recovery of fEPSPs, indicating that the Ca2+ overload
during OGD-SD (Dietz et al., 2008) is primarily responsible for the persistent depression
of synaptic activity. The residual injury could be due to incomplete removal of Ca2+, but
since our previous study showed an enhanced recovery after OGD with combined
removal of Zn2+ and Ca2+ (Medvedeva et al., 2009), we attempted to determine whether
the combined removal would enhance synaptic recovery following SD. However under
these slice and recording conditions, we were not able to induce OGD-SD with both Ca2+
and Zn2+ removal, as confirmed by a lack of a DC shift and intrinsic optical signals (n=6,
data not shown). This is in agreement with our prior report under different recording
conditions and conclusion that both cations contribute to SD initiation (Dietz et al., 2008,
2009). However, because of this block of OGD-SD it is currently unknown whether Zn2+
accumulation following SD can contribute with Ca2+ to neuronal injury. It is possible
that in preparations that do not undergo SD, postsynaptic Zn2+ accumulation contributes
to different forms of injury.

3.6 Conclusion
These results suggest that delay of the onset of OGD-SD can be sufficient to
explain the beneficial effects of Zn2+ chelation in a slice model of ischemia. Such effects
could be important for limiting the spread of ischemic injury in vivo.

Additional

deleterious effects of Zn2+ accumulation may also contribute significantly to injury, in
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other ischemia models or conditions where massive ionic disruptions associated with SD
events are not the predominant causes of injury.

3.7 Figure Legends
Figure 3.1:

Onset of persistent synaptic inhibition coincident with OGD-SD. A.

Monitoring propagation of SD by intrinsic optical imaging. Representative bright-field
image (showing placement of electrodes) and montage illustrating OGD-SD propagation
across CA1 hippocampal subfield. Scale bar 200µm, image interval 1.5s, advancing
wave front indicated by bright band. B. Loss of fEPSPs during OGD. OGD was
continued in each slice until SD was visualized, and then the superfusate was rapidly
switched back to normal buffer. A transient recovery of fEPSPs occurred immediately
prior to OGD-SD, and was followed by persistent (>1hr) inhibition (n=5).

Inset:

Representative fEPSP traces at time courses depicted on mean data plot. C: Correlation
between OGD-SD onset and loss of fEPSPs (r2 = 0.99).

Figure 3.2:

Delay of OGD-SD by TPEN was responsible for recovery of fEPSPs. A.

In these experiments, the duration of OGD was fixed (13 min), so that under vehicle
conditions OGD always produced SD (n=5, circles) but the OGD duration was never
long enough to generate SD in TPEN slices (50µM, n=5, triangles).

fEPSPs were

abolished in control, but fully recovered in TPEN. Lower panels show representative
traces of fEPSPs during time points indicated in the plot. B. In contrast, if OGD was
maintained until SD was generated in TPEN slices (average 14.03  0.38 min, n=5) no
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recovery of fEPSPs was observed. Inset: Representative fEPSPs traces at times indicated
on mean plot.

Figure 3.3:

Ca2+ influx was responsible for irrecoverable synaptic loss following

OGD-SD. A. Slices superfused with Ca2+-free buffer during OGD (and 5min pre-, postexposure) showed partial recovery of fEPSPs even after the generation of OGD-SD
(squares), when compared with paired control slices which showed irrecoverable fEPSP
loss (n=5, both groups).

B.

Representative fEPSP traces taken from time points

indicated on mean plot.
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4.1 Abstract
Spreading depolarization (SD) is a feed-forward wave that propagates slowly
throughout brain tissue and recovery from SD involves substantial metabolic demand.
Presynaptic Zn2+ release and intracellular accumulation occurs with SD, and elevated
intracellular Zn2+ ([Zn2+]i) can impair cellular metabolism through multiple pathways.
We tested here whether increased [Zn2+]i could exacerbate the metabolic challenge of SD,
induced by KCl, and delay recovery in acute murine hippocampal slices. [Zn2+]i loading
prior to SD, by transient ZnCl2 application with the Zn2+ ionophore pyrithione (Zn/Pyr),
delayed recovery of field excitatory post-synaptic potentials (fEPSPs) in a concentrationdependent manner, prolonged DC shifts, and significantly increased extracellular
adenosine accumulation. These effects could be due to metabolic inhibition, occurring
downstream of pyruvate utilization. Prolonged [Zn2+]i accumulation prior to SD was
required for effects on fEPSP recovery and consistent with this, endogenous synaptic
Zn2+ release during SD propagation did not delay recovery from SD. The effects of
exogenous [Zn2+]i loading were also lost in slices preconditioned with repetitive SDs,
implying a rapid adaptation. Together, these results suggest that [Zn2+]i loading prior to
SD can provide significant additional challenge to brain tissue, and could contribute to
deleterious effects of [Zn2+]i accumulation in a range of brain injury models.

4.2 Introduction
Spreading depolarizations (SD) are waves of neuronal and glial depolarization
that propagate slowly throughout brain tissue (Leao, 1944c, Somjen, 2001).

SD is

commonly recorded as a large extracellular negative direct current (DC) potential shift
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and results in a transient suppression of both electrocorticographic activity (Leao, 1947,
Somjen, 2001). Large amounts of energy are required to restore ionic gradients before
normal function can return, as demonstrated by large reductions in ATP and glucose
levels following SD (Shinohara et al., 1979, Mies and Paschen, 1984). Extracellular
adenosine accumulation occurs with severe metabolic challenges (Dale et al., 2000,
Dunwiddie and Masino, 2001), and can contribute to the transient suppression of field
excitatory postsynaptic potentials (fEPSPs) in brain slice models of SD (Lindquist and
Shuttleworth, 2012). In healthy brain tissue SD is not injurious (Nedergaard and Hansen,
1988), however under conditions where metabolism is already compromised, such as in
ischemic brain tissue, the additional metabolic challenge of repetitive SD events can lead
to irrecoverable damage (Busch et al., 1996, Hartings et al., 2003). A growing body of
literature from both animal and human recordings suggests that clusters of SDs can be a
significant contributing factor to the enlargement of acute brain injuries (Nakamura et al.,
2010, Oliveira-Ferreira et al., 2010, Dreier, 2011, Hartings et al., 2011a, Lauritzen et al.,
2011).
We have recently demonstrated a significant release of synaptic Zn2+ following
SD, and subsequent intracellular accumulation (Carter et al., 2011). Zn2+ is highly
regulated and normally kept at very low intracellular levels, however excessive
intracellular Zn2+ ([Zn2+]i) accumulation has been associated with a wide range of brain
injuries including ischemia and trauma (Sensi et al., 2011, Shuttleworth and Weiss,
2011). It is not yet known whether release and accumulation of Zn2+ following SD may
be a significant contributor to Zn2+ toxicity in a variety of brain injury settings. One
mechanism for toxic effects of Zn2+ involves disruption of cellular energy production.
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Zn2+ can directly bind to and inhibit both glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, (Sheline et al., 2000)) and the α-ketoglutarate dehydrogenase complex
(KGDHC, (Brown et al., 2000)), inhibiting glycolysis and the TCA cycle, respectively.
Additionally, Zn2+ can inhibit several steps in the mitochondrial electron transport chain
(ETC) (Dineley et al., 2003, Sharpley and Hirst, 2006). Indirectly, Zn2+ can also inhibit
metabolism by activating NAD+-catabolizing enzymes such as poly(ADP-ribose)
polymerase 1 (PARP-1) and the sirtuin family of proteins (Sheline et al., 2000, Cai et al.,
2006), depleting NAD+ levels and inhibiting glycolysis.
The aim of the current study was to determine whether increasing [Zn2+]i can
exacerbate the delay in recovery from SD. The results suggest that when [Zn2+]i levels
are sufficiently elevated prior to the passage of SD, there is a marked additional
metabolic challenge, leading to delayed recovery of synaptic transmission.

4.3 Materials and Methods
Slice preparation and recording
All procedures were carried out in accordance with the National Institutes of
Health guidelines for the humane treatment of laboratory animals, and the protocol for
these procedures was reviewed annually by the Institutional Animal Care and Use
Committee (IACUC) at the University of New Mexico School of Medicine. Acute
hippocampal brain slices (350µm) were prepared from wild type C57Bl/6J and ZnT3 KO
mice of either sex (4-8 weeks old). After cutting in ice-cold cutting solution and then
holding for 1hr at 35oC, artificial cerebrospinal fluid (ACSF) was changed, and slices
were held at room temperature until used for recording. Individual slices were then
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transferred to the recording chamber, and superfused with oxygenated ACSF at 2mL/min
at 32oC. Mice homozygous for deletion of the ZnT3 gene were originally obtained from
Dr. Richard Palmiter (Cole et al., 1999) and backcrossed onto C57Bl/6J for >13
generations (LSUHSC). A homozygous breeding colony of ZnT3 KO animals was then
established at the University of New Mexico.
Extracellular measurements of field excitatory postsynaptic potentials (fEPSPs),
were made via stimulation of Schaffer collaterals with a concentric bipolar electrode
(CBAEC75, FHC, Bowdoin, ME, USA). Stimulation intensity was set to achieve ~60%
maximum response during recording sessions. Extracellular recordings of fEPSPSs and
direct current (DC) shifts were made by glass microelectrodes (~2-5MΩ), filled with
ACSF and placed in stratum radiatum of CA1 ~50 μm below the surface of the slice.
Spreading depolarization (SD) was induced by brief pressure pulses (30psi, 80-100ms) of
1M KCl from a homemade picospritzer (UniBlitz Model D122, Vincent Associates,
Rochester, NY, USA; valve: 3-165-900, General Valve Corporation, Fairfield, NY,
USA). Onset and propagation of SD was monitored by intrinsic optical signals (IOS),
generated by transmission of red light through the tissue (>575nm). Propagation rate and
IOS analyses were performed in TillVision (Till Photonics, Rochester, NY, USA).
Comparison of fEPSP recovery between groups was defined by the time for fEPSPs to
return to 50% pre-SD levels (t50), unless stated otherwise.

Intracellular Zn2+ loading
To simulate conditions in which [Zn2+]i levels were increased, we used a transient
exposure (20min) to pyrithione (Pyr, 5µM) in the presence of 0, 30, or 100µM ZnCl 2
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(Zn/Pyr). This was followed by a 10min washout prior to SD induction to minimize
possible contributions of increased extracellular Zn2+ during the passage of SD (Aiba et
al., 2012). Histidine (His, 200µM) was present during all Zn/Pyr exposures to help
solubilize Zn2+ and prevent it from precipitating out of solution (Rumschik et al., 2009).

Adenosine measurements
Measurements of extracellular adenosine accumulation were performed as
previously described (Lindquist and Shuttleworth, 2012).

Briefly, enzyme-coupled

electrochemical probes (SBS-ADO-05-50, Sarissa Biomedical, Coventry, UK) generate
an amperometric signal proportional to the concentration of adenosine. Measurements
reported here are estimates of accumulation at the slice surface, and synaptic levels may
be different due to transporter activities within the slice. Calibration of the probes with
exogenous adenosine (5-50µM) was performed immediately following individual
recording sessions. It is noted that in the present study calibration stocks were made
daily, and estimates of adenosine levels following SD are ~10-fold lower than previously
reported (Lindquist & Shuttleworth 2012). Adenosine probes were positioned between
the bipolar stimulating and recording electrodes in stratum radiatum of CA1.

Reagents and solutions
Slice cutting solution contained (in mM): 3 KCl, 1.25 NaH2PO4, 6 MgSO4, 26
NaHCO3, 0.2 CaCl2, 10 glucose, 220 sucrose, and 0.43 ketamine. ACSF contained (in
mM): 126 NaCl, 3 KCl, 1.25 NaH2PO4, 1 MgSO4, 26 NaHCO3, 2 CaCl2, and 10 glucose,
equilibrated with 95%O2 / 5%CO2. N,N,N’,N’-tetrakis(2-pyridylmethyl)-ethylenediamine
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(TPEN) was obtained from Intvitrogen (Carlsbad, CA, USA). All other reagents were
obtained from Sigma (St. Louis, MO, USA).

Statistical Analysis
Data are reported as mean±standard error of the mean (S.E.M.).

Statistical

analysis was performed in GraphPad Prism (La Jolla, CA, USA) using paired or unpaired
Student’s t-test, or analysis of variance (ANOVA), with Bonferroni correction for
multiple comparisons where appropriate. Differences were considered significant when
p<.05.

4.4 Results
Effects of transient [Zn2+]i loading on fEPSP suppression following SD
Transient loading of [Zn2+]i (using pyrithione, see methods) prior to SD resulted
in significant delay in recovery of fEPSPs after SD. In slices not loaded with Zn2+ (5µM
Pyr control), SD resulted in fEPSP amplitude suppression that took 11.22±0.95min (n=6)
to return to baseline levels (Fig 1A), similar to previously published data (Lindquist and
Shuttleworth, 2012). [Zn2+]i loading produced a concentration-dependent increase in the
duration of fEPSP suppression following SD (Fig 1A) and final fEPSP amplitudes
remained substantially depressed 25min following SD with the higher Zn2+
concentrations (30 & 100µM).
We noted a slight run-down of fEPSP amplitude immediately prior to the onset of
SD when slices were loaded with Zn2+. Therefore a set of time-control studies was
completed to test whether progressive run-down of fEPSP amplitude alone (without SD)
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could have produced the results seen. Thus slices were loaded with 0, 30, or 100µM
Zn/Pyr (20min followed by wash out) without inducing SD (Fig 1B). Figures 1C&D
compare the effects of [Zn2+]i loading on final fEPSP amplitudes (assessed at the same
time point, i.e. 60min from start of recording) with and without the additional challenge
of SD.

A concentration-dependent increase in fEPSP run-down was detected even

without SD, but the degree of suppression was greatly increased by the combination of
Zn2+ with SD.

[Zn2+] i loading increased DC shift duration
We next assessed the characteristics of SDs, generated under the conditions
shown in Figure 1A. In Pyr control slices, the waveform and duration of DC shifts were
similar to those previously described (Somjen, 2001) and recorded under near-identical
conditions without Pyr (Aiba and Shuttleworth, 2012) (Figure 2A). Following [Zn2+]i
loading, the duration of DC shifts were markedly increased (Figure 2B) in a
concentration-dependent manner. Propagation rates of SD were assessed using IOS
signals (see Methods) and no significant changes in rates were observed (Figure 2C).
The effects of [Zn2+]i loading on DC shift duration are consistent with previous reports
that impaired metabolism is associated with increased DC shift duration and worse
clinical outcome (Hartings et al., 2011b).
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Extracellular adenosine accumulation and A1R activation following SD with [Zn2+] i
loading
Impaired metabolism can lead to increased adenosine accumulation (Dunwiddie
and Masino, 2001).

It was recently shown in brain slices that secondary fEPSP

suppression after SD is mainly mediated by extracellular adenosine accumulation and
activation of adenosine A1 receptors (A1Rs) (Lindquist and Shuttleworth, 2012). As
shown in Figure 3A, pre-exposure to a selective A1R antagonist (8-cyclopentyl-1,3dipropylxanthine, DPCPX, 200nM), significantly decreased the duration and degree of
fEPSP suppression after SD with [Zn2+]i loading, compared to the suppression shown in
Figure 1.

The degree of fEPSP suppression under these different conditions is

summarized in Figure 3B. These results are consistent with the effective reversal of
secondary fEPSP suppression described previously (Lindquist and Shuttleworth, 2012),
and imply that the sustained suppression observed in Figure 1A is largely due to A1
receptor activation rather than neuronal injury.
We next tested whether additional extracellular adenosine accumulation
contributed to the A1R-mediated fEPSP suppression seen above. Estimated extracellular
adenosine concentration was measured at the slice surface using an enzyme linked probe
(see Methods). A test concentration of 30µM Zn/Pyr in combination with SD was chosen
as these conditions resulted in a substantial suppression of fEPSPs (see Fig 1A) that was
completely mediated by A1R activation (see Fig 3A). Estimated peak extracellular
adenosine accumulation during SD was significantly greater when [Zn2+]i loading was
combined with SD (Fig 3C, n=5 each). To test whether exogenous adenosine could
replicate the effects of Zn/Pyr exposure, adenosine (50µM) was applied immediately
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following the induction of SD in a separate set of experiments (Fig. 3D). The recovery of
fEPSPs following SD was significantly decreased by exogenous adenosine, compared
with control slices (Fig. 3D). Together, these findings suggest that the enhanced fEPSP
suppression by [Zn2+]i loading with SD was mediated predominantly by increased
extracellular adenosine and A1R activation.

Potential intracellular targets for [Zn2 +] i loading effects
We next tested potential mechanisms which could link [Zn2+]i loading to
metabolic inhibition. Enhanced levels of [Zn2+]i can deplete NAD+ and thereby inhibit
glycolysis either by induction of poly(ADP-ribose) polymerase 1 (PARP-1) or activation
of SIRT protein pathways (Sheline et al., 2000, Cai et al., 2006). These possibilities were
tested by using selective inhibitors for either PARP-1 (3,4-dihydro-5-[4-(1piperidinyl)butoxyl]-1(2H)-isoquinolinone DPQ, 25µM) or SIRT (sirtinol, 30µM). As
shown in Figure 4, DPQ with 30µM Zn/Pyr did not increase fEPSP recovery compared to
vehicle treated slices with 30µM Zn/Pyr (p=.073, n=8 each). In addition, slices preexposed to sirtinol with 30µM Zn/Pyr did not result in a significant recovery of fEPSPs
following SD when compared with preparations exposed to Zn/Pyr alone (p=.8, n=3, data
not shown).
In a third set of slices, 5mM pyruvate was superfused for the entire recording
session to provide additional TCA metabolic supplementation. In the presence of 5mM
pyruvate, fEPSPs suppression following SD was not significantly different compared to
slices exposed to 30µM Zn/Pyr alone (Fig 4B, n=6 each).

Additionally, in slices

supplemented with lactate (5mM), fEPSP suppression following 30µM Zn/Pyr with SD
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was similar to slices without exogenous lactate (p=.6, n=3, data not shown). Taken
together, these results suggest that [Zn2+]i loading with SD may lead to increased
extracellular adenosine accumulation via mechanisms downstream of glycolysis and
pyruvate utilization.

Intracellular accumulation prior to SD is required for Zn2+ effects
To test whether the enhanced fEPSP suppression (seen in Fig 1A) was indeed a
result of [Zn2+]i accumulation and not a result of an extracellular of Zn2+, a set of slices
was exposed to 30µM ZnCl2 in the absence of Pyr. Figure 5A shows full recovery of
fEPSPs to pre-SD levels following 30µM ZnCl2 application (n=6), indicating that the
enhanced suppression of fEPSPs seen in Figure 1A was due to intracellular accumulation
and action of Zn2+. As seen in Figure 1, a small but significant decrease in fEPSP
amplitude was also seen upon the addition of 30µM ZnCl2 prior to SD induction
(baseline: 101.2±1.62 vs. pre-SD: 89.41±3.05, p<.01).
We next tested whether [Zn2+]i loading prior to SD was required for the observed
effects on fEPSPs (as seen in Fig 1A). To test this, Zn/Pyr application was begun only
5min before SD induction to allow equilibration within the slice prior to the SD
challenge. In contrast to the results shown in Figure 1, this exposure resulted in no
combined effect of 30µM Zn/Pyr with SD (Fig 5B).

Together, these data suggest

sufficient time is required (>5min) to allow for [Zn2+]i accumulation and activation of
intracellular targets to generate a significant effect on fEPSP suppression when combined
with SD.
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Contributions of endogenous Zn2+
We next evaluated whether intracellular accumulation of endogenous Zn2+
contributes to the metabolic burden of SD, and prolonged fEPSPs recovery. We first
tested whether removal of all chelatable Zn2+ with a membrane permeable Zn2+ chelator
(TPEN, 20µM throughout entire recording session) would influence fEPSP recovery
from SD. TPEN pre-exposure resulted in a significant increase in the rate of fEPSP
recovery after a single SD challenge (Fig 6A). Interestingly, there also was a significant
increase in the fEPSP amplitude following SD in TPEN that was not observed in vehicle
slices (TPEN baseline vs. post-SD amplitude: 99.80±1.14 vs. 107.6±1.40, p<.01; Vehicle
baseline vs. post-SD amplitude: 99.32±0.74 vs. 100.5±1.99, p=.58, n=6 all groups).
We next tested potential sources of endogenous Zn2+ responsible for these effects.
Zn2+ can be accumulated to high concentrations in many glutamatergic terminals, as a
consequence of loading via the transporter ZnT3 (Cole et al., 1999). As terminals
depolarize during the propagation of SD, a significant release of synaptic Zn2+ occurs and
can be visualized as a propagating wave of extracellular Zn2+ accumulation (Carter et al.,
2011). Since significant postsynaptic [Zn2+]i accumulation also occurs after SD (Carter et
al., 2011), we investigated here whether endogenous synaptic Zn2+ release during SD
could provide an additional metabolic burden to subsequent SDs. To test this, a series of
three SDs were induced at 20min intervals, to allow sufficient time for uptake and
activation of intracellular targets following Zn2+ release from the first SD (see section 5
above) to influence recovery from prior SDs. However, as shown in Figure 6B, there was
no stepwise increase in the duration of fEPSP recovery after multiple SDs, suggesting
that synaptic Zn2+ release may not be a significant contributor. Figures 6C&D are
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consistent with this, as there was no difference in fEPSP recovery after SD in slices from
ZnT3 knockout animals, when compared with wild-type animals.
The results shown in Figure 6 were surprising, since we previously showed that
there is no evidence of run-down of synaptic Zn2+ release during repetitive SDs (Carter et
al., 2011), and the figures above suggest that repetitive [Zn2+]i accumulation in advance
of SD should lead to delayed functional recovery. Figure 7 provides an explanation for
this apparent discrepancy, showing two consecutive SDs separated by 20min, with
similar recovery rates as shown in Figure 6D. We next tested whether exogenous [Zn2+]i
loading with Zn/Pyr was still effective in suppressing fEPSPs in these slices following
repetitive SD. Interestingly, the effects of Zn/Pyr on the enhanced fEPSP suppression
described above (in SD-naïve slices, Fig 1A) were completely lost under conditions
following repetitive SD (Fig 7A, n=6). A set of time-control experiments showed that
exogenous [Zn2+]i loading was still effective in slices where repetitive SDs were not
generated (Fig 7B).
Figure 7C shows extracellular adenosine measurements under these conditions of
repetitive SD shown in Figure 7A&B. In slices pre-exposed to two SDs, subsequent
Zn/Pyr addition did not produce any increase in the amplitude of extracellular adenosine
following SD. This is consistent with the lack of effect of Zn/Pyr exposure in Figure 7A.
In time-control slices not previously exposed to SDs (matching Fig. 7B), there was still a
significant increase in extracellular adenosine accumulation by Zn/Pyr with SD.
Exogenous adenosine application (25µM) following the end of the recording session
produced similar decreases in fEPSPs under both SD pre-exposed and time-control
conditions (final fEPSP amplitudes: 28.29±3.14 vs. 28.16±2.56% baseline, SD pre-
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exposed vs. time-control respectively, p=0.97, n=5 each). These results suggest that the
loss of effectiveness of Zn/Pyr on fEPSP recovery is likely a consequence of decreased
extracellular adenosine accumulation, rather than a change in sensitivity of synaptic
transmission to adenosine, or other desensitization mechanisms.

4.5 Discussion
General
This study assessed the contributions of [Zn2+]i accumulation to the recovery from
spreading depolarization (SD) in acute hippocampal brain slices.

Transient [Zn2+]i

loading with pyrithione (Zn/Pyr) appeared enhance the metabolic burden following SD,
measured by enhanced fEPSP suppression, prolonged extracellular DC shift durations,
and increased extracellular adenosine accumulation. Transient [Zn2+]i loading alone led
to a slow run-down of fEPSPs, however when combined with SD, the cumulative
metabolic challenge was significantly enhanced.

Endogenous Zn2+ release and

accumulation during SD propagation did not lead to a significant delay in fEPSP
recovery. This could be explained by the need for sufficient time prior to SD for [Zn2+]i
accumulation to have significant additive effects, as well as competition with a rapid
adaptive mechanism activated following SD that confers resistance to [Zn2+]i effects
during repetitive SDs in the brain slice model.

Additional adenosine accumulation following [Zn2+] i loading together with SD
Previous work has demonstrated accumulation of extracellular adenosine and
suppression of evoked fEPSPs under metabolically compromised conditions (Rudolphi et
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al., 1992b, Masino et al., 1999). Such a mechanism appears to explain the additive effect
of Zn2+ with SD in the current study, as extracellular adenosine accumulation was
significantly enhanced by [Zn2+]i loading, and the A1R antagonist DPCPX improved
fEPSP recovery (Fig 3A). The adenosine measurements reported here are estimates of
adenosine concentrations at the slice surface, determined by comparison with exogenous
adenosine applications (Lindquist and Shuttleworth, 2012).

Concentrations of

endogenous adenosine at synaptic sites within slices may be quite different, but
regardless of absolute levels, the results here show significant functional increases in
adenosine accumulation after SD in slices pre-loaded with Zn2+.
A significant run-down of fEPSPs was seen with [Zn2+]i loading in the 60min
time-control experiments where SD was not induced (Fig 1), and suggestions of this rundown could be seen even in the initial 10min washout period prior to SD challenges. It
seems likely that A1R suppression also contributes to this slow run-down, and is additive
with the metabolic challenge of SD. Curiously, a small transient increase in fEPSPs was
seen upon the addition of Zn/Pyr (seen most easily in Fig 4). This increase was present
during the addition of either pyrithione or histidine alone (data not shown, n=6 each),
which suggests that extracellular or contaminating Zn2+ (Carter et al., 2011) may
contribute by effects on either excitatory or inhibitory transmission (Xie et al., 1994, Kim
et al., 2002, Huang et al., 2008).
Suppression of excitatory neurotransmission by adenosine acting on A1Rs has
been widely considered neuroprotective, and following hypoxic challenges, fEPSP
recovery was impaired in the presence of DPCPX or in mice lacking A1Rs (Johansson et
al., 2001, Sebastiao et al., 2001). However in the current study of SD in normoxic
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conditions, we did not detect deleterious effects of DPCPX, and found instead that
synaptic recovery was improved under all conditions tested. The majority of fEPSP
suppression was mediated by A1R activation following 30µM Zn/Pyr. While fEPSP
recovery was significantly improved by DPCPX with the 100µM Zn/Pyr challenge, some
sustained fEPSP suppression was still seen (Fig. 3A). This suggests that under conditions
of greatly increased metabolic inhibition, SD can result in either irrecoverable injury, out
competition of DPCPX by excessive adenosine accumulation, or a combination of both.
It remains to be determined whether adenosine accumulation following SD can contribute
to delayed neuroprotection under other conditions, for example with clusters of SDs in
ischemic conditions.

Mechanisms coupling [Zn2+] i accumulation to adenosine accumulation
Several possibilities can be considered for mechanisms coupling [Zn2+]i loading to
adenosine accumulation.

Sufficient time (many minutes) was required for [Zn2+]i

accumulation to have significant additive effects when combined with SD, consistent
with a mechanism involving inhibition of metabolism or depletion of metabolic stores
prior to SD. Based on the lack of effectiveness of selective inhibitors, PARP-1 or SIRT
protein activation (see Introduction) did not appear to be significant contributors to the
delayed fEPSP recovery following [Zn2+]i loading together with SD (see Section 4).
More prolonged Zn2+ exposures were utilized in studies which these pathways were
identified in toxic Zn2+ effects (Sheline et al., 2000, Cai et al., 2006) and it is possible that
postsynaptic [Zn2+]i accumulation here was not sufficiently high enough, or of long
enough duration to activate PARP-1 or SIRT pathways. An additional test of PARP-1
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and SIRT pathway involvement could involve NAD+ supplementation (Sheline et al.,
2000).

However, this possibility was difficult to test experimentally in these slice

experiments, as application of NAD+ alone was sufficient to suppress fEPSPs in a
DPCPX-sensitive manner (data not shown). This effect may be due to its ability to
mimic adenosine binding at A1Rs (Galarreta et al., 1993).
The lack of effect of pyruvate and lactate supplementation (see Section 4) suggest
that any metabolic inhibition caused [Zn2+]i loading is likely due to actions downstream
of pyruvate utilization, within either the TCA cycle (Brown et al., 2000) or the
mitochondrial electron transport chain (ETC) (Sharpley and Hirst, 2006). Interestingly,
fEPSP recovery was enhanced in the presence of the DMSO vehicle used for both the
DPQ and sirtinol studies (compare Figs 4A&B). DMSO has been reported to have
antioxidant properties (Sanmartin-Suarez et al., 2011), and it is possible that DMSO
reduced reactive oxygen species (ROS) generation by Zn2+.

Inhibition of ETC is

established to lead to ROS production (Adam-Vizi, 2005) and mitochondrial Zn2+
accumulation, impairment of mitochondrial function, and ROS production have all been
reported following Zn2+ accumulation in neurons (Sensi et al., 1999, Seo et al., 2001,
Dineley et al., 2005).
In addition to accumulation due to metabolic depletion, it is possible that other
sources of adenosine accumulation could also contribute to effects of Zn2+ loading.
Higher order metabolic precursors of adenosine, such as ATP release from astrocytes
(Halassa and Haydon, 2010) or cAMP release (Rosenberg and Dichter, 1989) can be
converted to adenosine extracellularly. It is not yet known whether Zn2+ may play a role
in either of these, or other, mechanisms of extracellular adenosine accumulation.
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Effects of [Zn2+] i loading on the characteristics of SD
Longer DC shift durations during SD are associated with worse clinical outcomes
in a variety of brain injuries that involve impaired metabolism (Dohmen et al., 2008,
Hartings et al., 2011b, Lauritzen et al., 2011). Recent work in vitro has also shown that
longer DC shifts are associated with longer fEPSP suppression in hippocampal slices
(Lindquist and Shuttleworth, 2012). We found here that [Zn2+]i loading prior to SD
significantly prolonged the duration of DC shifts (Fig 2), together with the effects on
fEPSP recovery and adenosine accumulations discussed above. These results further the
notion that longer DC shifts, both in vitro and in vivo, can be an indicator of larger
metabolic challenges, and support a metabolic depletion mechanism for the Zn2+ effects
described here.
Interestingly, there was no effect of [Zn2+]i loading on SD propagation rate (Fig
2C), despite the fact that depletion of metabolic substrates can increase SD propagation
rates (Seidel and Shuttleworth, 2011). This suggests that either the degree of metabolic
inhibition with [Zn2+]i loading is mild prior to SD, or the nature of metabolic inhibition
(i.e.. substrate removal vs. direct metabolic inhibition) determines effects on propagation
rate.

Endogenous Zn2+ accumulation
We previously showed waves of synaptic Zn2+ release and intracellular
accumulation following SD propagation (Carter et al., 2011). However, results from the
present study suggest that synaptic Zn2+ release and subsequent postsynaptic
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accumulation does not lead to signs of progressive metabolic depletion, even when SDs
were generated repetitively within the same slice (see Fig 6). One explanation for this
lack of effect could be that endogenous [Zn2+]i levels achieved following SD are much
lower than those achieved during [Zn2+]i loading with pyrithione. However, the results of
Figure 7 also suggest the potential for a significant and rapid adaptation following SD in
brain slices, making the tissue entirely resistant to a subsequent metabolic challenge with
Zn2+ loading. SD is established to precondition tissues against subsequent ischemic
challenges in vivo, although this effect has been tested only at relatively late time points
(24hrs or greater) following SD induction (Matsushima et al., 1996, Yanamoto et al.,
1998).

It is not yet known whether the adaptation observed at early time points here

shares a similar mechanism with ischemic preconditioning in vivo, or with PKC
mechanisms linking intracellular Zn2+ increases to preconditioning in cultured cortical
neurons (Aras et al., 2009).
The small increase in fEPSP recovery seen in the presence of TPEN, together
with the lack of effect on fEPSP recovery in ZnT3 KO animals (see Fig 6), suggests that
other endogenous, non-synaptic sources of Zn2+ can influence fEPSP recovery following
SD. Potential contributors could include liberation of [Zn2+]i from Zn2+-binding proteins
(Aizenman et al., 2000) that may occur during conditions generated by SD, or from
influx of contaminating Zn2+ present in the superfusate (see discussion in Carter et al.,
2011). However, the effect of TPEN on fEPSP recovery was quite small, and possibly
counteracted by adaptive mechanisms following SD as described above.
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Implications for injury
The results here emphasize potentially deleterious effects of intracellular Zn2+
accumulation, when combined with SD. Sustained [Zn2+]i increases are known to occur
in the days following stroke injury (Koh et al., 1996), and it seems likely that these
sustained increases would make neurons more vulnerable to additional metabolic
challenges of SDs that occur in the post-stroke brain (Hartings et al., 2003, Selman et al.,
2004, Dreier, 2011, Lauritzen et al., 2011).

However, we have also shown that

extracellular actions of Zn2+ can limit the propagation of SD (Aiba et al., 2012).
Therefore, selectively targeting intracellular Zn2+ accumulation may be more effective in
limiting neuronal injury and improving outcome following several brain injury models,
particularly those that involve SD. However it is important to also emphasize that
clusters of repetitive SD have been associated with poor clinical outcomes under some
conditions (Dreier, 2011, Hartings et al., 2011a, Lauritzen et al., 2011) and a rapid
adaptation following SD appears to protect tissues against the additive metabolic burden
of intracellular Zn2+ (Figure 7). Therefore deleterious metabolic effects of intracellular
Zn2+ accumulation may not be significant during repetitive SDs clusters, and under such
conditions, extracellular effects of Zn2+ may dominate and limit the spread of these
events (Aiba et al., 2012).

These and other divergent actions of intracellular and

extracellular Zn2+ are likely contributors to different effects of Zn2+ chelation that have
been reported in experimental injury settings (Lee et al., 2002, Kitamura et al., 2006c).
4.6 Figure Legends
Figure 4.1:

Transient [Zn2+]i loading resulted in increased fEPSP suppression

following SD. A: Plots showing the effects of a single SD on fEPSP amplitude. SDs
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were generated at the time indicate (arrow), and resulted in a rapid and near-complete
initial suppression of fEPSP amplitude.

Under control conditions (Pyr), this was

followed by recovery over the next ~11min to baseline levels. Slices treated with Zn2+
together with the ionphore (Zn/Pyr, applied during time indicated by the black bar),
resulted in a concentration-dependent increase in secondary suppression following SD
(p<.0001, ANOVA with Bonferroni post hoc test, 5µM Pyr vs. 10, 30, and 100µM
Zn/Pyr, n=6 each). Circle: Pyr; Square: 30µM Zn/Pyr; Diamond: 100µM Zn/Pyr, n=6
each. B: Plots showing effects of Zn/Pyr exposure on fEPSP amplitudes in the absence
of SD in a separate set of slices (Circle: Pyr; Square: 30µM Zn/Pyr; Diamond: 100µM
Zn/Pyr, n=6 each). C: Representative fEPSPs from time points indicated in (A): i-iv,
and (B): v-viii. D: Mean data showing final fEPSP amplitudes (measured at 60min),
determined from experiments shown in (A) & (B) (* p<.01unpaired Student’s t-test, n=6
each).

Figure 4.2: [Zn2+]i loading resulted in prolonged DC shifts. A: Representative
extracellular DC potential shifts recorded during SD in control conditions (Pyr) or 30 and
100µM Zn/Pyr.

B:

Mean data from recordings as shown in (A) showing a

concentration-dependent increase in DC duration (measured at 80% recovery, p<.0001,
ANOVA with Bonferroni post hoc test, n=6 each). C: [Zn2+]i loading had no significant
effect on SD propagation rate, as measured from intrinsic optical signals in the same data
set as shown in (B) (p=.15, ANOVA with Bonferroni post hoc test, 5µM Pyr vs. 30 and
100µM Zn/Pyr, n=6 each).
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Figure 4.3: A1R activation and enhanced adenosine accumulation after SD with
[Zn]i loading.

A:

Experiments conducted in the presence of an adenosine A1R

antagonist, DPCPX (200nM) showed substantially larger recovery of fEPSPs following
SD (arrow) after Zn/Pyr exposure (black bar) (compare with Figure 1, n=6 each). B:
Comparison of fEPSP suppression under control and DPCPX conditions. Suppression of
fEPSP for each preparation was calculated as the area between baseline amplitude and
the recovered fEPSP amplitude, from immediately following the onset of SD to the end
of the recording (25 min total duration). Suppression was significantly decreased by
DPCPX under all conditions tested (*p<.01, **p<.001 unpaired Student’s t-test, n=6
each). C: Amperometric measurements using an adenosine-sensitive electrochemical
probe, showing responses to SD as compared with calibration exposures to exogenous
adenosine (5µM) to generate estimated adenosine concentrations at the slice surface (see
Methods). Adenosine accumulation during SD (arrow) was significantly enhanced by
prior exposure to 30µM Zn/Pyr, compared with Pyr controls (p<.001 at peak, n=5 each).
D: Application of exogenous adenosine immediately following SD induction (arrow)
resulted in a significant reduction in fEPSP recovery that mimicked the effect of Zn/Pyr
exposure (n=5 each).

Figure 4.4: Lack of effect of PARP-1 inhibition or pyruvate supplementation on
[Zn2+]i loading effects. A: Slices exposed to the PARP-1 inhibitor DPQ (25µM)
showed little difference in recovery of fEPSP following SD after 30µM Zn/Pyr compared
to slices exposed to 30µM Zn/Pyr alone (p=.13, n=8 each). DMSO (0.1%) was used as a
vehicle in these studies. B: Addition of 5mM pyruvate together with 30µM Zn/Pyr had
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no effect on the recovery of fEPSPs following SD compared to slices exposed to 30µM
Zn/Pyr alone (p=.60, n=6 each).

Figure 4.5: Intracellular accumulation and exposure time needed for [Zn2+]i loading
effects. A: Slices exposed to extracellular ZnCl2 alone (black bar, without the ionophore
to enhance intracellular accumulation) did not result in slowed recovery of fEPSPs
following SD (compare with suppression in Figure 1) (n=6). Representative fEPSPs are
shown at times (i-iv) indicated on main plot. B: Similarly, no significant delay in fEPSP
recovery was observed if [Zn2+]i loading (Zn/Pyr, black bar) was applied beginning only
5min prior to SD induction (n=6). Representative fEPSPs are shown at times (i-iv)
indicated on main plot.

Figure 4.6: Contributions of endogenous Zn2+. A: A small but significant effect of
the membrane permeable Zn2+ chelator TPEN on fEPSP recovery (20µM TPEN in 0.1%
DMSO, 15 min pre-exposure and maintained throughout) (p=.04 for 50% recovery time,
Veh vs. TPEN, n=6 each). B: Responses to three consecutive SD events in the same
slices as (A) (20min intervals, onset indicated by arrows). TPEN exposure (20µM, 15
min pre-exposure and maintained throughout) revealed no cumulative effects due to
progressive [Zn2+]i accumulation on fEPSP recovery rate after repetitive SDs. C&D:
Lack of effect of synaptically-released Zn2+ on fEPSP recovery rate after both single SDs
(C) and repetitive SDs (D). Experiments are as described for A&B, but using comparison
of wild type and ZnT3 KO slices rather than TPEN. p=.71 for 50% recovery time in C,
and n=6 for all traces.
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Figure 4.7: Loss of effectiveness of exogenous [Zn2+]i loading, if slices were first
subjected to repetitive SDs. A: In slices exposed to 2 SDs before loading with 30µM
Zn/Pyr exposure (black bar), the expected suppression of fEPSP following a subsequent
(third) SD challenge was completely lost (n=6, compare with Fig 1A). Representative
fEPSPs are shown above at times (i-iv) indicated on main plot. B: Mean time control
data, showing that exogenous [Zn2+]i loading was still effective when given in SD-naïve
slices, at the same time point as shown in (A) (n=6). Representative fEPSPs are shown
above at times (i-iv) indicated on main plot.
compared to the same time point in (A).

Note the difference at time point iv
C:

Estimated extracellular adenosine

accumulation at the surface of slices during SD under conditions shown in panels A & B
above, in a separate set of preparations. In slices pre-exposed to two SDs (1st and 2nd
SD), subsequent Zn/Pyr addition did not produce any increase in the amplitude of
extracellular adenosine following SD (3rd SD).

No statistical difference was seen

between the three SD challenges in the same slices (repeated measures ANOVA with
Bonnferroni’s multiple comparison). In time-control slices not previously exposed to
SDs (matching Fig. 7B), there was still a significant increase in extracellular adenosine
accumulation by Zn/Pyr with SD (see also Fig. 3C). (*p<0.01 Student’s unpaired t-test,
n=5 for each group).
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5.1 Abstract
Excess Zn2+ accumulation contributes to ischemic injury, however, the source(s)
of neurotoxic Zn2+ remain incompletely understood. We have previously shown large
releases of synaptic Zn2+ during waves of spreading depolarization (SD) in hippocampal
brain slice preparations. SD is a coordinated depolarizing event that occurs repetitively
following ischemic insults. In the present study we investigated whether SD results in
synaptic Zn2+ release in neocortical tissues in vitro and in vivo, and whether synaptic Zn2+
contributes to ischemic injury. Fluorescence detection of FluoZin-3, by single- and twophoton microscopy, revealed synaptic Zn2+ release during SD generated in normoxic
conditions, in both neocortical brain slices, and in somatosensory cortex in anesthetized
mice. Signals were abolished in tissues from mice lacking the transporter responsible for
synaptic Zn2+ accumulation (ZnT3 KO). Focal ischemia was generated by distal middle
cerebral artery occlusion (dMCAO), and resulted in SD events being generated around
the infarct core. SDs generated by focal ischemia also produced significant synaptic Zn2+
release, which were absent in ZnT3 KO animals.

Furthermore, ischemic infarcts

generated by dMCAO were significantly smaller in ZnT3 KO animals. Together, these
results provide the first visualization of synaptic Zn2+ release in vivo, and suggest that SD
events following ischemia may be a significant source of neurotoxic zinc that contributes
to injury progression.

5.2 Introduction
High levels of Zn2+ are present throughout the brain, bound to intracellular
proteins and localized into a subset of glutamatergic synaptic nerve terminals by the Zn2+
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transporter ZnT3 (Palmiter et al., 1996b, Cole et al., 1999). While levels of Zn2+ are
tightly maintained, excessive accumulation of Zn2+ is well known to be neurotoxic to
both neurons and glia (Sensi et al., 2009).

Prior work has shown that

intracerebroventricular injections of a membrane impermeable Zn2+ chelator (CaEDTA)
significantly reduced neuronal damage following ischemia (Koh et al., 1996, Calderone
et al., 2004), suggesting that Zn2+ accumulated in the extracellular space can be
neurotoxic under ischemic conditions. Subsequent in vivo microdialysis studies detected
increased levels of extracellular Zn2+ accumulation following experimental stroke
(Kitamura et al., 2006a, b). While accumulating evidence supports a toxic role for
extracellular Zn2+ following ischemia, the source of this toxic Zn2+ has not been clearly
identified.

Synaptic Zn2+ can be released in an activity-dependent manner from

hippocampal slices (Assaf and Chung, 1984, Howell et al., 1984), and recent work has
utilized the high affinity fluorescent Zn2+ indicator FluoZin-3 to visualize synaptic Zn2+
release during electrical stimulation in hippocampal tissues (Qian and Noebels, 2005,
2006). While evidence exists for the capability of synaptic Zn2+ release in multiple brain
regions, based on the localization of ZnT3 and synaptic Zn2+ by histochemical staining
techniques (Lee et al., 2011), direct real-time fluorescence detection of release and
quantification in brain regions other than the hippocampus is less understood.
Spreading depolarization (SD) is a coordinated depolarizing event that propagates
through neuronal tissue in a feed-forward manner by the release of synaptic glutamate
and the extracellular accumulation of K+ (Somjen, 2001, Dreier, 2011, Lauritzen et al.,
2011). While SD does not generally result in injury in healthy tissue (Nedergaard and
Hansen, 1988), accumulating evidence, from both clinical and animal recordings,
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suggests that repetitive SDs occur and are a contributing factor in the expansion of
numerous brain injuries, including ischemic stroke (Hartings et al., 2003, Dohmen et al.,
2008, Dreier, 2011, Lauritzen et al., 2011). As Zn2+ is co-stored with glutamate in
synaptic vesicles and due to the sharply coordinated depolarization of large neuronal
populations, these events provide an excellent model system to study synaptic Zn2+
release in brain tissues.

We have recently exploited the phenomenon of SD to

characterize significant synaptic Zn2+ release and postsynaptic accumulation in
hippocampal tissues (Carter et al., 2011). As repetitive SDs can occur in neocortical
tissues in the hours to days following the initial ischemic insult, we have considered the
possibility that synaptic Zn2+ release during these events could be a significant
contributor to the toxic extracellular Zn2+ accumulation previously reported.
In the current study, we tested whether synaptic Zn2+ release could be
fluorescently detected in real-time during SD in neocortical tissues in vitro and in vivo.
The studies utilize a selective Zn2+ fluorescence indicator (FluoZin-3), and mice lacking
synaptic Zn2+ (ZnT3 KO mice). We also assessed the contribution of synaptic Zn2+
release to the progression of ischemic injury in a mouse model of distal middle cerebral
artery occlusion (dMCAO). The results presented here show that there are sufficient
levels of synaptic Zn2+ present in neocortical tissues to be released and fluorescently
detected during SD both in vitro and in vivo. Following experimental stroke, synaptic
Zn2+ significantly contributed to the progression of ischemic injury. These data suggest
that targeting synaptic Zn2+ stores or release associated with SD events may be beneficial,
even at relatively late time points following stroke onset.

120

5.3 Materials and Methods
Slice preparation and recording
All procedures were carried out in accordance with the National Institute of
Health guidelines for the humane treatment of laboratory animals, and the protocol for
these procedures was reviewed annually by the Institutional Animal Care and Use
Committee at the University of New Mexico School of Medicine. Acute brain slices
(350µm) were prepared from wild type C57Bl/6J and ZnT3 KO mice from either sex (4-8
weeks old). After cutting in ice-cold solution and then holding for 1 hour at 35oC,
artificial cerebrospinal fluid (ACSF) was changed, and slices were held at room
temperature until used for recording.

Individual slices were then transferred to the

recording chamber, and were superfused with oxygenated artificial cerebrospinal fluid
(ACSF) at 2 mL/min. Mice homozygous for deletion of the ZnT3 gene were originally
obtained from Dr. Richard Palmiter (Cole et al., 1999) and backcrossed onto C57Bl/6 for
>13 generations (LSUHSC). A homozygous breeding colony of ZnT3 KO animals was
then established at the University of New Mexico.
Extracellular measurements of direct current (DC) potentials were made using
borosilicate glass microelectrodes, filled with ACSF (~5MΩ) and placed in layer III ~50
μm below the surface of the slice. SD was generated by bath application of a high KCl
modified ACSF (40mM KCl, equimolar reduction of NaCl), and was identified as a sharp
negative deflection of the extracellular direct current (DC) potential.

In some

experiments, the spread of SD was monitored by using intrinsic optical signals, generated
by transmission of red light (>575nm).
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Brain Slice Zn2+ indicator measurements
Extracellular Zn2+ measurements were made using the charged form of the Zn2+sensitive indicator FluoZin-3, using approaches developed by others (Kay, 2003, Qian
and Noebels, 2005, 2006) and utilized in our recent work (Dietz et al., 2008, Carter et al.,
2011). FluoZin-3 was dissolved in ACSF at 1.5µM and superfused over the slice at
35oC. Background fluorescence was then reduced by addition of CaEDTA (1mM) in all
experiments, except where indicated otherwise. Responses are reported as (%ΔF/F0), as
Zn2+ binds to multiple components of the recording buffer (Rumschik et al., 2009),
making absolute calibration from addition of exogenous Zn2+ standards problematic.
FluoZin-3 excitation at 495nm (150ms), and emission was detected at 535/50nm using a
monochromator-based imaging system (Till Photonics). Images were acquired every 1.5
seconds and analyzed with TillVision software (Till Photonics).

Surgical preparation
Wild type C57Bl/6 and ZnT3 KO of either sex (3-6months old) were deeply
anesthetized with 2.5% isoflurane in a mixture of 70% N2O / 30% O2. Mice were then
placed into a stereotaxic frame and maintained with 1% isoflurane provided via nose
cone. Body temperature was maintained at 37°C by a rectal feedback controlled heating
blanket (Harvard Instruments). The skin above the skull was cut and removed and a
cranial window (~1mm diameter) was created over the left somatosensory cortex
(centered 2mm lateral and 1mm caudal to bregma). Care was taken to leave the dura
intact. A ring of dental cement was placed around the craniotomy with a piece of
polyethylene tubing (PE10) embedded in to allow the inflow of solutions. A burr hole
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was created over the frontal bone, ~2mm rostral from the craniotomy for SD induction.
Application of a piece of gel foam soaked in 1M KCl to the burr hole for 1-2s, followed
by saline wash, was used to elicit a single SD.

Single-photon in vivo imaging
Tissue autofluorescence and FluoZin-3 imaging was performed at 490nm
(350ms), with emission detected at 535/50nm using similar set up for slice work (Till
Photonics), through the dura intact open cranial window. Images were collected at 2Hz,
with 2x2 binning, resulting in an image with pixel dimensions of 320x240. Fluorescence
data was collected using 4x air (NA 0.13) or 10x water immersion (NA 0.3) objective as
indicated in text.

Extracellular recordings of DC potential changes were via glass

electrodes (~3-5MΩ) filled with ACSF, placed approximately 200µm below the cortical
surface, using PowerLab software (PowerLab). FluoZin-3 (10µM) and CaEDTA (1mM)
were applied together in normal saline over the cortical surface via a syringe pump.
Initial wash-in was applied at 200µL/min for 2min, followed by 1µL/min for 10min prior
to any recording session. Unless indicated otherwise, FluoZin-3 and CaEDTA were
continually superfused over the cortex throughout the entire experiment.

Two-photon in vivo imaging
Two-photon imaging utilized a Ti:Sapphire femtosecond mode-locked IR laser
(Spectra Physics Tsunami) connected to a Prairie Ultima two-photon upright microscope.
Images were acquired using Prairie View software at 810nm and a 4µs pixel dwell time.
A 20x WI (NA 0.5) objective was used to acquire images, with a final image size of
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512x512 pixels. For time series acquisition of FluoZin-3 wash in, images where acquired
every 10s. Z-stacks were acquired at 10µm steps starting 50µm above the surface of the
dura to 150µm into the brain. In studies were SD was monitored, images were acquired
every 1.5s for a duration of 5min. SD induction and FluoZin-3 (10uM) and CaEDTA
(1mM) superfusion was as described for single-photon imaging.
For electrical stimulation, procedures for animal preparation and cranial window
placement were the same as for CSD recordings.

A custom made parallel bipolar

stimulating electrode was inserted into the neocortex at the caudal edge of the
craniotomy. One second square pulses of 500µA, 200µs at 20, 50, and 100Hz were
delivered through a stimulation box (Isoflex) connected to a Master8 control box. Twophoton images were acquired using a 20x WI (NA 0.5) objective at 2Hz with a final
image size of 256x256 pixels and were analyzed using ImageJ (NIH), or imported and
analyzed in TillVision (Till Photonics). For all in vivo FluoZin-3 responses (single- and
two-photon), data are expressed as (%ΔF/F0).

Distal Middle Cerebral Artery Occlusion Model
The procedure for distal middle cerebral artery occlusion (dMCAO) was modified
from previously published studies (Chen et al., 1986, Kuraoka et al., 2009). Mice were
anesthetized as above and placed in the stereotaxic frame, rotated to lay on their right
side. An incision was made in the skin between the lateral portion of the left orbit and
external auditory meatus. The temporalis muscle was separated and resected to reveal the
distal portion of the MCA through the zygoma. A small rectangular craniotomy was
made over the MCA and a loose square knot (8-0 suture) was created on the MCA to tie
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off later during imaging. Care was taken to ensure that the suture was not occluding the
vessel prior to imaging. Mice were then positioned in the stereotaxic frame in the prone
position and a cranial window was created for FluoZin-3 imaging as described above for
single-photon imaging.
For survival studies, the distal MCA was immediately tied off and Laser Doppler
measurements were recorded in a subset of animals to ensure proper occlusion in both
genotypes. A piece of bone wax was placed over the craniotomy, and following would
closure, animals were placed back into their home cages, and were monitored for 1hr to
ensure proper recovery from the surgery. All animals were supplied with soft food
supplements following surgery.
Imaging was performed at low power (4x air) for visualization of a large portion
of the cortical surface. FluoZin-3 (10µM) and CaEDTA (1mM) were superfused and
imaged as described above for in vivo single-photon imaging. After image acquisition
started the suture was tightened over the MCA to occlude the vessel. Care was taken to
not sever the MCA during tie off, and animals in which this occurred were excluded from
the analysis and data presented in this report.

Infarct volume measurements
Infarct volumes were measured 24hrs following permanent dMCAO by TTC
staining. The brains were rapidly removed in ice-cold cutting solution and sectioned into
2mm thick slices and incubated in 1% TTC in ACSF for 1hr at 35°C. Slices were then
fixed in 4% PFA overnight, and infarct volumes were subsequently quantified.
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Reagents and solutions
Cutting solution contained (in mM): 3 KCl, 1.25 NaH2PO4, 6 MgSO4, 26
NaHCO3, 0.2 CaCl2, 10 glucose, 220 sucrose and 0.43 ketamine. ACSF contained (in
mM): 126 NaCl, 3 KCl, 1.25 NaH2PO4, 1 MgSO4, 26 NaHCO3, 2 CaCl2, and 10 glucose
and was equilibrated with 95%O2 / 5%CO2. Cutting and recording solutions were both
315-320 mOsm. FluoZin-3, prepared as a 10mM stock in water, was obtained from
Invitrogen (Carlsbad, CA). All other reagents were obtained from Sigma (St. Louis,
MO).

Statistical Analysis
Data are reported as mean ± standard error of the mean (S.E.M.). Significant
differences between group data were evaluated using unpaired or paired Student’s t-tests,
with correction for multiple comparisons where appropriate.

5.4 Results
Fluorescence detection of synaptic Zn2+ release in neocortex during SD in vitro
To confirm that SD could be generated in the neocortex in our model, brain slices
were superfused with 40mM KCl in ACSF for 2min to induce SD (see (Zhou et al.,
2010a)). SD could be reliably generated by this stimulation, and Figure 1A shows the
propagation of SD through the neocortex visualized from the intrinsic optical signals
(IOS) (Andrew et al., 1999).

Upon the passage of SD (arrows in Fig. 1A, mean

propagation rate:4.56±0.35mm/min (n=7)), a sharp negative DC deflection occurred
(bottom right trace of Fig. 1A) characteristic of SD.
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To test for extracellular Zn2+ accumulation during SD, a separate set of slices
were superfused with FluoZin-3 (1.5µM) in the presence of CaEDTA (1mM). In wild
type slices, SD resulted in an increase in FluoZin-3 fluorescence (Fig. 1B), which
followed a similar rate of propagation as the IOS signal (mean rate: 4.37±0.44mm/min,
n=7). The peak FluoZin-3 signal (199.671±13.37 %ΔF/F0) occurred coincident with the
sharp negative DC deflection. In order to test whether synaptic Zn2+ contributed to the
increase FluoZin-3 fluorescence during SD above, experiments were repeated in slices
from ZnT3 KO animals. SD was still generated in ZnT3 KO tissues, however instead of
an increased FluoZin-3 signal, there was a small decrease in fluorescence that propagated
during SD (-15.59±4.27 %ΔF/F0, propagation rate: 3.86±0.47mm/min, n=6).

This

decrease in fluorescence can be attributed to emission of intrinsic autofluorescence of
flavoproteins at the wavelength used to excite FluoZin-3 (Qian and Noebels, 2005, Carter
et al., 2011). A summary of the peak FluoZin-3 response during SD is provided in Figure
1D. Taken together, these results show that synaptic Zn2+ release can occur during SD in
neocortical tissues in vitro.
Imaging of flavoprotein autofluorescence (in the absence of FluoZin-3) revealed
similar responses in wild type and ZnT3 KO tissues (-6.64±0.48 vs. -5.80±0.23 %ΔF/F0,
wild type (n=7) vs. ZnT3 KO (n=5) respectively, p=0.19) during SD that propagated
through the tissue at similar rates (4.27±0.79 vs. 4.41±0.50 mm/min, wild type (n=7) vs.
ZnT3 KO (n=5) respectively, p=0.90). These results indicate that SD in the neocortex
was similar in both genotypes, and that autofluorescence changes associated with SD
cannot account for the differences in FlouZin-3 signals between wild type and ZnT3 KO
tissues.

127

In vivo fluorescence detection of synaptic Zn2+ release during SD
We next assessed whether similar approaches used to visualize synaptic Zn2+
release in vitro could be adapted to evaluate synaptic Zn2+ release in vivo. SD was
induced in vivo by a brief application of KCl to the cortical surface through a burr hole in
isoflurane-anesthetized mice (see Materials and Methods).

This procedure is well

established to generate SDs, and the occurrence of SD was verified in the present study
with optical propagation measurements and extracellular DC recordings. In the absence
of FluoZin-3, the propagation of SD was accompanied by autofluorescence decreases in
both wild type and ZnT3 KO animals (propagation rate: 3.14±0.42 vs. 2.58±0.63
mm/min, p=0.47; autofluorescence decrease: -12.40±1.37 vs. -11.34±1.53 %ΔF/F0,
p=0.62, n=5 WT, n=4 ZnT3 KO respectively).
In initial studies, FluoZin-3 (10M) and CaEDTA (1mM) were continually
superfused over the cortical surface (dura intact) and visualized with single-photon
excitation (490nm) using a low power air objective (4X, NA 0.13), which permitted
simultaneous recording of extracellular DC potential shifts associated with SD. SD
induction resulted in a large FluoZin-3 fluorescence increase in wild type animals (Fig.
2A) coincident with the extracellular negative DC shift. Increased FluoZin-3 signals
during SD were completely absent in ZnT3 KO animals (Fig. 2B). Instead, a decrease in
fluorescence was detected with the electrical DC shift, similar to the fluorescence
responses described in the slice experiments above (see Fig. 1C).
Subsequent studies were performed without electrical recordings and using the
FluoZin-3 signal as an indicator for SD occurrence. Higher power imaging (10x water
immersion objective, NA 0.3) was used to quantify FluoZin-3 changes, and showed that
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the wave-like increase in FluoZin-3 fluorescence propagated at a rate of
2.81±0.14mm/min in wild type animals (n=5), while the decrease seen in ZnT3 KO
animals propagated at 2.71±0.37mm/min (n=4). Repetitive SD challenges in the same
animal were examined to determine if each event releases similar levels of synaptic Zn 2+.
Little change in the peak fluorescence level was observed during repetitive challenges,
consistent with our previous in vitro work (Carter et al., 2011), indicating similar release
characteristics with each SD (Fig. 2C). The peak FluoZin-3 amplitude during the first SD
in wild type animals and ZnT3 KO animals is shown in Figure 2D.

Source of fluorescence signals in vivo
We considered the possibility that FluoZin-3 signals acquired during singlephoton excitation could be contributed to by Zn2+ diffusing away from the source of
release and binding with indicator above the dura, in addition to signals generated close
to release sites within the brain parenchyma. To address this issue, we utilized twophoton microscopy to image FluoZin-3 fluorescence (see Methods) at three levels of
interest during the propagation of SD: 1) superfusion well (70µm above dura); 2) dura
surface; and 3) within the brain parenchyma (50µm below the dura). FluoZin-3 and
CaEDTA were applied continuously in the superfusion well above the dura, identically to
the single-photon experiments above. During the passage of SD, the majority of the
fluorescence increase was observed within the brain, with only a slight signal detectable
above the dura surface (Fig. 3A). The average peak FluoZin-3 fluorescence increase
during SD within the parenchyma was 1181.79±222.18 %ΔF/F0 (n=4) in wild type
animals and autofluorescence decreases (-38.94±10.54%ΔF/F0, n=4) were seen in ZnT3
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KO animals during the propagation of SD, consistent with our previous findings (see
above).

Comparative amplitudes of FluoZin-3 responses in vivo
To determine if synaptic Zn2+ release could be detected in vivo during a less
intense stimulus than SD, we used direct electrical stimulation of the cortex. Repetitive
electrical stimulation (200µs pulse duration, 500µA, at 20, 50, or100Hz for 1s) was used
to stimulate a region of the brain encompassing the somatosensory cortex, at the same
coordinates as SD imaging. Figure 4A shows a representative trace following 50Hz
stimulation from a wild type animal. In the absence of FluoZin-3, very little to no
response was detected at the wavelength used for two-photon excitation (810nm).
However, after the addition of FluoZin-3 (10µM) and CaEDTA (1mM), a robust signal
was detected upon stimulation. In ZnT3 KO animals, no autofluorescence response was
seen during electrical stimulation, and in contrast to wild type animals, no FluoZin-3
response was detected following stimulation (Fig. 4B). FluoZin-3 responses in wild type
animals were frequency-dependent as shown in Figure 4C.

Synaptic Zn2+ release during SDs generated by distal MCAO
We used a distal focal ischemia technique to permanently occlude a portion of the
left distal middle cerebral artery (dMCAO, see Materials and Methods). Confirmation of
loss of blood flow following occlusion was imaged with laser speckle contrast imaging of
the entire cerebral cortex (LSCI, Fig 5A). Shortly after occlusion, an SD event was
detected (mean onset time 6.19±2.70min after occlusion), and could be visualized with
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LSCI, with similar characteristics to the first SD reported in previous stroke models in
rats and cats (Nakamura et al., 2010, Kumagai et al., 2011). We next tested whether
synaptic Zn2+ was released during this SD event following ischemia by superfusing
FluoZin-3 and CaEDTA over the exposed cortex of a different group of wild type and
ZnT3 KO animals. Imaging with single-photon excitation allowed for a larger field of
view with a low power objective, similar to that used in Figure 2. Following dMCAO in
a wild type animal, a wave of increased FluoZin-3 fluorescence was detected (Fig. 5A),
similar to that seen with SD induced by KCl (Fig 2A).
(232.1±67.43%ΔF/F0,
(2.71±0.25mm/min).

n=4)

propagated

at

a

rate

The FluoZin-3 signal

consistent

with

the

SD

In ZnT3 KO animals, SD was still generated from dMCAO

(2.52±0.09mm/min, n=4), however no increase in FluoZin-3 fluorescence was seen (Fig
5C). Like SD induced by KCl application, a decrease in fluorescence was detected (22.78±5.19%ΔF/F0) in ZnT3 KO animals, again attributed to autofluorescence changes.
These results suggest that synaptic Zn2+ release during SD could be a source of
extracellular Zn2+ accumulation following ischemia in vivo.

Synaptic Zn2+ contributes to ischemic injury
To test the contribution of synaptic Zn2+ release to the progression of ischemic
injury, permanent dMCAO, as described above, was induced in a separate set of wild
type and ZnT3 KO mice. Laser Doppler measurements were recorded in both genotypes
immediately following dMCAO and no difference in CBF reduction was seen (data not
shown) indicating successful occlusion in both genotypes.

Infarct volumes were

measured 24hrs after dMCAO with TTC (see Materials and Methods). Representative
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whole brain TTC staining revealed a robust infarct area in a wild type animal with a
substantial reduction in infarct area in the ZnT3 KO animal (Figs. 6A&B).
Correspondingly, brain slices stained with TTC showed an infarct restricted to the cortex
in both genotypes, however, the infarct volume was significantly reduced in ZnT3 KO
animals (10.46±2.72 vs. 3.22±0.93mm3, wild type (n=12) vs. ZnT3 KO (n=11), p=.02,
Figs. 6C,D,&E).

5.5 Discussion
General
This study investigated whether synaptic Zn2+ release could be detected in
neocortical tissues and if synaptic Zn2+ could be neurotoxic in the post-ischemic period.
Sufficient levels of synaptic Zn2+ were present in the neocortex to be detected during SD
in vitro, and single- and two-photon microscopy confirmed fluorescence detection of
synaptic Zn2+ release within the brain parenchyma during SD in vivo. Visualization of
synaptic Zn2+ release during direct electrical stimulation could imply that synaptic Zn2+
release occurs during a wide range of stimuli in vivo. The large release of synaptic Zn2+
during SD following dMCAO, combined with the significant reduction in infarct volumes
in ZnT3 KO mice, implicates synaptic Zn2+ release during SD as a major source of
neurotoxic Zn2+ during ischemia.

Comparison between hippocampal and neocortical synaptic Zn2+ release in vitro
A large number of studies have examined characteristics of Zn2+ release and
actions in hippocampal preparations. Zn2+ in synaptic vesicles is readily detectable in the
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large mossy fiber boutons that terminate on CA3 pyramidal neurons, and release and
actions in mossy fiber – CA3 plasticity have been identified (Li et al., 2001, Sensi et al.,
2009). However, synaptic Zn2+ is also demonstrable with Timm’s staining throughout
the neocortex (Frederickson et al., 2000), and the results in the current study show that
synaptic Zn2+ release during SD in neocortical slices was quantitatively comparable to
our previous work in hippocampal tissues (Carter et al., 2011). The propagation rates and
DC shifts associated with SD were also comparable between the two studies, indicating
that the underlying characteristics of SD are also similar between hippocampal and
neocortical tissues. While fluorescence visualization was only examined from layers
II/III in neocortical slices encompassing the somatosensory cortex, it is possible that
release characteristics may differ in different cortical regions. Staining for synaptic Zn 2+
and ZnT3 has revealed a heterogeneous distribution throughout the cortical layers, with
the highest levels present in layers I, II, III, and V (Lee et al., 2011). However, as
synaptic Zn2+ is present throughout the entire neocortex (Frederickson et al., 2000), it is
likely that synaptic Zn2+ release can occur throughout all neocortical regions. Therefore,
synaptic Zn2+ release in the neocortex may be involved in similar physiological
processes, such as synaptic plasticity, in the neocortex that have previously been
described in hippocampal tissues (Li et al., 2001, Pan et al., 2011).

Technical issues imaging FluoZin-3 fluorescence in vivo
Utilizing single- and two-photon microscopy, we have demonstrated that it is
possible to image FluoZin-3 through the intact mouse dura. Additionally, as CaEDTA
has been previously utilized to increase the signal/noise of FluoZin-3 fluorescence (Qian
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and Noebels, 2005, Carter et al., 2011), the apparent ability of this slow-acting chelator to
also penetrate the dura aided in the detection of FluoZin-3 transients in vivo. In the
absence of CaEDTA, relatively low basal FluoZin-3 fluorescence levels were seen with
two-photon imaging within the parenchyma, indicating a relatively low extracellular
concentration of Zn2+ in vivo. Previous in vitro work indicated the presence of a large
source of extracellular Zn2+, likely from contaminating Zn2+ from solution salts (Kay,
2004), or the proposed “Zn2+-veneer” coating the extracellular surface of cells (Nydegger
et al., 2012). In the current study, only contaminating Zn2+ signals were seen in the well
above the dura (see supplemental Fig. 1), however, basal fluorescence signals decreased
rapidly within the brain parenchyma. The maintenance of a relatively low level of
extracellular Zn2+ during resting conditions, possibly mediated by membrane Zn2+
transporters such as the ZIP family of Zn2+ transporters (Qian et al., 2011), could indicate
the importance of maintaining low extracellular levels of Zn2+ for normal brain function.
A large fluorescence increase was seen at the dura surface upon the addition of
FluoZin-3.

This signal was greatly reduced, but not completely by CaEDTA (see

supplemental Fig 1), suggesting that a fraction of this fluorescence increase may not be
due to Zn2+. Additional increases in FlouZin-3 fluorescence not abolished by CaEDTA
were apparent in surface blood vessel walls. It is possible that FluoZin-3 is sequestered
or trapped in these structures, thus preventing CaEDTA from interacting with FluoZin-3
and decreasing the fluorescence. Similar residual FluoZin-3 signals were present in both
wild type and ZnT3 KO animals suggesting that synaptic Zn2+ does not contribute to the
generation of these potential artifacts.
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FluoZin-3 signals obtained using single-photon epifluorescence excitation with
low power (4x air) objectives had lower signal intensities compared with two-photon
excitation, likely due to the higher signal/noise ratio with single-photon imaging. In
addition, optical artifacts were more prevalent while imaging FluoZin-3 fluorescence
with single-photon excitation. Amplification of tissue autofluorescence was observed in
ZnT3 KO animals in the presence of FluoZin-3, indicating that the FluoZin-3 transients
observed in wild type animals are likely to be underestimated using single-photon
excitation.

Waves of synaptic Zn2+ release in vivo during SD
The present study demonstrates large waves of synaptic Zn2+ release, detectable
through intact dura, during SD induced by KCl in vivo (Fig. 2). This observation may
suggest a role for synaptic Zn2+ release during several pathological states where SDs are
known to occur, such as migraine with aura (Hadjikhani et al., 2001), traumatic brain
injury (Hartings et al., 2011b) and stroke (Dreier, 2011). In addition, as there was little
run-down in FluoZin-3 signal observed following repetitive SDs in the same animal (Fig.
2C), it is possible that each event is capable of releasing large amounts of Zn2+ into the
extracellular space.
Extracellular Zn2+ is well known to inhibit NMDA receptors (Paoletti et al.,
1997), and NMDA receptors are essential for the propagation of SD through neuronal
tissue (Somjen, 2001). Therefore, synaptic release of Zn2+ may serve as an intrinsic
modulator of CSD propagation in vivo. Recent work has supported this notion, both in
brain slices and in vivo (Aiba et al., 2012), suggesting a role for synaptic Zn2+ in limiting
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the spread of SD. In the current study, CaEDTA was present in a majority of the studies
to improve the signal/noise for FluoZin-3 measurements. Consistent with our prior work
(Aiba et al., 2012), similar SD propagation rates were observed in wild type and ZnT3
KO tissues in the presence of CaEDTA.

Visualization of synaptic Zn2+ release during electrical stimulation
As mentioned above, SD is a large stimulus, providing an ideal model system to
evaluate synaptic Zn2+ release in brain tissue.

More moderate stimuli (electrical

stimulation to the dura surface) also generated detectable FluoZin-3 signals, extending
previous work with electrical stimuli in brain slices (Qian and Noebels, 2005, 2006,
Carter et al., 2011). The characterization performed by Quian and Noebels suggests that
imaging FluoZin-3 fluorescence could be used as a surrogate for glutamate release, and
the present work implies that this could be utilized for studies of physiological activation
in vivo. Immunohistochemical and immunofluorescence stains have shown the presence
of synaptic Zn2+ and ZnT3 in the barrel cortex of mice (Liguz-Lecznar et al., 2005). In
recent studies investigating experience dependent plasticity of the barrel cortex in mice,
alterations in the levels of synaptic Zn2+ have been reported (Brown and Dyck, 2005,
Nakashima and Dyck, 2010). It would be of interest to determine whether fluorescence
visualization of synaptic Zn2+ release can be detected following whisker stimulation. It is
important to note that due to the significant decrease in signal from SD to electrical
stimulation with two-photon excitation, it may be technically difficult to visualize
synaptic Zn2+ release during physiological activity.
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Synaptic Zn2+ and ischemic injury
Recent reports have described the occurrence of SD in the neocortex in humans
following a wide range of brain traumas (Dreier, 2011, Lauritzen et al., 2011). SDs are
emerging as a potentially important and targetable causative factor in the enlargement of
ischemic infarcts following stroke in animal models (Hartings et al., 2003), and in human
patients (Dreier, 2011, Lauritzen et al., 2011).

Previous microdialysis studies have

detected increases in extracellular Zn2+ following forebrain ischemia in vivo (Kitamura et
al., 2006b). However, due to the temporal resolution in sampling frequency it is difficult
to determine whether a slow steady increase in extracellular Zn2+, or pulsatile increases
from SD contribute. The present results suggest that coordinated release from SD events
following ischemia could significantly contribute to the increases in extracellular Zn2+
accumulation following ischemia. Thus, it is possible that Zn2+ release during SDs could
be a significant contributor to metabolic compromise, and injury following repetitive SD
in post-ischemic tissues. We have recently shown that intracellular Zn2+ loading prior to
SD significantly worsens recovery of synaptic activity (Carter et al., 2013). Evidence for
the worsened metabolic status under these conditions comes from increased duration of
DC shifts associated with SD, and also significant increases in extracellular accumulation
of the metabolic product adenosine (Carter et al., 2013).
The results with focal ischemia model provide support for the idea that Zn2+
released from synaptic vesicles during SD could contribute to the progression of stroke
injury. SDs were demonstrated to propagate around the edge of the ischemic core,
similar to previous reports in the middle cerebral artery occlusion model (Nakamura et
al., 2010). Furthermore, waves of extracellular Zn2+ increases were verified as being of a
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synaptic source based on the loss of signals in ZnT3 KO animals. These results imply
synaptic Zn2+ release during these events, and identify a potentially large pulsatile source
of Zn2+ in the post-ischemic period. Finally, infarct volumes were significantly reduced
in ZnT3 KO animals, following the same ischemic challenges.

This provides

circumstantial evidence that the Zn2+ released during ischemic SDs contributed to infarct
volume, as SD-induced Zn2+ release appears to be by far the largest possible source of
Zn2+ detectable with these methods in the early post-ischemic phase. It is of course
possible that other sources emerge and contribute to injury later in the time course of
stroke progression, after the imaging sessions were terminated. However, the reports of
numerous, repetitive SDs in the late post-stroke phase, in animals models (Hartings et al.,
2003) and in clinical recordings (Dohmen et al., 2008) emphasize that SDs should be
considered for these later times as well.

5.6 Figure Legends
Figure 5.1: Synaptic Zn2+ release in neocortical slices during SD. A. Intrinsic optical
signal (IOS) depicting the propagation of SD. SD was induced by bath application of
40mM KCl, and in this representative slice propagated from the right to the left of the
slice (arrows). (top right) Representative IOS trace showing the kinetics of the light
transmission during and after the passage of SD.

(bottom right) Extracellular DC

potential recording showing the sharp negative deflection characteristic of SD.

B.

Fluorescence imaging of FluoZin-3 in a representative wild type slice with kinetic profile
of a large extracellular FluoZin-3 signal coincident with the extracellular DC shift. C.
Fluorescence imaging of FluoZin-3 in a representative ZnT3 KO slice depicting a small
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decrease in the fluorescence signal coincident with the passage of SD. D. Summary data
from wild type and ZnT3 KO slices showing the peak FluoZin-3 response during SD.
Numbers in bars represent the number of slices used from each genotype.

Figure 5.2:

Synaptic Zn2+ release during SD in vivo imaged with single-photon

microscopy.

A.

Large FluoZin-3 fluorescence increases were observed during the

passage of SD in a wild type animal. The kinetics of the FluoZin-3 response was plotted
with the extracellular DC recording, and shows that the FluoZin-3 fluorescence increase
occurs with the sharp negative DC shift. B. FluoZin-3 responses were completely
abolished in a ZnT3 KO animal imaged under the same conditions as A. Instead, an
amplified autofluorescence decrease was observed, consistent with in vitro observations.
C. Repetitive SDs generated in the same animal show similar FluoZin-3 peak increases
with each event. Arrows indicate KCl application to induce SD. Data was collected with
10x water immersion objective. D. Summary data from 10x water immersion objectives
showing the larger peak FluoZin-3 response to the first SD in wild type animals, and the
small decreases attributed to autofluorescence in the ZnT3 KO animals. Numbers in bars
represent the numbers of animals from each genotype.

Figure 5.3: Source of FluoZin-3 signals during two-photon microscopy in vivo. A. Raw
fluorescence image from a wild type animal after FluoZin-3 and CaEDTA superfusion
(20x water immersion objective). Three regions of interest are drawn to include: brain (50µm, red), dura (0µm, blue), and well (+70µm, green). Scale bar 200µm. A series of
images (ΔF/F0) acquired during the passage of SD show the vast majority of FluoZin-3
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fluorescence detected occurred within the brain. A small response is seen in the well
above the brain following the passage of SD. B. Two-photon imaging of FluoZin-3
fluorescence from a representative ZnT3 KO animal showed small fluorescence
decreases during SD, in agreement with previous in vitro slice and in vivo single-photon
work.

Figure 5.4: Detection of synaptic Zn2+ release during bipolar electrical stimulation. A.
FluoZin-3 response from a wild type animal during a 50Hz stimulation train. Images at
the top show raw FluoZin-3 fluorescence (left), baseline ΔF/F0 1s before (middle), and
0.5s after stimulation (right). The dura surface is outlined for reference in the ΔF/F0
images. (*) indicates location of the bipolar stimulating electrode. Scale bar 200µm.
Traces at bottom compares the autofluorescence response (in the absence of FluoZin-3,
open circles) to the response generated in the presence of FluoZin-3 (filled squares) to a
50Hz stimulation train (grey bar). B. Representative images and traces from a ZnT3 KO
animal to a 50Hz stimulation train, as in A. C. Stimulation response curve showing
greater FluoZin-3 signals to higher stimulation frequencies in wild type animals.

Figure 5.5:

Synaptic Zn2+ release during SD generated by focal ischemia.

A.

Confirmation of loss of cerebral blood flow during dMCAO. (left) Baseline image of
cerebral blood flow.

(middle) Montage of images following dMCAO showing

propagation of SD (arrows indicating leading edge of SD). (right) Kinetic trace of CBF
during dMCAO. SD onset indicated by arrow. B. FluoZin-3 imaging in a representative
wild type animal during dMCAO. (left) Low power (4X air) autofluorescence image of
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cortical surface through open cranial window (dura intact). (middle) Series of FluoZin-3
fluorescence images (in the presence of CaEDTA) depicting the propagation of Zn2+
release during SD generated by dMCAO.

(right) Kinetic profile of FluoZin-3

fluorescence during SD (indicated by arrow). C. FluoZin-3 imaging in a representative
ZnT3 KO animal during dMCAO. (left) Low power (4X air) autofluorescence image of
cortical surface through open cranial window (dura intact). (middle) Series of FluoZin-3
fluorescence images (in the presence of CaEDTA) showing a lack of increased FluoZin-3
fluorescence during SD generated by dMCAO. (right) Kinetic profile of FluoZin-3
fluorescence during SD (indicated by arrow).

Figure 5.6: Synaptic Zn2+ contributes to acute ischemic injury. A. Whole brain TTC
stain from a wild type animal 24hrs following permanent dMCAO showing the cortical
infarct area. B. Whole brain TTC stain from a ZnT3 KO animal 24hrs following
dMCAO revealed a smaller surface cortical infarct. C. Wild type brain slices (2mm
thickness) from a representative animal stained with TTC 24 hours after dMCAO show
an infarct restricted to cortical tissues spread over several sections. D. Slices from a
representative ZnT3 KO animal stained with TTC showed a reduced cortical infarct. E.
Summary data of infarct volumes from wild type and ZnT3 KO animals 24hrs following
permanent dMCAO. Numbers in bars represent the number of animals included in the
analysis (*p=.024).

Supplemental Figure 5.1: Permeation of FluoZin-3 through the dura. A. Fluorescence
intensity of FluoZin-3 was plotted as a function of time at a depth of 50µm below the
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dura. Arrows indicate when agents were applied, and the durations of applications. A
marked fluorescence increase was observed immediately following FluoZin-3 application
to the cortical surface (200µL/min for 2min). Addition of CaEDTA reduced fluorescence
levels to that of the tissue autofluorescence (indicated by dashed line). FluoZin-3 and
CaEDTA were then both washed for an extended period of time (~80 min) from the
imaging well. Subsequent application of ZnCl2 caused a large fluorescence increase.
This indicates that FluoZin-3 was still present in the brain parenchyma following
application and subsequent wash-out. Letters in parentheses represent times where Zstacks were obtained and plotted in (B). B. Fluorescence Z-stacks acquired at time
intervals depicted in (A). Application of FluoZin-3 (open circles) showed a marked
increase in fluorescence above the dura, with a rapid decrease to near autofluorescence
levels (filled squares) around 50µm below the dura. Addition of 1mM CaEDTA (open
triangles) resulted in the reduction of fluorescence above the dura. It is noted that there
was still an increased signal at the dura surface in the presence of CaEDTA. After wash
out of FluoZin-3 and CaEDTA, the signals obtained (open diamonds) were nearly
identical to autofluorescence levels. Following the wash out period, ZnCl2 was added to
determine if any FluoZin-3 was still present. The addition of ZnCl2 (asterisks) resulted in
an increase both above and well below the dura, with clear increases evident to 100µm
below the dura.
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Figure 5.2
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Figure 5.3
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Figure 5.4
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Figure 5.5
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Figure 5.6
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Supplemental Figure 5.1
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Chapter 6: Discussion

6.1 Summary of Dissertation Studies
The work presented here provides new insights into the sources of toxic Zn2+
accumulation relevant for ischemic injury. Studies from Chapter 2 provide the first
evidence for large releases of synaptic Zn2+ during the passage of SD with little
decrement in the levels of synaptic Zn2+ released with each event triggered by high K+SD.

Further studies supported true synaptic release of Zn2+ and translocation into

postsynaptic cells following SD through the use of intracellular indicators for, and
extracellular chelators of, Zn2+.
Results from Chapter 3 expanded on and clarified previously published work and
provide evidence that Zn2+ chelation by a membrane permeable Zn2+ chelator, TPEN,
was only protective by significantly delaying the onset of OGD-SD (Medvedeva et al.,
2009). When slices were exposed to a defined length of OGD, in the presence of TPEN,
where SD did not occur, there was complete neuronal recovery. However, even when
OGD-SD occurred in the absence of Zn2+, irrecoverable neuronal injury still occurred,
which was mediated by Ca2+. Thus, the current work suggests that the recovery seen
previously was likely due to Zn2+ chelation delaying the onset of SD (Dietz et al., 2008),
and sheds light on the importance for monitoring the time-course of experiments when
testing new neuroprotective treatments.
The work presented in Chapter 4 provided evidence that Zn2+ accumulation can
significantly impair the ability to recover from SD. Suppression of evoked synaptic
potentials, DC shift durations, and extracellular adenosine accumulation were all
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prolonged only when there was significant Zn2+ accumulation combined with SD.
Additionally, there was a surprising finding that a rapid adaptation occurs following
repetitive SDs that preconditions tissues to a subsequent Zn2+ challenge. This work
suggests that not only can Zn2+ accumulation contribute to impaired recovery following
SD, but that SD itself may have some significant short term beneficial effects that need to
be further investigated.
In Chapter 5, the first fluorescence visualization of synaptic Zn2+ release in vivo is
provided.

Synaptic Zn2+ release was seen following three paradigms, electrical

stimulation, SD in healthy tissue, and SD generated by distal middle cerebral artery
occlusion (dMCAO). Both single- and two-photon microscopy were used to verify that
synaptic Zn2+ release occurred within the brain parenchyma. Finally, this work also
provides the strong evidence that synaptic Zn2+ significantly contributes to the
progression of ischemic injury by measuring infarct volumes in wild-type and ZnT3 KO
animals following dMCAO.

6.2 Imaging Synaptic Zn2+ Release
There has been a controversy in the Zn2+ field as to whether there is indeed
synaptic Zn2+ release. Previous studies have utilized extracellular Zn2+ indicators, which
may produce a false signal, as suggested by the works of Alan Kay’s group (Kay, 2003).
This point was addressed in the current studies by using the following approach. First, by
using the extracellular Zn2+ chelator CaEDTA, all sources of extracellular Zn2+ were
removed, including contaminating Zn2+ as well as any possibility of the presence of Zn2+
coating the extracellular surface of cells, before SD induction. Secondly, by combining
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this with intracellular measurements from single cells loaded with FluoZin-3
(experiments performed by Isamu Aiba) any increases in intracellular fluorescence can be
attributable to synaptic Zn2+ translocation. Increases in intracellular fluorescence were
only seen following SD in wild-type animals and not in ZnT3 KO animals.

This

observation, combined with the large releases of synaptic Zn2+ following SD, supports
the hypothesis that synaptic Zn2+ is released upon neuronal activation and translocates
into postsynaptic cells.
The implication that synaptic Zn2+ release occurs in vivo is based on in vitro
evidence for the presence of synaptic Zn2+ and the detection of release previously
described in the Introduction (see section 1.2.1). By utilizing similar approaches used for
imaging synaptic Zn2+ release in slice work, the results from Chapter 5 provide the first
real-time fluorescence detection of synaptic Zn2+ release in vivo. The FluoZin-3
fluorescence signal seen during SD did not decrease following repetitive episodes of SD
in the same tissue, both in vitro and in vivo. This could suggest that there is only a
subpopulation of synaptic vesicles released during SD, that synaptic Zn2+ is completely
re-filled between SD episodes, or a contribution of both mechanisms, contribute to this
lack of decreased signal.
Little is known about synaptic vesicle dynamics during and following SD. Three
pools of synaptic vesicles have been identified and their release characteristics depend on
the intensity and duration of the stimulation. The readily releasable pool (RRP) and the
recycling pool are released and can refill within seconds of the stimulation, while the
reserve pool requires a more prolonged stimulation (seconds to minutes) to be released
and is much slower, on the order of minutes, to refill (Rizzoli and Betz, 2005). Due to
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the intense neuronal depolarization that can last for minutes during SD, it remains unclear
if all available synaptic vesicles could be released during SD. Synaptic vesicle fusion is
dependent on the influx of Ca2+ into the presynaptic terminal, predominantly through
P/Q-type calcium channels (Pietrobon, 2005).

These calcium channels show more

sensitive voltage-dependent inactivation compared to L-type Ca2+ channels (Villarroya et
al., 1999), which could suggest that, despite the prolonged neuronal depolarization during
SD, complete synaptic vesicle release may not occur. In support of this, it was recently
shown that immediately following the passage of SD, the frequency of spontaneous
excitatory postsynaptic currents was significantly increased (Aiba and Shuttleworth,
2012), suggesting that at this time-point, sufficient amounts of synaptic vesicles are still
present. It is not known if and how synaptic vesicle re-filling contributes to the refractory
period of SD, but further study might indicate if it is possible to target this process to
prevent the occurrence of these events selectively in ischemic tissue.
It is not yet known how Zn2+ is cleared from the synapse following normal
neuronal activity or SD, and whether this clearance is similar to classical neurotransmitter
clearance mechanisms. Astrocytes play a major role in glutamate clearance, mediated by
both the glutamate transporter-1 (GLT-1) and the glutamate/aspartate transporter
(GLAST) (Rothstein et al., 1996). Several Zn2+ transporters are expressed on the plasma
membrane and could contribute to Zn2+ clearance, with the primary Zn2+ importer being
ZIP1 (Gaither and Eide, 2001b). This transporter appears to play a role in the clearance
of Zn2+ following seizure-like activity ((Qian et al., 2011) and see section 6.4 below),
suggesting the presence of clearance mechanisms for extracellular Zn2+.

The

mechanism(s) underlying ZnT3 transport of Zn2+ into synaptic vesicles also remains to be
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elucidated. Studies conducted with bacterial analogues of Zn2+ transporters suggest that
Zn2+ transport into vesicles is dependent on an electrochemical H+ gradient generated by
a V-ATPase (MacDiarmid et al., 2002, Smidt and Rungby, 2012). Whether or not a
similar mechanism exists for ZnT3 is not known, and how this relates to glutamate refilling after SD could be assessed in future studies.
Utilizing the phenomenon of SD was an ideal starting model to investigate
fluorescence detection of synaptic Zn2+ release. Having shown large, robust signals
following not only SD, but direct electrical stimulation, leads to the question of whether
synaptic Zn2+ release can be detected following normal physiological stimulation in vivo.
Recent work utilizing whisker stimulation in rodents has revealed alterations in the levels
of synaptic Zn2+, assessed by histochemical stains, in the barrel cortex of mice (Brown
and Dyck, 2002, 2005, Nakashima and Dyck, 2010). It should be noted that these studies
utilized prolonged (up to 24hrs) whisker stimulation to see reductions in synaptic Zn 2+
levels. This may result in adaptations to the constant stimulation by reducing the amount
of postsynaptic glutamate receptors. Zn2+ can inhibit NMDA receptors (Paoletti et al.,
1997) and act to modulate neuronal communication by influencing glutamate signaling.
Therefore, the constant stimulation may result not in a depletion of synaptic Zn 2+ due to
constant release, but in a modulation of synaptic Zn2+ present in vesicle to decrease the
postsynaptic inhibition on fewer receptors and allow for proper signaling. Nevertheless,
from these studies, it would seem apparent that the barrel cortex could be an ideal region
to test for synaptic Zn2+ release during physiological activation in vivo.
Pilot studies were conducted for the present dissertation work to investigate the
possibility of imaging synaptic Zn2+ release during whisker stimulation in mice.
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However, FluoZin-3 fluorescence signals could not be detected in those studies following
whisker stimulation. It would seem appropriate to investigate this possibility further, for
example by utilizing different anesthetics to optimize the stimulus conditions, using
electrophysiological measures of effective activation. Isoflurane, the main anesthetic
used in the current work, significantly inhibits evoked responses (Rojas et al., 2006) and
could have significantly reduced the intensity of whisker stimulation-evoked cortical
signals. Other anesthetics which are more suited for electrophysiology in vivo may be
useful in re-examining this possibility. However, based on the relatively small FluoZin-3
signal amplitudes acquired from strong direct electrical stimulation of the cortex (Chapter
5), it still may be necessary to utilize higher power objectives to image a smaller portion
of the cortex, and improve detection sensitivity for small events such as whisker
stimulation. Additionally, the use of CaEDTA should be avoided here to allow for any
synaptic Zn2+ release to interact solely with the indicator and remove the possibility of
added Zn2+ chelation, and therefore decreased FluoZin-3 responses, during whisker
stimulation.
Direct fluorescence detection of synaptic Zn2+ release in vivo (Chapter 5) further
supports the possibility of using FluoZin-3 fluorescence as a surrogate for “imaging”
synaptic glutamate release. This hypothesis was originally based on studies conducted in
hippocampal slice preparations that found that the levels of extracellular FluoZin-3
fluorescence were positively correlated with the amplitudes of evoked excitatory
postsynaptic potentials (Qian and Noebels, 2005, 2006). This has the potential for
applications investigating either increased or decreased neurotransmitter release in vivo,
such as during synaptic plasticity (LTP and/or LTD). Interestingly, certain mutations in
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presynaptic P/Q-type Ca2+ channels have been implicated in migraine with aura, a
condition which is thought to be mediated by SD.

These mutations can result in

increased Ca2+ conductance leading to enhanced neurotransmitter release, which is
thought to facilitate the occurrence of SD (Tottene et al., 2009). Imaging synaptic Zn2+
release in these models could be another measure of increased neurotransmitter release.

6.3 Targets for Synaptically Released Zn2+
While the present work does not directly address actions of synaptic Zn2+ release
on postsynaptic targets, one of the more relevant targets for SD and ischemia would be
the NMDA receptor.

The NMDA receptor can be inhibited by extracellular Zn2+

interacting with the NR2A subunit (Paoletti et al., 1997). As described earlier, NMDA
receptors are critical for the propagation of SD, and therefore it seems likely that the large
amounts of synaptic Zn2+ released during SD may have an impact on NMDA receptor
function. Indeed, studies from our lab conducted in parallel with the present work have
indicated that synaptic Zn2+ release during SD acts as an intrinsic inhibitor on SD
propagation in vitro and in vivo (Aiba et al., 2012), further supporting synaptic Zn2+
release but also implicating a physiological role for Zn2+ release in vivo. The inhibition
of SD by synaptic Zn2+ could account for the increased numbers of SDs seen in ZnT3 KO
animals in response to KCl applications in the previous (Aiba et al., 2012) and in the
current studies (Chapter 5). However, whether this inhibition occurs under ischemic
conditions is still unclear.
The experiments from Chapter 5 show that ZnT3 KO animals have significantly
smaller infarcts compared to wild type animals. If the ZnT3 KOs are still experiencing a
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greater number of SDs in the post-ischemic period, based on previous reports they should
have larger infarcts with the increased occurrence of SDs (Back et al., 1996, Busch et al.,
1996). Yet ZnT3 KO animals have smaller infarcts. The number of SDs occurring in
these animals following dMCAO was not investigated in the current work and future
studies should examine the frequency of SDs during longer recording sessions in these
two genotypes to determine whether there is a difference. If there is still an increased
number of SDs in ZnT3 KO animals, it could support the hypothesis that synaptic Zn2+
release and postsynaptic accumulation has a major role in limiting the recovery from SD
(see Chapter 4) and contributes to the progression of ischemic injury.
Recently, an orphan G protein-coupled receptor was found to be sensitive to Zn2+
(GPR39/mZnR) and activation of this receptor in response to exogenous Zn2+ application
results in release and accumulation of intracellular Ca2+ (Hershfinkel et al., 2001). This
receptor was then identified within the hippocampus, where similar intracellular Ca2+
increases were observed in slices in response to exogenous applications of Zn2+, as well
as from the release of endogenous synaptic Zn2+ (Besser et al., 2009).

Following

electrical stimulation of the mossy fibers in hippocampal slices, increases in intracellular
Ca2+ were seen in control animals, while Ca2+ increases were significantly reduced in
ZnT3 KO animals (Besser et al., 2009). In addition, subsequent studies utilizing GPR39
KO mice found similar levels of synaptic Zn2+ release in hippocampal slices following
similar mossy fiber stimulation, and subsequent postsynaptic Ca2+ increases were reduced
in these animals (Chorin et al., 2011), supporting a role for synaptic Zn2+ release and
postsynaptic interactions. Following SD there is an increase in postsynaptic [Ca2+] that
can either be fully recoverable resulting in no injury in healthy conditions, or can be
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irrecoverable leading to neuronal death depending on the metabolic status of the tissue
(Dietz et al., 2008, Aiba and Shuttleworth, 2012). From the current work, the large levels
of synaptic Zn2+ release during SD may activate postsynaptic mZnRs and contribute to
the increased levels of intracellular Ca2+ following SD. Currently it is not known what
the effects of knocking out the zinc-sensing receptor are on SD and ischemic injury and
would be important to investigate in future studies.

6.4 Routes of Zn2+ Influx
Routes of Zn2+ influx may be important to investigate as potential targets to
prevent neurotoxic accumulation of extracellular Zn2+ following ischemia. Several routes
have been identified to allow Zn2+ entry, and not surprisingly, many of the pathways are
routes originally found to be Ca2+ permeable. Voltage-gated Ca2+ channels have been
found to be permeable to Zn2+, as by blocking these channels with Gd3+, Cd2+, or
nimodipine (an L-type Ca2+ channel blocker) reduced the uptake of Zn2+ into cultured
neurons (Weiss et al., 1993, Kerchner et al., 2000, Sheline et al., 2002). It was also
recently discovered that Zn2+ entry through L-type Ca2+ channels was an important
trigger for the initiation of some forms of SD in slice preparations (Dietz et al., 2008). Ltype Ca2+ channel blockers prevented Zn2+ uptake, and under certain conditions relevant
for ischemia, was sufficient in blocking SD alltogether (Dietz et al., 2008).
Zn2+ can also enter through Ca2+-permeable AMPA/kainate receptors. This was
shown by applying exogenous extracellular kainite and Zn2+ to cultured cortical neurons
in the absence of extracellular Na+, to prevent depolarization induced Zn2+ entry, and
found Zn2+ accumulation mediated by AMPA/kainate receptors (Yin and Weiss, 1995).
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AMPA receptors that lack the GluR2 subunit are permeable to both Ca2+ and Zn2+
(Pellegrini-Giampietro et al., 1997). Interestingly, it was reported that GluR2-containing
AMPA receptors are down-regulated in hippocampal CA1 neurons 72 hours following
global ischemia in gerbils (Gorter et al., 1997). Blocking Ca2+-permeable AMPA/kainate
receptors with a compound that only recognizes GluR2 lacking AMPA receptors
(Naspm), partially prevented toxic intracellular Zn2+ accumulation (assessed by TSQ
staining) and subsequent neuronal death assessed at the same 72 hour mark after ischemia
(Noh et al., 2005). Therefore, it is possible that synaptic Zn2+ release during SD could
accumulate via Ca2+-permeable AMPA/kainate receptors in the days following the initial
ischemic event.
As noted above, a recent study has also suggested significant contributions of the
plasma membrane Zn2+ transporters ZIP1 and ZIP3 to intracellular Zn2+ accumulation
following seizure-like activity (Qian et al., 2011). Thus, knockouts of these transporters
significantly reduced Zn2+ accumulation in hippocampal brain slices, and reduced
neuronal damage following kainic acid induced seizures in vivo (Qian et al., 2011). The
results from Chapter 2 suggest that the extracellular Zn2+ levels remain elevated for
several minutes following SD. When other sources of Zn2+ flux may be blocked at this
time, such as from voltage-dependent channel inactivation due to persistent membrane
depolarization, Zn2+-selective transporters may continue to import extracellular Zn2+ into
cells.

Future studies could investigate these routes of Zn2+ entry following SD to

determine whether synaptic Zn2+ translocation can be prevented by ZIP inhibition.
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6.5 Potential Mechanisms Linking Synaptic Zn2+ to Ischemic Damage
Metabolic Inhibition
The current work provides evidence for a novel mechanism that links Zn2+ to
neuronal injury (Chapter 4). This study showed that intracellular Zn2+ accumulation was
found to enhance the metabolic burden associated with SD. The prominent hypothesis in
the SD field is that impaired metabolic activity following repetitive SDs in compromised
tissue is the major mechanism behind the deleterious effects of SD (Dreier, 2011,
Lauritzen et al., 2011). As mentioned in the Introduction, experimental recordings of SD
found that these events can continuously cycle around ischemic infarcts and result in the
expansion of infarct with each cycle (Nakamura et al., 2010, Kumagai et al., 2011).
Additionally, clinical recordings have identified clusters of SDs, defined as repetitive SD
events occurring within 2hrs from a previous event (Hartings et al., 2011b), to be
associated with enhanced metabolic burden resulting in the expansion of injured tissue
(Dreier, 2011, Hartings et al., 2011b, Sakowitz et al., 2013, Woitzik et al., 2013).
Enhanced metabolic challenges are associated with an increase in extracellular
adenosine accumulation from a wide range of sources, including from the breakdown of
ATP (Dunwiddie and Masino, 2001). This is thought to be neuroprotective, as adenosine
can decrease the release of glutamate and therefore help prevent excessive glutamate
signaling and excitotoxicity (Rudolphi et al., 1992b, Dunwiddie and Masino, 2001,
Lovatt et al., 2012).

It was recently found that SD results in a large extracellular

adenosine accumulation, providing a mechanism that mediates the secondary synaptic
suppression following SD (Lindquist and Shuttleworth, 2012). In the current study, when
intracellular Zn2+ levels were increased, SD resulted in larger extracellular adenosine
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accumulations and prolonged DC shift durations, both measureable indicators for an
increase in metabolic burden (Rudolphi et al., 1992a, Masino et al., 1999, Hartings et al.,
2011b). Therefore, the results of the current study suggest that the synaptic Zn2+ release
and accumulation following repetitive SD events could be a potential link for the
increased metabolic challenge associated with these events, under compromised
conditions, leading to neuronal injury.
This raises the question as to whether additional, or alternative, metabolic
substrate supplementation would enable tissues to better recover from elevated
intracellular Zn2+ combined with SD. Following metabolic inhibition by toxic Zn2+
exposures, pyruvate supplementation was beneficial in limiting the amount of neuronal
injury in culture (Sheline et al., 2000). Results from the current study suggested that
metabolic inhibition, in slice experiments, occurred downstream of pyruvate utilization
(Chapter 4), suggesting that metabolic supplementation would need to be provided at
later stages. This warrants further study to elucidate the site(s) where Zn2+ inhibits
metabolism to test whether metabolic supplementation could be a beneficial strategy to
help tissues recover following SD.
In a previous report, following OGD exposures in slice, rapid Zn2+ accumulation
into mitochondria significantly enhanced mitochondrial dysfunction leading to Ca2+
deregulation and impaired synaptic recovery, all of which was ameliorated by total Zn 2+
chelation (Medvedeva et al., 2009). While it was suggested that Zn2+ was contributing to
the majority of the effects reported, recent evidence (Dietz et al., 2008) and results from
Chapter 3 support the hypothesis that SD is the major culprit behind neuronal injury in
the slice OGD model. Zn2+ chelation with TPEN significantly delayed the onset of SD,
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consistent with prior work (Dietz et al., 2008), however, even with Zn2+ chelation, OGDSD could still be induced in the current study and resulted in irrecoverable neuronal
injury. These observations are consistent with a model where under complete metabolic
substrate removal, intracellular Zn2+ increases facilitate the generation of SD events and
subsequent Ca2+ deregulation leading to neuronal injury (Dietz et al., 2008, Vander Jagt
et al., 2008, Vander Jagt et al., 2009a). It could be possible that with repetitive rounds of
SD during ischemia, synaptic Zn2+ release and accumulation in mitochondria may
contribute to the initiation of subsequent SDs, furthering metabolic compromise and
leading to neuronal injury.

Blood-Brain Barrier Disruption
Synaptic Zn2+ release was found to significantly contribute to ischemic injury
progression in vivo (Chapter 5). One interesting possibility is the potential for synaptic
Zn2+ to activate extracellular matrix metalloproteases (MMPs) and result in the
breakdown of the extracellular matrix and components comprising the blood-brain barrier
(BBB). MMPs, specifically MMP-9, have been implicated to lead to BBB disruption in
brain pathologies, such as bacterial meningitis (Leppert et al., 2000) as well as following
ischemia/reperfusion (Aoki et al., 2002). MMP-9 protein expression was found to be upregulated starting at 3hrs and continued to increase for up to 24hrs following permanent
MCAO in mice (Asahi et al., 2000). Furthermore, utilizing MMP-9 knockout mice, the
same group showed a significant reduction in infarct volume in the MMP-9 KO mice
compared to wild types (Asahi et al., 2000). A more recent study revealed that following
3 repetitive SDs in normally perfused tissue in vivo, MMP-9 levels increased in a fashion
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similar to that described following ischemia above, steadily increasing and peaking at
24hrs (Gursoy-Ozdemir et al., 2004). Correspondingly, an increase in Evan’s Blue
leakage was seen in a similar manner to that of increased levels of MMP-9, and by either
blocking SD, inhibiting MMPs, or using MMP-9 KO mice there was a significant
reductions in Evan’s Blue leakage (Gursoy-Ozdemir et al., 2004), suggesting that MMP-9
activation following SD results in BBB disruption. As MMPs require Zn 2+ for catalytic
activity, it seems very possible that the synaptic Zn2+ released during SD shown in the
current studies contributes to the activation of MMP-9 and subsequent BBB disruption.
This could provide a potential mechanism behind the enhanced BBB disruption and
increased infarct volume reported in previous studies.

Further looking at MMP-9

activation in ZnT3 KO animals could provide new insights into how synaptic Zn2+ may
contribute to BBB disruption and ischemic injury.
Another potential mechanism for the decreased infarct size in ZnT3 KO animals
seen in Chapter 5 could result from an interesting effect that brain endothelial cells have
in response to Zn2+ depletion.

Di Cello et al. tested the transendothelial electrical

resistance (TEER) across a film of cultured human brain microvascular endothelial cells
(HBMEC) as a measure of the strength of the tight junctions created by these cells in
culture (Di Cello et al., 2005). They found that in response to Zn2+ removal, TEER
decreased in non-brain endothelial cells indicating disruption of the tight junctions,
however, brain endothelial cells displayed an increase in TEER in response to Zn2+
removal, indicating an enhancement of tight junctions (Di Cello et al., 2005). This
process could strengthen the BBB and help resist against breakdown and leakage
following SD and ischemia.

An exchangeable pool of Zn2+ was found in the
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cerebrovascular wall of mice (Friedlich et al., 2004). The source of this Zn2+ appeared to
originate from synaptic stores, as this pool was not detected in ZnT3 KO mice (Friedlich
et al., 2004). Therefore, one explanation of reduced infarct volumes in ZnT3 KO mice
could be from preventing BBB disruption by the lack of synaptic Zn2+ strengthening tight
junctions.

Another important contributor to the BBB function is from pericytes.

Pericytes are located mainly on the abluminal side of capillaries, express tight junction
markers, and can contribute to capillary constriction (Sa-Pereira et al., 2012).
Specifically, it was found that regardless of reperfusion following ischemia, contraction
of pericytes can still impair blood flow through capillaries (Yemisci et al., 2009). It is
unclear what role, if any, Zn2+ has on pericytes, but the presence of an exchangeable pool
of Zn2+ within the cerebrovascular space could suggest that synaptic Zn2+ might interact
with pericytes. Whether or not enhanced cerebral blood flow could contribute to the
reduction in infarct volume in ZnT3 KO mice remains an open question.

Inflammation
Inflammation also plays a major role in injury mechanisms following ischemia
(Yenari et al., 2010).

It was recently observed that extracellular Zn2+ can activate

microglial cells (Kauppinen et al., 2008), likely by Zn2+ uptake via ZIP1, and subsequent
signaling cascades (including PARP-1 and NADPH oxidase activation, reactive oxygen
species (ROS) generation, and ATP secretion) resulting in microglial activation
(Kauppinen et al., 2008, Higashi et al., 2011). Activated microglial cells can secrete proinflammatory cytokines, MMPs, and generate ROS, all of which could impair recovery
following ischemia (Yenari et al., 2010). It would seem possible that synaptic Zn2+
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release contributes to microglia activation following ischemia, as injections of CaEDTA
immediately following transient 20min global ischemia in mice decreased the number of
activated microglia (Kauppinen et al., 2008). As inflammation was thought to be one of
the major mechanisms for the expansions of some lesions at later times following
ischemia (Dirnagl et al., 1999), it seems important to investigate the possibility of
synaptic Zn2+ to this process.

6.6 Beneficial Effects of Spreading Depolarizations
Synaptic Zn2+ Release
As discussed above, numerous studies have investigated the deleterious roles Zn2+
plays following ischemia. However, there is a possibility that synaptic Zn 2+ may provide
some protection. Endogenous synaptic Zn2+ release may limit the occurrence of SDs, as
described above (Aiba et al., 2012). Synaptic Zn2+ release may also contribute to an
ischemic preconditioning effect in healthy and nominally healthy tissue surrounding the
penumbra and ischemic core. A recent report investigated the potential for Zn2+ to
contribute to preconditioning effects in cell culture and found that a sub-lethal exposure
to Zn2+ conferred neuroprotection to a later lethal challenge (Aras et al., 2009). The
observed Zn2+-induced preconditioning effect in that study was mediated by PKC
signaling, which has been implicated in other neuronal preconditioning paradigms (Li et
al., 2005, Sivaswamy et al., 2010).
Following ischemia, an increase in neurogenesis can occur that directs new
neuronal precursors to the injured areas and is thought to contribute to the repair process
(Ohira, 2011). The mechanism(s) of this increased neurogenesis remains unclear, but

165

recent experimental evidence suggests that SD might play a role. Inducing SD in the
neocortex in vivo led to an increase in neurogenesis in the dentate gyrus (Urbach et al.,
2008) and new immature neurons found in the cortex (Xue et al., 2009). In these studies,
neurogenesis was assessed days to weeks following a repetitive SD stimulation paradigm
ranging from hours to days. It was also recently found that by either chelating Zn 2+ or
using ZnT3 KO mice, there was a reduction in neurogenesis at basal conditions (in the
absence of SD) and following hypoglycemia (Suh et al., 2009), a condition found to
transiently influence hippocampal neurogenesis (Suh et al., 2005).

Therefore, it is

possible that synaptic Zn2+ released during repetitive SDs following ischemia could be a
potential mechanism for the increased neurogenesis reported following ischemia.

Reactive Oxygen Species Signaling
One interesting hypothesis of intracellular Zn2+ accumulation combined with SD
described in the discussion section of Chapter 4 is the possibility for the enhanced
generation of reactive oxygen species (ROS). The recovery of fEPSPs was enhanced in
the presence of DMSO following Zn/Pyr exposure with SD, and recently it was reported
that DMSO has antioxidant properties (Sanmartin-Suarez et al., 2011). As mentioned in
the Introduction, Zn2+ accumulation into mitochondria can lead to the generation of ROS,
likely due to inhibition of the electron transport chain. This effect could account in part
for the decreased recovery of fEPSPs seen following Zn/Pyr exposure combined with SD.
Interestingly, ROS are not thought to solely be involved in neuronal injury processes.
There has been accumulating evidence that ROS can act as a signaling molecule.
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Originally, ROS were found to be an important mediator in the formation of LTP
in the hippocampus in a series of studies by Eric Klann’s group, whereby application of
exogenous ROS scavengers or the overexpression of endogenous ROS scavengers greatly
decreased LTP formation (Klann, 1998, Klann et al., 1998, Thiels et al., 2000).
Following repetitive SDs, a potentiation of fEPSPs was observed, akin to LTP, and this
LTP-like effect was observed in the current studies (Chapter 4), as well as in rat (Footitt
and Newberry, 1998) and human tissues (Berger et al., 2008). It is not known whether
ROS plays a role in this LTP-like effect following SD. In a set of supplementary studies
in the presence of DMSO, the LTP-like effect was decreased following repetitive SDs
(see Appendix Figure A1).

Additionally, in these same supplementary studies, the

protective effect (metabolic adaptation) of SD was lost when these slices were
subsequently exposed to the Zn/Pyr challenge combined with SD (see Appendix Figure
A1). If DMSO is indeed acting as an ROS scavenger, it would seem that ROS not only
play a role in the observed LTP-like effect following SD, but can be neuroprotective
following SD.

Consistent with this idea is the observation that ROS can mediate

preconditioning effects to subsequent noxious stimuli, and this preconditioning effect was
attenuated by the antioxidant vitamin E (Ravati et al., 2000). Additional studies with
widely used antioxidants, such as the vitamin E or its analog trolox, will be useful to
confirm the possibility of neuroprotective ROS signaling following SD.

6.7 Differing Effects of Extracellular and Intracellular Zn2+
The development of new therapeutic targets for preventing the spread of ischemic
damage is greatly needed, especially if they can be given, and are effective, at time-points
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later than the only current FDA approved drug, t-PA. Blocking the occurrence of SD
following ischemia is potentially one such target that could have profound effects. These
events continuously occur for days following the initial ischemic event and can
significantly contribute to the evolution of the ischemic core. However, finding specific
blockers for SD has been challenging, and only one such drug has been identified to have
some clinical benefit, ketamine (Sakowitz et al., 2009). An adjunct approach would be to
target and limit the deleterious consequences following SD. Synaptic Zn2+ significantly
contributed to ischemic injury in the current study and prompts the question as to whether
this source of Zn2+ can be selectively targeted following ischemia.
There is a potential for a dual role of synaptic Zn2+ following ischemia. In the
current study, it was shown to be neurotoxic under ischemic conditions, however, as
mentioned above, synaptic Zn2+ can limit the occurrence of SDs in vivo under normal
conditions (Aiba et al., 2012). One hypothesis is that synaptic Zn2+ release is beneficial
while it remains in the extracellular space, but once it enters the postsynaptic cell it
becomes neurotoxic. Therefore, chelating intracellular Zn2+ might be more beneficial
than chelating either extracellular or all Zn2+. While the extracellular Zn2+ chelator
CaEDTA has been shown to be neuroprotective, the slow kinetics of the chelator make it
so that it may not be able to chelate all extracellular Zn2+ released during SD before it can
enter postsynaptic cells (see Chapters 2 and 5). Further understanding of the roles of
synaptic Zn2+ release during SD and ischemia are needed to determine if drugs that can
interfere with the activity of ZnT3, or that can selectively chelate intracellular Zn2+, will
be better suited to provide protection following ischemia and other disorders involving
excess Zn2+ accumulation.
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Recent experimental and clinical trials using a newly synthesized metal chelator
has utilized this approach and had some successful results. This chelator, DP-b99, is a
lipophilic chelator that integrates within the plasma membrane with the metal binding
domain facing the intracellular compartment (Barkalifa et al., 2009). The affinity is such
that it will not affect normal intracellular Zn2+ binding, but should help prevent toxic Zn2+
surges within the cell that are often seen following ischemia. DP-b99 has been shown to
prevent neuronal injury induced by Zn2+ in cell culture models (Barkalifa et al., 2009),
and has been tested in several phase II clinical trials, some of which have shown
beneficial effects on recovery rate within 9hrs of stroke onset (Diener et al., 2008).
However, subsequent major clinical trials failed to find any benefit of DP-b99 (Lees et
al., 2013). This does not suggest that the concept of chelating intracellular Zn2+ is futile,
as there may be some issues with using membrane associated chelators following
ischemia. Membrane integrity can become disrupted under ischemic conditions and
following SD (Tanaka et al., 1999), therefore potentially allowing dissociation and
removal of the metal chelator from the membrane. One other confound of the study was
that the chelator also bound Ca2+, and could therefore compete with Zn2+ chelation,
potentially allowing for toxic levels of Zn2+ to be attained. Nevertheless, the preliminary
results of this chelator are encouraging and the technical aspects of chelating intracellular
Zn2+ are one the right track. With future developments and research it seems possible to
build on these findings and create more effective intracellular Zn2+ chelators.
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6.8 Critiques of the Current Work
Slice Preparations
The propagation of SD requires the close association of neurons to allow for
extracellular levels of K+ and glutamate to reach threshold and allow for the feed-forward
nature of the event. Therefore, studies of SD are restricted to slice (acute or organotypic)
or in vivo preparations, and cannot be accurately studied in dissociated cell culture
models.

Slice preparations are extremely useful as experimental conditions can be

greatly controlled and manipulated, such as temperature, flow rate, and drug applications.
However, it is worth noting that due to the lack of perfusion throughout the slice from the
vasculature, the delivery of metabolic substrates (O2 and glucose) is limited by diffusion
and the concentration of these substrates in the superfusate. To compensate for this,
slices are usually superfused with high concentrations of glucose (10mM) and saturated
with O2 (typically 95%). These levels are necessary to keep relatively normal neuronal
functions within the slice. However, there may be a steep drop off in O 2 levels within
slice preparations, despite saturating levels in the superfusate, and this needs to be taken
into consideration when interpreting results that may be influenced by O2 levels.
When trying to assess studies of ischemia in slice, it is technically challenging to
reproduce the gradient of ischemia seen in vivo. Typically, entire slice preparations are
exposed to either hypoxia or OGD to assess the effects of ischemia, which limits the
interpretation of the results to either the corresponding hypoxic or ischemic core in vivo.
A recent study utilized focal applications of OGD solution to try and address this
important issue and found that they could create an ischemic core and surrounding
penumbra (Richard et al., 2010). This may be an important model to adapt for studying
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SD mechanisms in slice preparations in the future. Another important aspect of slice
preparations is that the temperatures used for recordings are lower than that in vivo. Most
studies in the current work was performed at either 32°C or 35°C, lower than the 37°C
maintained for in vivo preparations. This is typical for in vitro slice recordings as slice
viability is maintained longer at lower temperatures.

In vivo Preparations
Studies of in vivo brain function in healthy and pathological states are critically
important for scientific research, as they maintain all aspects of biological function.
There are some limitations when using in vivo preparations, however, some of which
have great impact on aspects of studying SD. Cerebral blood flow measurements seem to
be dependent on species, with pronounced hypoperfusion in mice and a transient
hyperemia in rats (Ayata et al., 2004). This may be influenced by the craniotomy
procedure used, as blood volume responses were more similar in intact skull preparations
compared to the exposed cortex (Chang et al., 2010). Both craniotomy techniques (intact
skull and open window) were used in Chapter 5, however blood flow measurements were
restricted to intact skull preparations to minimize the effects of exposed cortex previously
described.
The ability for FluoZin-3, CaEDTA, and Zn2+ to permeate the dura was an
additional surprise in the current studies. Therefore the technical challenge of removing
the dura was absent in the present work. Severe brain swelling can occur following the
removal of the dura in mice (personal observation) and requires the use of a closed
cranial window setup to preserve intracranial pressure. By leaving the dura intact in the
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current studies detailed in Chapter 5, drugs in the superfusate were able to diffuse into the
parenchyma, thereby leaving the system intact. The ability of FluoZin-3 to permeate the
dura is similar to that of in vivo applications of SR101 to label cortical astrocytes
(Nimmerjahn et al., 2004), and speculates as to whether other fluorescent dyes can be
topically applied to dura intact in vivo preparations, in order to reduce not only technical
but physiological issues in dura free preparations.
The anesthetic used for in vivo procedures may also influence SD. The impact of
several anesthetics on the occurrence of SDs has been investigated to test whether they
can inhibit or limit SDs to better understand which anesthetics to use for experimental
settings and which could have a beneficial impact following neurosurgical procedures
(Piper and Lambert, 1996, Kitahara et al., 2001, Kudo et al., 2008, Hertle et al., 2012). In
a set of studies that was conducted in parallel with the current work, it was found that
SDs can occur in mice under simulated neurosurgical anesthesia commonly used in
humans (Carlson et al., 2012). Therefore, when studying mechanisms of SD in vivo, it is
important to address which anesthetic should be used.

FluoZin-3 Measurements
The fluorescent Zn2+ indicator used throughout the current work (FluoZin-3) is
only a single wavelength indicator and therefore ratiometric measurements cannot be
made. This makes it very difficult to calibrate fluorescence signals and generate exact or
estimated Zn2+ concentrations. Genetically-encoded ratiometric Zn2+ indicators have
been developed for use in studying intracellular Zn2+ homeostasis in organelles (Miranda
et al., 2012). Future development of ratiometric indicators that can be exogenously
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applied extracellularly would greatly enhance our understanding of the levels that
extracellular Zn2+ can reach during SD.
Due to the existence of “contaminating Zn2+” in salt solutions and from plastic
tubing (Kay, 2004), an extracellular Zn2+ chelator, CaEDTA, was used in the majority of
the current studies. CaEDTA greatly reduces background fluorescence of FluoZin-3 to
almost autofluorescence levels. This makes reporting signals as %ΔF/F0 potentially
complicating as after background subtraction, F0 reaches very small values, potentially
leading to an overestimate of fluorescence signals. This was noticed when using twophoton imaging of FluoZin-3 and comparing fluorescence signals acquired from singlephoton imaging. FluoZin-3 signals obtained from two-photon imaging were almost 10
times larger than single-photon signals, presumably due to the extremely small
background fluorescence of FluoZin-3 from two-photon excitation. As such, it has been
suggested that FluoZin-3 measurements be internally calibrated to maximal FluoZin-3
fluorescence intensity with applications of saturating exogenous Zn2+ (Kiedrowski,
2011). All FluoZin-3 responses were reported as %ΔF/F0 in the current studies to
maintain consistency throughout and with previous studies. However, future studies
utilizing FluoZin-3 should adopt this as the new standard for reporting fluorescence
signals.

6.9 Concluding Remarks
The major findings of the current dissertation studies is that synaptic Zn2+ release
occurs following SD in vitro and in vivo and that this source of Zn2+ is neurotoxic in the
post-ischemic period. While the mechanism(s) of how synaptic Zn2+ contributes to
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neuronal injury following ischemia remains unclear, several possibilities exist and require
further investigation. This could lead to the development of new therapeutics targeting
synaptic Zn2+ and subsequent actions to potentially provide better outcomes following
stroke.
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Appendix Figure A1
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Figure A1: Preconditioning effect of SD lost in the presence of DMSO. Slices were
exposed to 2 SDs before loading with 30µM Zn/Pyr exposure (black bar). In the
presence of 0.1% DMSO, fEPSPs remained suppressed following a subsequent SD
challenge after Zn/Pyr exposure, and the metabolic adaptation effect (see Chapter 4) was
lost.
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Abbreviations Used
A1R

adenosine A1 receptor

ACSF

artificial cerebral spinal fluid

Ado

adenosine

AIF

apoptosis inducing factor

AMPA

α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid

ATP

adenosine triphosphate

BBB

blood-brain barrier

CA1

Cornu Ammonis 1

CA3

Cornu Ammonis 3

CBF

cerebral blood flow

COSBID

Co-operative study on brain ischemic depolarizations

CNS

central nervous system

CT

computed tomography

DC

direct current

dMCAO

distal middle cerebral artery occlusion

DMSO

dimethyl sulfoxide

DPCPX

8-cyclopentyl-1,3-dipropylxanthine

DPQ

3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone

EDTA

ethylenediaminetetraacetic acid

EEG

electroencephalogram

ECoG

electrocorticography

fEPSP

field excitatory post-synaptic potential
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GAPDH

glyceraldehyde-3-phosphate dehydrogenase

IOS

intrinsic optical signal

KGDHC

α-ketoglutarate dehydrogenase complex

KO

knockout

LSCI

laser speckle contrast imaging

LTD

long-term depression

LTP

long-term potentiation

mPTP

mitochondrial permeability transition pore

MT

metallothioneins

NMDA

N-methyl-D-aspartic acid

OGD

oxygen/glucose deprivation

PARP-1

poly(ADP-ribose) polymerase 1

PFK

phosphofructokinase

Pyr

pyrithione

SD

spreading depolarization

SEM

standard error of the mean

slm

stratum lacunosum moleculare

so

stratum oriens

sp

stratum pyramidale

sr

stratum radiatum

t-PA

tissue plasminogen activator

TCA cycle

tricarboxylic acid cycle

TPEN

N,N,N’,N’-tetrakis(2-pyridylmethyl)-ethylenediamine
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TSQ

6-methoxy-8-p-toluene sulfonamide quinolone

TTC

2,3,5-triphenyltetrazolium chloride

TTX

tetrodotoxin

[Zn2+]i

intracellular Zn2+

Zn/Pyr

ZnCl2 together with pyrithione
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